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1. GENERAL INTRODUCTION 
 
In order to enable effective oxygen distribution to the body, our circulation 
consists of systemic circulation and a pulmonary circulatory loop. The 
pulmonary circulation’s primary role is to enable gas exchange and reoxygenate 
oxygen poor systemic blood and return its oxygenated form to the heart. The 
pulmonary circulation involves an intricate network of thinly walled arteries 
with low luminal pressure and high flow rates. Each pulmonary artery is 
composed of several layers including the adventitia, the media and the intima 
with each individual layer made up of specific cell types: fibroblasts, smooth 
muscle cells (SMCs) and endothelial cells respectively surrounded by 
extracellular matrix components. The adventitia also contains a population of 
progenitor cells which have the ability to differentiate into SMCs (Torsney et al., 
2005). In the pulmonary circulation, the media layer is very thin compared to 
the systemic vasculature with the distal pulmonary arteries having little or no 
SMCs.  
Pulmonary arterial hypertension (PAH) is a potentially devastating disease 
characterised by the occlusion and narrowing of the pulmonary arteries, 
leading to increased vascular resistance and right ventricular pressure and 
eventual right heart failure. Diseased vessels have been shown to have a 
dramatically thickened medial layer and lesions characteristic to pulmonary 
hypertension display excessive SMC deposition. Much work has been done to 
try and understand the structural pathogenesis of the disease but it is still little 
understood what is driving the vascular remodelling process. Inflammatory 
cells are thought to have a role and there is evidence of immune cell infiltrates 
in diseased vessels in both animal models of PAH and in PAH patient lung 
sections. Within these immune cell infiltrates, the monocyte is of particular 
interest. Monocytes have been shown to be present in a variety of animal 
models of PH and have been shown to be actively entering pulmonary vessels in 
rats prior to the development of monocrotaline (MCT) induced PH. Also 
monocytes have been found in plexiform lesions of pulmonary arteries isolated 
from children with the sporadic form of the disease but not in left heart disease 
11 
 
associated forms of pulmonary hypertension. Moreover, with systemic pro-
inflammatory cytokine expression found to be altered in PAH and monocytes 
being a major source of cytokines, the monocyte is a very interesting cell type to 
study in relation to PAH. 
Interestingly, the hypoxia inducible transcription factor, HIF, has also been 
found within diseased vessels. HIF is essential for myeloid cell function 
therefore perhaps there is a related role of the monocytes and HIF in the 
remodelled vessels. HIF can also be an indirect indicator of hypoxia, although 
the exact oxygen tensions of these areas are yet to be established. The effect of 
hypoxia on SMCs is controversial but there is a body of data suggesting that 
hypoxia induces SMC proliferation. Therefore my hypothesis is that hypoxia can 
induce SMC proliferation which monocytes can alter via the HIF pathway and 
this is different in PAH.  
 
1.1 PULMONARY ARTERIAL HYPERTENSION 
 
Haemodynamically, pulmonary hypertension is characterized by an elevated 
mean pulmonary artery pressure ≥ 25 mmHg (mm Mercury) at rest, compared 
to normal resting pressure of 15-20 mmHg (Simonneau et al., 2009). Pulmonary 
hypertension has many different forms with various aetiologies. The umbrella 
of pulmonary hypertension can be divided into PAH, previously known as 
primary pulmonary hypertension (PPH), pulmonary hypertension and left heart 
disease, pulmonary hypertension and lung disease and /or hypoxia, chronic 
thromboembolic pulmonary hypertension (CTEPH) and pulmonary 
hypertension with unclear multifactorial mechanisms (Table 1.1) (Simonneau, 
2009). In 2008 at the Dana Point 4th World Health Organisation (WHO) 
symposium on pulmonary hypertension, PAH was sub-divided into the 
following categories: idiopathic PAH (IPAH), heritable PAH, drug- and toxin- 
induced PAH, associated with (APAH) including connective tissue disease APAH, 
HIV APAH and congenital heart disease APAH and persistent pulmonary 
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hypertension of the newborn (McGlothlin, 2012). The 5th WHO symposium on 
pulmonary hypertension is set to take place in Nice in 2013.   
The severity of the disease can be further assessed in accordance to the New 
York heart association classification which is used when deciding on 
treatments. The classifications describe the limitations on the patient with least 
severe functional class (Class I) being pulmonary hypertension patients without 
limitations to ordinary physical activity and the most severe functional class 
(Class IV) being patients with the inability to perform any physical activity 
without dyspnoea and /or fatigue (Table 1.2). Patients presenting with early 
stage disease tend to show general symptoms or are even asymptomatic. Initial 
indicators are dyspnoea, fatigue, syncope, peripheral oedema and chest pain. 
Further diagnosis is usually made by physical examinations, chest radiographs 
and electrocardiogram examination followed by computed tomography and 
eventual confirmation by right heart catheter. Although if left untreated 
prognosis is poor, recent developments in treatments and better understanding 
have extended prognosis by more than 10 years (McLaughlin et al., 2004).  
The PAH group, which can all be characterised by vascular remodelling 
processes during the development of the disease, is of particular interest as it 
is a deadly form which, if left untreated, gives rise to a median survival of only 
2 ½ years (Gaine and Rubin, 1998). Females have a predisposition of 2:1 to 
males of contracting the idiopathic form of PAH (Barst et al., 2012). 
Interestingly, more than 60 % of people with IPAH have a germline mutation 
in bone morphogenetic protein receptor 2 (BMPR2) (Aldred et al., 2006) 
(Cogan et al., 2006) but surprisingly only 20 % of all people with this mutation 
develop the disease (Cogan et al., 2012). However, mutations in the gene for 
BMPR2 are recognised as being responsible for 80 % cases of heritable PAH 
(Machado et al., 2006). This receptor and its ligand are part of transforming 
growth factor β (TGF- β) family and their role in PAH is expanded below with 
regards to SMC proliferation. 
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1. Pulmonary Arterial Hypertension 
 
1.1 Idiopathic pulmonary hypertension 
 
 
1.2 Heritable 
 
  
1.2.1 BMPR2 
 
  
1.2.2 ALK1. endoglin  
 
  
1.2.3 Unknown 
 
 
1.3 Drug- and toxin- induced 
 
 
1.4 Associated with  
 
  
1.4.1 Connective tissue diseases 
 
  
1.4.2 HIV Infection 
 
  
1.4.3 Portal hypertension 
 
  
1.4.4 Congenital heart diseases 
 
  
1.4.5 Schistosomiasis 
 
  
1.4.6 Chronic hemolytic anaemia 
 
 
1.5 Persistent pulmonary hypertension of the newborn 
1'. Pulmonary venoocclusive disease (PVOD) and /or pulmonary capillary hemangiomatosis (PCH) 
2. Pulmonary hypertension owing to left heart disease 
 
2.1 Systolic dysfunction 
 
2.2 Diastolic dysfunction 
 
2.3 Valvular disease 
3. Pulmonary hypertension owing to lung diseases and /or hypoxia 
 
3.1 Chronic obstructive pulmonary disease 
 
3.2 Interstitial lung disease 
 3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
 
 
3.4 Sleep disordered breathing 
 
3.5 Alveolar hypoventilation disorders 
 
3.6 Chronic exposure to high altitude 
 
3.7 Developmental abnormalities  
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
 
5.1 Hematologic disorders 
 
5.2 Systemic disorders  
 
5.3 Metabolic disorders 
 
5.4 Others 
 
Table 1.1 World Health Organisation clinical classification of pulmonary 
hypertension as described in Dana Point, 2008. 
Rewritten from Journal of the American College of Cardiology, Simonneau, G. et al, 
Updated Clinical Classification of Pulmonary Hypertension, S43-S54, copyright (2009) 
with permission from Elsevier.  
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 Patients with disease but without limitation of physical activity. Ordinary 
physical activity does not cause undue dyspnea or fatigue or chest pain.  
Class I 
  
  Patients with disease resulting in slight limitation of physical activity. 
Comfortable at rest but ordinary physical activity causes undue dyspnea 
or fatigue or chest pain. 
Class II 
  
  Patients with disease resulting in marked limitation of physical activity. 
Comfortable at rest but less than ordinary activity causes undue 
dyspnea or fatigue or chest pain. 
Class III 
  
  Patients with disease with the inability to carry out any physical activity 
without symptoms. Patients present signs of heart failure. Dyspnea 
and/or fatigue may even be present at rest.  
Class IV 
  
 
 
 
 
Table 1.2 World Health Organisation and New York Heart Association 
classification of functional class of patients with pulmonary hypertension 
Rewritten from CHEST, Rubin L. J., Introduction; Diagnosis and Management of 
Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines, 
126, 1S, copyright (2004) with permission from the American College of Chest 
Physicians. 
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The pathogenesis of PAH is still poorly understood, however, it has previously 
been demonstrated that all three layers of the vasculature, intima, media and 
adventitia, are involved in arterial remodelling in PAH patients (Chazova et al., 
1995) (Stenmark et al., 2006). Endothelial cell apoptosis is thought to be the 
trigger inducing SMC proliferation in the vascular remodelling process (Cool et 
al., 1999) as the intimal layer plays a role in mediating homeostasis, aiding 
adhesion, maintaining the balance between vasodilators and vasoconstrictors 
and interacting with cells in the blood (Davies, 1986). A leaky intima due to 
endothelial cell apoptosis can lead to vasoconstriction, causing dedifferentiated 
SMCs to proliferate (Cool et al., 1999). The media contains both fully 
differentiated contractile SMCs which are resistant to proliferative stimuli and 
an inter-dispersed dedifferentiated synthetic population which readily 
proliferate (Frid et al., 1997). The adventitia also contains a diverse population 
of cells consisting of both fibroblasts and dedifferentiated SMCs which not only 
influence expression of extracellular matrix proteins (Stenmark et al., 2006) but 
also have a role in regulating vascular tone in response to ROS and injury (Irani 
et al., 1997) (Touyz and Schiffrin, 2004).  
During the vascular remodelling process both obliterative concentric and 
plexiform lesions can form (Figure 1.1). Muscularisation of the pulmonary 
arteries from excess SMC proliferation leads to medial hypertrophy and loss of 
precapillaries, followed by neointima and plexiform lesion formation (Atkinson 
et al., 2002) (Rubin, 1997). Neointima formation describes the infiltration of 
dedifferentiated SMCs and extracellular matrix components between the 
endothelium and internal lamina preventing vessel elasticity. Altered 
proliferation and survival of endothelium contributes to the formation of 
plexiform lesions (Sakao et al., 2006). Each lesion consists of opened channels 
separated by proliferating SMCs and endothelial cells embedded in a cellular 
matrix (Atkinson et al., 2002) (Cool et al., 1999). Prevalence of lesions is 
increased in IPAH where endothelial cells tend to be deficient in genes for 
endothelial growth suppressors such as TGF-β (Humbert et al., 2004) 
(Stenmark et al., 2006).  
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Figure 1.1 Lesion formation in pulmonary hypertension 
Images are of human lung tissue samples stained for smooth muscle actin. They 
illustrate how normal pulmonary arteries have thin SMC walls that are dramatically 
thickened in PAH. In disease, pulmonary artery SMCs proliferate and swell decreasing 
lumen size and increasing vascular resistance. Plexiform lesion formation occurs by 
endothelial cell dysregulation and aberrant growth therefore SMC walls remain 
relatively thin with neointima formation.  
Reprinted from The American Journal of Pathology, 172, Lawrie, A. et al, Evidence of a 
Role for Osteoprotegerin in the Pathogenesis of Pulmonary Arterial Hypertension, 256-
264, copyright (2008) with permission from Elsevier.  
Normal pulmonary artery 
Concentric lesion Plexiform lesion 
Smooth muscle cell 
proliferation and 
deposition.  
Endothelial cell 
proliferation and 
dysregulation.  
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1.2 SMOOTH MUSCLE CELL PROLIFERATION 
 
One protein which has been linked to PAH and SMC proliferation is a member of 
the TGF-β super-family, BMPR2. Bone morphogenetic protein (BMP) ligands 
exert their effects through heterodimerization and phosphorylation of BMP 
receptor 1a or b (BMPR1a /ALK-3 or BMPR2b /ALK6) and BMPR2 on the cell 
surface (Chen et al., 2004). Receptor activation leads to phosphorylation of 
SMAD 1 /5 /8 proteins before binding the co-SMAD, SMAD4, and translocating 
to the nucleus where the SMAD complex regulates gene expression (Yoshida et 
al., 2000) (Humbert et al., 2004). BMPs are synthesised by cells in the 
pulmonary vasculature and maintain the balance of apoptosis and proliferation 
in these cells. BMPs inhibit growth, downregulate Bcl-2 (an anti-apoptotic 
protein) in SMCs and promote endothelial cell survival. In pulmonary 
hypertension, the roles of BMPs are reversed causing SMC proliferation and 
survival followed by endothelial death (Yuan et al., 1998). The BMPR2 gene 
encodes a TGF- β type II receptor, which is involved in apoptosis and cell cycle. 
Mutations in this gene lead to impaired SMC signalling and cell death (Yoshida 
et al., 2000). TGF-β itself acts on SMC proliferation by binding its type 1 and 
type 2 receptors. Once bound the receptors dimerise inducing phosphorylation 
of the regulatory SMAD proteins, SMAD2 and SMAD3. These phosphorylated 
proteins then bind the co-SMAD, SMAD4, and translocate to the nucleus where 
they form complexes with DNA binding proteins to induce transcription of cell 
cycle mediators such as c-Myc (Figure 1.2). More specifically this pathway has 
been shown to be upregulated in SMCs from IPAH patient lung explants coupled 
with dysregulation of the related BMPR2 pathway emphasising its importance 
in vascular remodelling (Morrell et al., 2001).  
Similarly, SMCs from pulmonary hypertensive patients have also been shown to 
have altered growth response to growth factors such as VEGF and PDGF. 
Interestingly, expression of both VEGF itself and the type 1 receptor, Flt-1, is 
also increased in SMCs from pulmonary hypertension patients compared to 
controls (Hirose et al., 2000). Moreover, lungs from patients with pulmonary 
hypertension have been shown to have an increase PDGF as well enhanced 
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proliferation in response to the growth factor compared to healthy SMCs (Berg, 
1998). Both VEGF and PDGF receptors contain kinase domains which upon 
ligand binding, dimerise and activate the protein kinase C (PKC) and 
phosphoinositide-3 kinase (PI3K) pathways. During receptor activation, 
intracellular calcium ion concentrations are regulated by the calcium binding 
protein calmodulin via PKC. Intracellular calcium influx directly modulates SMC 
proliferation. The PI3K pathway also regulated cell proliferation by kinase 
cascade from protein kinase B (also known as AKT) cascade culminating in 
mammalian target of rapamycin (mTOR) activity leading to transcription of 
genes inducing cellular proliferation (Figure 1.2).  
Another pathway thought to regulate SMC proliferation is the IL- 1 pathway 
with IL- 1β being shown to directly induce SMC proliferation (Lawrie et al., 
2011). Moreover, increased IL- 1 protein and RNA expression is found in lesions 
of IPAH patients as well as an increase in circulating levels when compared to 
healthy donors (Wong et al., 1996) (Fartoukh et al., 1998). Binding of IL- 1 to its 
type 1 receptor (IL- 1R1) and its accessory protein MyD88 leads to a 
phosphorylation cascade. IL- 1 associated kinase 1 (IRAK 1) and IRAK 4 are 
subsequently activated leading to downstream release of the transcription 
factor NF-κB. Degradation of inhibitor of κB (IκB) allows nuclear NK-κB 
translocation and transcription of genes such as cyclin D which regulate cell 
cycle progression (Figure 1.2). All these pathways contribute to SMC 
proliferation and are highly regulated in healthy SMCs. In disease many of these 
pathways are dysregulated either by increased ligand availability, receptor 
dysfunction or alterations to downstream pathway mediators. By fully 
understanding these processes new therapeutics can be developed in the hope 
to prevent or reverse vascular remodelling.   
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Figure 1.2 Summary of pathways influencing smooth muscle cell 
proliferation 
A schematic depicting transforming growth factor β (TGF-β), bone morphogenetic 
protein (BMP), growth factors and interleukin- 1 (IL- 1) signalling pathways. Upon 
ligand binding each receptor induces a phosphorylation reaction and activation of 
separate pathway members culminating in SMC proliferation. 
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1.3 PULMONARY ARTERY CELLS AND HYPOXIA 
 
Local hypoxia has been implicated as a potential initiating factor for PAH with 
hypoxia exposure causing proliferation of both SMCs and fibroblasts in vitro. In 
humans systemic hypoxia exposure can directly induce pulmonary 
hypertension as seen in Dana Point classification group 3. Although the 
pathogenesis of hypoxia induced pulmonary hypertension is different from PAH 
we can gain insights into a role of hypoxia in the disease. Altitude studies by 
Maggiorini and Penazola showed that residents at high altitudes and low 
oxygen bioavailability had increased pulmonary arterial pressures than those at 
sea level. Also newcomers to high altitude were more susceptible to developing 
pulmonary hypertension but this phenomenon was reversed upon maintained 
residence at altitudes close to sea level (Maggiorini, 2003) (Penaloza and Arias-
Stella, 2007). Exact oxygen tensions of the pulmonary artery vessel wall are 
unknown but perhaps the local oxygen mismatch could be an initiating trigger 
for SMC proliferation in both hypoxia induced PH and PAH.  
Further evidence that hypoxia may be a trigger for disease progression comes 
in the form of pulmonary hypertension mammalian models. Many pulmonary 
hypertension murine models have used incubation in hypoxia along with a 
secondary stimulus to induce the diseased state (Beppu et al., 2004) (Liu et al., 
2005) (Eddahibi et al., 1999) (Steiner et al., 2009) (Frid et al., 2009). Hypoxia 
has also been shown to affect the vascular cells directly but this is controversial. 
Whilst some in vitro studies show that 3-5 kPa oxygen in the media can induce 
pulmonary artery SMC proliferation in both human derived cells (Cooper and 
Beasley, 1999) (Yang et al., 1997) (Tamm et al., 2004) and bovine SMCs 
(Hassoun et al., 1989) others have shown an anti-proliferative phenotype of 
SMCs in oxygen tensions of 0-3 kPa oxygen (Dempsey et al., 1991) (Eddahibi et 
al., 1999). The controversy surrounding SMC proliferation in hypoxia is 
compounded by the fact that within the same paper Frid et al. have shown a 
dual proliferative phenotype of SMCs exposed to 3 kPa oxygen but with 
different serum concentrations (Frid et al., 1997). However, seeing as none of 
these papers used the same culture conditions or SMCs derived from the same 
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sourse it is difficult to determine the effect of hypoxia on SMC proliferation. 
Despite the controversy, most papers suggest that in 5-10 % serum and 3-5 kPa 
oxygen in the media, SMCs proliferate. However, the method by which hypoxia 
induces SMC proliferation is still unknown. An in vivo study using auto 
antibodies against potassium voltage-gated channels found that hypoxia can 
inhibit potassium channels and initiate vasoconstriction in rat vascular SMCs 
(Archer et al., 1998). Further to this potassium channels were found to be 
inhibited in human SMC incubated under 5 % hypoxia (Post et al., 1992). These 
data give us insights into potential mechanisms by which hypoxia can induce 
the diseased state but it is still unknown how hypoxia can induce SMC 
proliferation.  
 
1.4 MONOCYTES IN DISEASE 
 
Monocytes are short lived circulating phagocytes that can live between 1 to 3 
days in the circulation and represent approx. 10 % of the total mononuclear cell 
population (Fogg et al., 2006). Although few in number these cells have 
important pro-inflammatory roles and are a major source of cytokines. Further 
to this, monocytes have patrolling roles in the circulation allowing interactions 
with antigen presenting cells thus activating the adaptive immune response and 
the complement cascade targeting pathogens for degradation and killing. 
Moreover, monocytes are able to aid margination of neutrophils into tissues 
from the circulation (Kreisel et al., 2010) and can themselves migrate into 
damaged or injured tissues.  
The monocyte population can be divided into groups based on their 
differentiation state (Thomas and Lipsky, 1994). Circulating monocyte 
populations consist of the more common cluster of differentiation 14 positive 
(CD14+) monocyte and the more mature cluster of differentiation 16 positive 
(CD16+) monocyte (Ziegler-Heitbrock et al., 1988) (Sunderkotter et al., 2004). 
CD16+ monocytes are a longer lived subset (Hilgendorf and Swirski, 2012) but 
only form 20- 30 % of total monocyte populations (Passlick et al., 1989). 
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Analysis of both subsets found upon stimulation both were able to induce 
respiratory burst but CD16+ showed less phagocytosis or adhesion molecule 
expression (Passlick et al., 1989). Moreover CD16+ monocytes lack the 
monocyte chemotactic protein- 1 (MCP-1) receptor so are thought not to be the 
first cell type to be recruited to sites of inflammation and have a more 
regulatory and patrolling role in the vasculature (Weber et al., 2000). Therefore 
my work has explored the role of the CD14+ ‘classical’ monocyte also known as 
the ‘pro-inflammatory’ monocyte due to its large contribution to ROS and 
inflammatory cytokine expression upon activation.  
In relation to PAH, monocyte infiltration seems to occur prior to disease onset.  
For example, the monocrotaline (MCT) rat model of PAH shows monocyte and 
lymphocyte infiltration into the pulmonary vasculature from 1-24 hours post 
injection prior to vascular remodelling (Voelkel and Tuder, 1994). The insult of 
MCT may cause the monocytes to alter their protective phenotype to allow 
severe vascular remodelling. Perivascular monocytes have been shown to 
increase expression of many stress markers such as nitrotyrosine upon MCT 
injection (Dorfmuller et al., 2011) which may induce a phenotypic alteration 
preventing monocytes from being able to maintain vascular tone. Further 
evidence for a role of immune cells in the pathogenesis of PAH have been 
provided in humans by work from Klein et al. who have shown the 
predominance of leukocytes in lung tissue from treatment naive children with 
IPAH. These sections were compared to normal post-mortem child lung 
sections and those from children with congenital heart disease associated 
pulmonary hypertension of which both had considerably less leukocyte 
presence (Hall et al., 2009). Moreover, Voelkel’s group described aggregations 
of macrophages within the plexiform lesions themselves from seven of ten 
severe PAH patient lung tissue isolates. Interestingly T cells and macrophages 
were seen invading the vascular wall of pulmonary arteries with early signs of 
remodelling (Tuder et al., 1994). It is postulated that these immune cells have a 
direct role in the pathogenesis of PAH by influencing vascular remodelling 
(Dorfmuller et al., 2003). This theory is strengthened by the fact that myeloid 
cells have been shown to be present in the vasculature during the remodelling 
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process from lung sections of patients with PAH compared to unaffected 
explanted lung (Cool et al., 1999) (Frid et al., 2006). Moreover, in the hypoxic 
murine model of PH depletion of circulating leukocytes prevented remodelling 
in pulmonary arteries. However, these data are descriptive and the actual role 
of these immune cells in the pathogenesis of PAH is yet to be established.   
Not only are monocytes themselves thought to be involved in the pathogenesis 
of PAH but also cytokines produced from these cells. In pulmonary 
hypertension, circulating serum concentrations of both IL- 1 and IL- 6 pro-
inflammatory cytokines are upregulated compared to healthy controls. IL- 1 
acts on both vascular cells (endothelial cells and SMCs) and monocytes inducing 
proliferation and migration of vascular cells and exacerbating inflammation 
(Humbert et al., 2004) Although not in pulmonary SMCs it is known that IL- 1 
signalling has been shown to modulate systemic artery remodelling. Work by 
Chamberlain et al. showed that mice deficient in IL- 1 receptor type 1 (IL-1R1-/-) 
had decreased neointima formation upon vascular injury by ligation of the 
carotid artery compared to IL- 1R1+/+ control mice after 14 days (Chamberlain 
et al., 2006). Furthermore, IL- 1R1 antagonist (IL- 1ra) fed pigs also had 
reduced neointima formation after injury from oversized stents in coronary 
arteries compared to control pigs which were injured but not administered IL- 
1ra (Morton et al., 2005). Extrapolating from this data perhaps the IL- 1 
pathway also plays a role in pulmonary arterial remodelling. In relation to 
pulmonary hypertension monocrotaline (MCT) treated rats, which develop 
severe pulmonary hypertension, were administered twice daily injections of 2 
mg /kg IL- 1ra or PBS. Rats administered with IL- 1ra had significantly reduced 
pulmonary hypertension progression after 3 weeks as determined by 
hemodynamic analysis compared to controls (Voelkel et al., 1994). Taken 
together, these data and the knowledge that IL- 1β can directly influence 
pulmonary artery SMC migration and proliferation (Lawrie et al., 2011) 
implicate a role of IL- 1 in PAH progression, however, the mechanism is yet to 
be established.  
Another important proinflammatory cytokine in disease is IL- 6, it is 
consistently increased in the serum and lungs of patients with IPAH and 
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rheumatoid arthritis (Humbert et al., 1995) (Nishimaki et al., 1999). Moreover, 
lung specific IL-6 over expressing mice showed significant vascular remodelling 
as seen in progressed PAH. Interestingly, 5 % hypoxia progressed remodelling 
of pulmonary vessels further (Steiner et al., 2009). Previous work in rats with 
MCT induced pulmonary hypertension showed proinflammatory cytokines 
highly expressed in remodelled pulmonary arteries than compared to those 
resistant to remodelling (Voelkel et al., 1994). Interestingly, 
immunosuppressant therapy has been shown to reduce PAH progression in 
mice with hypoxia induced PAH again showing the importance of inflammation 
in PAH progression (Dorfmuller et al., 2003). Overall, although most of these 
data are descriptive both the presence of monocytes in remodelling vessels and 
the fact that they are a major source of cytokines involved in the disease 
strengthen the argument that these cells are important in PAH. 
 
1.4.1 MONOCYTE RECRUITMENT  
 
Cross talk between inflammatory immune cells and vascular tissue cells may 
play an important role in IPAH. Cell and tissue interactions are essential for 
chemotaxis, inflammation and myeloid cell invasion into tissue. For example, 
endothelial cells produce platelet activating factor that induces myeloid cell 
adherence in hypoxia (Milhoan et al., 1992). Endothelial cells also express E- 
and P- selectins, vascular cell adhesion molecules, MCP-1 and chemokines 
which is essential for recruitment of circulating myeloid cells. Monocytes can in 
turn activate endothelial cells via cytokines such as tumour necrosis factor α 
(TNF α) enabling them to recruit more circulating lymphocytes and monocytes 
(Tsouknos et al., 2003).  
Monocyte recruitment involves several steps namely capture, rolling, slow 
rolling, adhesion and finally transmigration through the endothelium. The 
capture process involves transient interactions between Selectin proteins and 
their transmembrane glycoprotein ligands. Selectin mediated low affinity 
binding is strengthened by chemokine activation leading to rolling of the 
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leukocyte along the endothelium. The transit time of leukocyte recruitment 
depends on chemokine stimulation. Chemokine signalling aids high affinity 
integrin binding, this allows slow rolling of leukocytes along the endothelium 
and finally adhesion with the aid of the immunoglobulins intercellular adhesion 
molecule- 1 (ICAM- 1) and vascular cell adhesion molecule- 1 (VCAM- 1) 
(Chavakis et al., 2009). With respect to PAH, expression of these 
immunoglobulins is decreased in diseased vessels proportionally to vessel 
damage by monocrotaline particularly in the case of platelet/ endothelial cell 
adhesion molecule-1 (PECAM-1) (Huang et al., 2012). By blocking this leukocyte 
recruitment in endothelial cell specific BMPR2 knockout mice, PAH is 
significantly reduced both heamodynamically and pathologically (Burton et al., 
2011). These findings reflect work using anti-inflammatory drugs to reduce the 
progression of PAH in these same mice and mice with hypoxia induced PH 
(Dorfmuller et al., 2006). Incidentally, also in the endothelial cell specific 
BMPR2 knockout mice, it was shown that the increased circulating levels of 
endothelin- 1 (ET- 1) in mice with PH was not only due to endothelial derived 
ET- 1 but also monocytes themselves were adding to ET- 1 secretion (Talati et 
al., 2010). ET -1 is a potent vasoconstrictor which is thought to contribute 
directly to vascular remodelling, these data suggest that monocytes may be 
driving the remodelling either by systemically secreting ET- 1 or expressing ET- 
1 locally once recruited and thus driving the remodelling process.  
Expression profiles of adhesion molecules, with regards to integrins, are 
increased in pulmonary hypertension compared to healthy controls in humans. 
This is true for both vascular cell expression and circulating cell expression 
(Larsen et al., 2011). This means that not only are more cells recruited to 
pulmonary vessels but also the circulating cells themselves are expressing more 
adhesion molecules and are more ready to infiltrate the pulmonary artery. It 
has also been found that chemokine stimulation induces this increase in 
integrin expression on circulating cells emphasising the important role of 
chemokine in monocyte recruitment (Larsen et al., 2011). Moreover, many of 
the chemokines have been shown to be increased in murine models of PAH. For 
example, macrophage migration inhibitory factor which is an early 
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inflammatory cytokine has been found to be increased in lungs of rats with 
hypoxia induced pulmonary hypertension. Subsequent investigation identified 
that migration inhibitory factor specifically induces pulmonary artery SMC 
proliferation via activation of the ERK phosphorylation cascade (Zhang et al., 
2011). Also in the rat, MCP- 1 inhibition by intramuscular injection of a deletion 
mutant MCP- 1 gene significantly reduced vascular remodelling when compared 
to non-injected controls. In humans, patients with developed PAH have been 
found to have significant increases in circulating levels of the chemokine 
regulated and normal T cell expressed and secreted (RANTES) (Dorfmuller et 
al., 2007), the CX(3)C chemokine fractalkine (Balabanian et al., 2002) and the 
chemokine macrophage inflammatory protein- 1α (Fartoukh et al., 1998) 
compared to healthy controls. It was proposed that the chemokines and 
cytokines produced by the inflammatory cells may, in fact, encourage 
pulmonary artery SMC proliferation (Cool et al., 1999).  
 
Chemokine or Adhesion molecule Secreted by Studied in  Reference 
Increased 
E- Selectin   EC       
P- Selectin EC porcine in vivo Milhoan, 1992 
PAF  EC         
TNFα  monos human in vitro Tsouknos, 2003 
ET-1  EC murine in vivo Talati, 2010 
CX3CL1 circulating human in vivo Larsen, 2011 
MIF circulating rat in vivo Zhang, 2011 
RANTES circulating human in vivo Dorfmuller, 2007 
Fractalkine circulating human in vivo Fartoukh, 1998 
Decreased 
ICAM-1 EC         
VCAM-1  EC rat in vivo Huang, 2012 
PECAM-1  EC         
CCR7 leukocytes murine in vivo Larsen, 2011 
 
Table 1.3 Adhesion molecule and chemokine changes in pulmonary 
arterial hypertension. 
A table illustrating the changes in chemokine and adhesion molecule expression found 
in the literature with regards to pulmonary arterial hypertension. 
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1.5 HYPOXIA 
 
Ambient oxygen tension is in the region of 150 mmHg, however, biologically 
cells rarely see such high tensions. High oxygen tensions can dramatically affect 
cell homeostasis, for example, exposure to ambient oxygen tension directly 
effects human endothelial cell expression of plasminogen activator inhibitor, an 
important protein in clot breakdown in vitro (Gertler et al., 1993) and isolated 
islets of Langerhans release of insulin (Kuhtreiber et al., 1993).  Human body 
oxygen tensions are about 40 mmHg in liver, 30 mmHg in muscle, 20 mmHg in 
tissue but much lower at sites of inflammation (Wiener et al., 1982) (Lund et al., 
1995). Mammalian cells utilise oxygen for energy production by aerobic 
mitochondrial respiration. Critically, once the Pasteur point of oxygen is 
reached, human cells revert to energy production by anaerobic glycolysis. The 
ability of myeloid cells to function in inflamed areas depends on their capacity 
to utilise glycolysis, as opposed to mitochondrial respiration, as an energy 
source. Myeloid cells use the anaerobic glycolysis pathway for their ATP 
production independent of oxygen tensions. When glycolysis is inhibited in 
neutrophils and macrophages their functional capacity is rapidly impaired 
(Cramer et al., 2003), but the same is not seen if mitochondrial inhibitors are 
used (Borregaard and Herlin, 1982), indicating the importance of glycolysis and 
also suggesting that these cells evolved very early in phylogeny prior to our 
symbiotic relationship to mitochondria. All human cells have the innate ability 
to sense oxygen, which is controlled by oxygen sensitive hydroxylases and their 
influence upon hypoxia inducible transcription factor (HIF). HIF activation leads 
to transcription of many essential genes for host defence, disease susceptibility 
and glycolysis.  
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1.5.1 HIF PATHWAY 
 
HIF is a hypoxia induced transcription factor and is found in all metazoans. Greg 
Semenza’s group discovered the HIF protein and over 1-4 % genome is directly 
HIF regulated (Ahmed, 2010). HIF proteins are basic-helix-loop-helix (bHLH) –
PAS proteins (containing sequence homology to the Drosophila Per-ARNT-AHR-
Sim domains) as determined by genetic screening and protein microsequence 
analysis (Wang et al., 1995). HIF is a heterodimer comprising of HIF- 1α and 
HIF- 1β subunits. The HIF- 1β subunit (also known as aryl hydrocarbon nuclear 
translocator (ARNT)) is constitutively expressed in all cells while the HIF- 1α 
subunit is precisely regulated by cellular oxygen (Semenza, 2000). HIF α 
subunit has 3 isoforms: HIF- 1α, HIF- 2α and HIF- 3α. The expression patterns of 
these isoforms differ in various tissues. HIF expression is also altered by 
hypoxia shown by rats having increased mRNA levels of HIF- 1α, -2α and -3α 
after 12 days incubation in hypoxia (Chen et al., 2006). Little is known about 
HIF- 3α, other than that multiple splice variants can inhibit HIF- 1 (Makino et al., 
2002). HIF- 3α has a low expression profile in most cells except lung epithelial 
cells where it is found in abundance and increased further in response to 1 % 
oxygen in comparison to HIF- 1α expression (Li et al., 2006). HIF- 2α is not 
found in all cell types but has large sequence homology to HIF- 1α. Despite their 
similarities, HIF- 1α and HIF- 2α have not been proven to have functional 
redundancy (Gleadle et al., 2006). Being the most abundant isoform, HIF- 1α is 
the best studied of the three isoforms and is found in all cell types. 
HIF is regulated by two post-translational mechanisms: by the oxygen sensing 
prolyl hydroxylases (PHD) and by factor inhibiting HIF (FIH). These enzymes 
are dependent on iron uptake into their core for activation. Iron chelators can 
effectively inhibit both PHD and FIH function (Semenza, 2004). There are three 
PHD enzymes that directly control HIF, named PHD 1, PHD 2 and PHD 3. In 
oxygen abundant conditions, these enzymes hydrolyse HIF- 1α at proline-402 
and proline-564 residues in the oxygen dependant degradation domain (ODDD) 
using oxygen available from tissue (Pugh, 1997), thus targeting it to the von 
Hippel Lindau (VHL) tumour suppressor protein (a subunit of E3 ubiquitin 
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ligase) for ubiquitination and subsequent degradation (Percy et al., 2006). 
Disruption of proline-402 and proline-564 residues in HIF- 1α prevents VHL 
binding. The binding efficiency of VHL to HIF- 1 is increased 1000 times 
following proline hydroxylation showing the important role PHD enzymes have 
in HIF regulation (Chowdhury et al., 2009). FIH also regulates HIF but to a lesser 
extent than the PHDs. FIH exerts its effects by hydroxylating asparagine-803 
residue on HIF- 1α to reduce its affinity to co-activators CREB binding protein 
(CBP) and p300. This reduces its binding to hypoxia response elements (HREs) 
in promoters of target genes (Masson et al., 2012) (Figure 1.3). 
In reduced oxygen tensions, stabilised HIF- 1α binds HIF- 1β subunits allowing 
transcription of genes containing HREs in their promoters including the genes 
for PHD 2 and PHD 3 which negatively feedback upon HIF protein expression 
(Figure 1.4). Discovery of genes with HRE in their promoters has a constant 
turnover with the latest being identified as early as this year. This gene was 
KCNMB1 which encodes for the β-1 subunit of large conductance calcium 
dependant potassium channels. These channels are tetramer complexes 
consisting of four α subunits that interact with β-1 subunits (Wu, 2003). 
Expression of the β-1 subunits have been found to be increased in hypoxia and 
further examination identified two HREs in the promoter of KCNMB1 (Ahn et 
al., 2012).  
In some cases, HIF can also be regulated in an oxygen independant manner. For 
example, Nizet’s group showed that HIF-1 alpha expression at the 
transcriptional level can be regulated in a TLR4 dependant fashion by the TLR4 
agonist LPS in myeloid cells (Peyssonnaux, 2007). How bacterial stimuli can 
induce HIF-1 expression in myeloid cells is yet to be explored as does the effect 
of hypoxia on monocyte HIF expression and monocyte function. However, the 
effect of hypoxia on monocyte-derived macrophages has been looked at. It has 
been shown that monocyte-derived macrophages exposed to hypoxia have 
increased expression of HIF-1 both in vitro and in those located at sites of 
tumours in mice (Burke et al., 2003) (Elbarghati et al., 2008).   
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Although HIF is primarily regulated by oxygen tension and by bacterial stimuli 
in myeloid cells, there is also evidence of indirect HIF regulation by growth 
factors such as PDGF and VEGF involving cross-talk with the NF-κB pathway 
(Tsapournioti et al., 2013) (ten Freyhaus et al., 2011). It is unknown how both 
the NF-κB and the HIF pathway interact but Ruis et al. have shown that the 
interaction of HIF and the NF-κB pathway member IKKβ is important in innate 
cell function in vitro and in mice (Ruis et al., 2008). Further to this, in the field of 
cancer, much data supports a differential regulation of HIF-1 and HIF-2 (Wu et 
al., 2011)(Raghavan et al., 2012). Perhaps this is also true of vascular cells and 
myeloid cells but it is an area that is yet to be explored.  
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Figure 1.3 HIF oxygen dependant regulation  
The HIF- 1α subunit of HIF is regulated by two oxygen sensitive hydroxylases. In 
hypoxia the HIF- 1α subunit is stabilised and is able to bind to its co-factors p300 and 
CREB binding protein (CBP) allowing transcription. When cellular oxygen 
concentrations are high, prolyl hydroxylase domain proteins (PHDs) use oxygen to 
hydroxylate proline-402 and proline-564 residues allowing binding of von Hippel 
Lindau tumour suppressor protein. This is an E3 ubiquitin ligase protein targeting HIF-
1α for degradation. Furthermore, factor inhibiting HIF (FIH) hydroxylates aspargaine-
803 reducing its affinity to p300 and CBP. Based on diagram from Semenza, (2004) 
Hydroxylation of HIF-1: oxygen sensing at the molecular level, Physiology, 19, 176-182. 
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Figure 1.4 The HIF pathway 
HIF-1 is a transcription factor regulated by oxygen sensitive hydroxlases. In normoxia 
and iron replete conditions the oxygen sensitive prolyl hydroxylase proteins-1, -2, -3 
(PHD-1, -2, -3) and factor inhibiting HIF (FIH) prevent HIF downstream effects. 
Hypoxia and bacterial stimuli such as LPS, stabilises HIF allowing it to bind to hypoxia 
response elements (HRE) in promoters of varies genes. HIF activated genes include 
glycolytic enzymes enabling anaerobic energy production, myeloid cell pro-survival 
proteins and enzymes for iron export. 
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Better understanding is needed to fully elucidate the role of hypoxia and the HIF 
pathway in pulmonary hypertension. It is known that prolonged hypoxia in 
murine models induces pulmonary hypertension (James and Thomas, 1968) 
(Meyrick and Reid, 1978) but the mechanism of disease progression is unclear. 
Hypoxia is also used as a secondary stimulus to induce pulmonary hypertension 
in mice. For example, the VEGF receptor inhibitor, Sugen- 5416, causes mild 
increases in pulmonary arterial pressures but when administered to hypoxic 
rats it caused a severe pulmonary hypertension phenotype with vascular 
remodelling (Taraseviciene-Stewart et al., 2001) (Laird et al., 2002). Also mice 
heterozygous for BMPR2 have been shown to develop pulmonary hypertension 
but vascular remodelling is progressed further with exposure to chronic 
hypoxia (Beppu et al., 2004). Chronic hypoxic mice which develop pulmonary 
hypertension have been found to have pulmonary vascular infiltrates of 
fibocytes which are circulating precursor cells of monocyte lineage. During 
vascular injury fibroblasts and fibrocytes are first recruited to pulmonary 
arteries. Here they contribute to neointima formation by proliferating and 
inducing deposition of extracellular matrix proteins. This suggests that hypoxia 
helps initiate neointima formation in diseased arteries (Frid et al., 2006).  
As previously mentioned, oxygen depletion leads to impaired potassium 
channel function in SMCs, the resulting cell membranes depolarise giving 
intracellular calcium ion influx. Increased intracellular calcium concentrations 
lead to vasoconstriction and cell proliferation. Humbert et al have shown that 
hypoxia depolarises vascular membranes at sites of vascular remodelling in rats 
(Humbert et al., 2004). The proliferative effects of hypoxia have been difficult to 
replicate in vitro giving contradictory data as to the effects of hypoxia on 
vascular cells. In spite of this, it has been shown that hypoxia increases 
proliferation of SMC and endothelial cells by inhibition of anti-mitogenic factors 
and production of mitogenic stimuli, which in turn induces extracellular matrix 
protein production (Pak et al., 2007). 
Interestingly, when explants from PAH patients were investigated, HIF- 1α was 
found at both the mRNA and protein level in the plexiform lesions of diseased 
pulmonary vessels (Tuder et al., 2001). Expression of HIF is highly regulated by 
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oxygen sensing enzymes which are very responsive to iron availability. 
Unsurprisingly, iron prevalence modifies pulmonary arterial pressure in 
hypoxia. To further investigate the effects of iron in the pulmonary vessel 
response to hypoxia, Smith et al, carried out in vivo studies on healthy subjects. 
The group gave intra venous iron or iron chelator over several weeks to 
patients followed by 8 hours sustained hypoxia. Results showed lower 
pulmonary arterial systolic pressure in hypoxia from subjects given iron 
supplements compared to non-administered controls (Smith et al., 2008). This 
further strengthens the view that hypoxia is important in the development of 
pulmonary hypertension and understanding of the mechanisms involved could 
potentially aid defence against disease progression. 
Work from Celeste Simon’s group implicated a role for HIF itself in the 
pathogenesis of pulmonary hypertension using a murine model of Chuvash 
polycythemia. The Chuvash form of erythrocytosis is a rare form found locally 
in Chuvashia hence its name. The disease results from an autosomal recessive 
mutation in the VHL protein. Similar to human disease, mice with a homozygous 
mutation for arginine substitution to tryptophan at residue 200 of VHL (VHLR/R) 
are susceptible to spontaneously develop pulmonary hypertension. Lungs from 
VHLR/R mice with pulmonary hypertension were found to have substantial 
vascular remodelling and macrophage infiltration characteristic to pulmonary 
hypertensive diseased vessels but also increased endothelial cell expression 
HIF- 2α protein (Hickey et al., 2010). HIF- 2 target genes as well as HIF- 2 
protein itself has also been shown to be increased in pulmonary artery 
endothelial cells from lung sections of mice exposed to hypoxia (Krotova et al., 
2010). Furthermore, loss of function experiments in VHLR/R HIF- 2α+/- mice 
showed delayed onset of pulmonary hypertension when compared to VHLR/R 
mice with fully competent HIF- 2 (Hickey et al., 2010). Together with the fact 
that dominant active mutations in HIF- 2α are linked with development of 
severe pulmonary hypertension (Gale et al., 2008) a potential role for the HIF 
pathway in pulmonary hypertension pathogenesis is postulated. Further 
investigation could identify potential therapeutic interventions targeting the 
HIF pathway for reduction in the development of pulmonary hypertension.  
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1.6 RATIONALE AND AIMS 
 
IPAH is a devastating disease characterised by the narrowing and occlusion of 
the pulmonary arteries leading to increase right ventricular pressure and 
eventual failure. Inflammation has been linked as a contributor to the vascular 
remodelling process which occurs in this disease however, the mechanism by 
which it contributes is unknown. Within the characteristic lesions of the 
disease, there is a predominance of innate immune cells but the relevance of 
this is still to be established. Pulmonary arterial SMCs have been shown in vivo 
to proliferate to hypoxia and plexiform lesions from IPAH patients stain positive 
for the hypoxia inducible factor HIF-1. Despite the exact oxygen tensions of 
these areas being unknown a role for hypoxia and the HIF pathway in IPAH is 
postulated.  
Therefore my hypothesis is that hypoxia induces pulmonary artery SMC 
proliferation which monocytes can inhibit in a HIF dependant manner and 
this is altered in disease.  
In order to prove my hypothesis I hope:    
 To culture SMCs in normoxia (19 kPa) and hypoxia (3 kPa) and measure 
SMC proliferation 
 To use a co-culture model to investigate monocyte and SMC interactions 
both in normoxia (19 kPa) and hypoxia (3 kPa) and discover if 
monocytes can regulate SMC proliferation 
 If monocytes have a role in SMC proliferation regulation, identify if this is 
dependant on the HIF pathway 
 To ascertain if monocytes or SMCs from IPAH patients alter my observed 
phenotype. 
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2. METHODS 
 
2.1 WHITE BLOOD CELL ISOLATION AND PURIFICATION 
 
2.1.1 WHITE BLOOD CELL ISOLATION BY THE OPTIPREP™ METHOD 
 
Peripheral blood was taken from healthy volunteers or PAH patients with 
informed consent in accordance with the South Sheffield Local Research Ethics 
Committee or the Sheffield Cardiovascular Biomedical Research Unit Ethics 
respectively. Sterile technique and good lab practice was carried out throughout 
to avoid infection or activation of cells. Centrifuge spins were carried out at 
room temperature and reagents warmed to 37 °C in a pre-warmed water bath. 
Whole blood was decanted into a 50 ml conical tube (SARSTEDT AG & Co) 
containing 4.4 ml 3.8 % tri sodium citrate (Martindale Pharmaceuticals) per 50 
mls blood to prevent coagulation. The blood was spun at 1200 rpm for 20 mins 
to give two phases of upper platelet rich plasma (PRP) and lower cell rich 
phase. The upper phase was transferred to a clean 50 ml conical tube and spun 
at 2000 rpm for 20 mins leaving platelet poor plasma (PPP) supernatant and a 
hard platelet rich pellet. The supernatant was poured into a clean 50 ml conical 
tube to avoid resuspension of the platelet pellet. To the lower cell rich phase 6 
mls 6 % dextran (Sigma-Aldrich Ltd) was added and topped up to 50 mls with 
0.9 % saline (Baxter Healthcare Ltd). Gentle inversion was used to mix the tube 
and all air bubbles removed with a Pasteur pipette (Greiner bio-one).  The lid 
was loosened and erythrocytes left to sediment for 20 mins in a warm incubator 
at 37 °C after which the upper phase removed and spun at 1000 rpm for 6 mins.  
Gradients were prepared for cell separation by an adapted protocol using 
OptiPrep™ (Axis-shield, Alere), a 60 % iodixanol in water solution. OptiPrep™ 
can be used in conjunction with 80 % 1 x Hanks’ Balanced Salt Solution (Gibco, 
Life Technologies) and 20 % PPP (buffer) to make a gradient suitable for 
immune cell separation. Before making the gradient, OptiPrep™ must be shaken 
to disrupt the naturally forming density layers. The gradient is formed on a soft 
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cell pellet resuspended in 4 ml OptiPrep™ and 6 ml buffer. OptiPrep™ 1.095 % 
(8.036 ml buffer and 3 ml OptiPrep™) was carefully overlaid on the cell layer 
followed by OptiPrep™ 1.080 % (10.435 ml buffer + 3 ml OptiPrep™) and finally 
10 ml buffer. The gradients were spun at 1978 rcf for 30 mins with no brake to 
avoid disturbing the layers. Three populations of cells were observed 
(erythrocytes, polymorphonuclear cells and peripheral blood mononuclear 
cells) and the peripheral blood mononuclear cells (PBMC) isolated (Figure 2.1). 
Haemocytometer counts were then performed on the washed isolated cells.   
  
2.1.2 MONOCYTE ISOLATION BY MAGNETIC NEGATIVE SELECTION 
 
Monocytes were obtained from a mixed PBMC population isolated by 
OptiPrep™ density gradient sedimentation using negative magnetic selection 
(Figure 2.1). Macs Monocyte Isolation Kit II (Miltenyi Biotec) and magnetic 
columns (Miltenyi Biotec) were used according to the manufacturer’s 
instructions. The antibody cocktail contained anti- CD3, CD7, CD16, CD56, 
CD123 and Glycophorin A antibodies for depletion of T cell, NK cell, 
macrophage, B cell, dendritic cell, basophil and erythrocyte contaminants. 
Column buffer was made up by adding 200 µl EDTA (Gibco, Invitrogen) and 250 
µl foetal calf serum (FCS) (Autogen Bioclear, Source BioScience) to 50 ml sterile 
1 x phosphate buffered saline (PBS) (Biowhittaker, Lonza). Columns were 
washed by the addition of 9 ml column buffer and discarding flow through. 
Careful preparation was used throughout and care taken to ensure sterile 
conditions. For every 10 million PBMCs 30 µl column buffer, 10 µl FCR blocking 
agent and 10 µl biotin conjugated antibody cocktail was added.  The cell 
suspension was transferred to clean 1.5 ml microcentrifuge tube (SARSTEDT 
AG & Co) and incubated at 4 °C for 10 mins. Following incubation, 20 µl 
vortexed anti- biotin magnetic beads and 30 µl column buffer were added and 
incubated again for 15 mins at 4 °C. The cells were then spun at 1000 g for 2 
mins in a microcentrifuge to pellet cells and the supernatant discarded. The 
pellet was resuspended in 500 µl column buffer and applied to the washed 
column. Pure unlabelled monocytes were obtained by depletion of the 
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magnetically labelled unwanted cells. Haemocytometer counts were carried out 
and cells resuspended in RPMI 1640 (Gibco, Life Technologies), 10 % FCS and 1 
% penicillin G and streptomycin (P/S) (Gibco, Invitrogen) at 1 x 10⁶ /ml. 
 
2.1.3 CALCULATING MONOCYTE PURITY 
 
Monocyte purity was assessed by CD14 positivity on a FACS Calibur flow 
cytometer (Becton Dickenson, Oxford) as CD16 positive monocytes will have 
been depeted by the antibody cocktail used for monocyte isolation. Negative 
selected monocytes were resuspended at 1 x 10⁶ /ml in RPMI, 10 % FCS and 1 
% P/S. Then 0.5 x 10⁶ monocytes added into two clean 0.5 ml microcentrifuge 
tubes (SARSTEDT AG & Co). Tubes were spun at 2000 rpm for 2 mins in a 
microcentrifuge to pellet the cells. Supernatants were discarded, pellets washed 
with PBS and resuspended in either 2.5 µl phycoerythrin (PE) conjugated CD14 
(eBioscience) or 2.5 µl PE conjugated immunoglobulin G1 kappa (IgG1κ) 
isotype (eBioscience) in a total volume of 25 µl with PBS. Samples were 
incubated at 4 °C in the dark for 20 mins. After incubation, samples were spun 
again at 2000 rpm for 2 mins, supernatants discarded and pellets resuspended 
in 250 µl 1 x cell fix (BD Biosciences) and stored at 4 °C until transferred to 
FACS tubes (BD Biosciences) and run on the FACS Calibur flow cytometer. PE 
positivity was measured on the FL-2 parameter, cell size by the forward scatter 
(FSC) and granulation by the side scatter (SSC). The results were calculated 
using FlowJo 8.7.1 software (Tree Star, Inc.) (Figure 2.2). Monocyte populations 
were determined by their FSC and SSC properties. From this population, 
histograms of FL-2 intensity were generated. Using the bisector tool IgG1 peaks 
were isolated to identify negative CD14+ population. Intensities above this were 
used as readouts of purity (percentage CD14+ positive).   
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Figure 2.1. OptiPrep™ density gradients 
OptiPrep™ is a density gradient medium ideal for isolating cells and organelles. Using a 
modified protocol established from manufacturers’ instructions, peripheral blood 
mononuclear cells (PBMCs) and polymorphonuclear leukocytes (PMN) were isolated 
from whole blood. Cell pellets were resuspended in Hanks’ Balanced Salts Solution 
containing 20 % platelet poor plasma (buffer) and OptiPrep™. To make the gradient 
OptiPrep™ 1.095 % contained 8 ml buffer and 3 ml 60 % OptiPrep™ and OptiPrep™ 
1.080 % contained 10.5 ml buffer and 3 ml 60 % OptiPrep™. This was spun at 1978 rcf 
for 30 mins to obtain cell layers shown above.  
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Figure 2.2 Calculating monocyte purity 
Representative forward scatter (FSC) and side scatter (SSC) flow plots for a) mixed 
PBMC population and b) CD14 purified monocytes. To further illustrate the difference 
in cell samples representative cytospins of c) mixed PBMC population and d) CD14 
positive monocytes are shown. Purity was measured by CD14 positivity as seen on the 
above histogram compared to isotype controls. Purity values ranged from 86.7 to 97.9 
% with average purity being 89.8 % +/- 3.5 % (n=23). 
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2.2 CULTURING LEUKOCYTES IN HYPOXIA 
 
In order to confirm the effect of hypoxia on monocytes in my culture conditions, 
RPMI 1640, 10 % FCS and 1 % P/S was placed into a Ruskin InVivo₂ 400 
hypoxic workstation (Ruskin Technology Ltd, Bridgend) overnight. The gas 
settings were pre-set with 1 % oxygen (O₂) and 5 % carbon dioxide (CO₂) and 
the pO₂, pCO₂ and pH measured by an NPT7 automated blood gas analyser 
(Radiometer Copenhagen) (n=4) (Figure 2.3). 
Isolated monocytes were spun at 1500 rpm and supernatants discarded. Pellets 
were taken into the hypoxic chamber and resuspended in pre-equilibrated 
media at 0.1 x 10⁶ monocytes /ml. Cells were plated out and 250,000 cells 
/condition were left to equilibrate for 1 hour then incubated with and without 
10 ng /ml LPS (Alexis Corporation, Enzo Life Sciences) for 4 and 20 hours. 
Normoxic conditions were carried out in parallel using a room air 37 °C 
incubator supplemented with 5 % CO₂.  
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Figure 2.3 Culturing cells in hypoxia 
Mean partial pressure and pH readings from a) hypoxic pre-equilibrated media n=4 
and b) normoxic media n=4. Graph to show partial pressures of oxygen and carbon 
dioxide in both normoxic (19 kPa) (open bars) media and hypoxic (3 kPa) (closed bars) 
media. Bars represent mean +/- SEM, n=4. 
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2.3 PRIMARY CELL CULTURE 
 
2.3.1 GROWING PRIMARY HUMAN PULMONARY ARTERY SMOOTH MUSCLE CELLS 
 
Cryopreserved primary human pulmonary artery SMCs were purchased at 
passage three from Cascade Biologics now Life Technologies (catalogue 
number: C-009-5C). Each vial contains more than 500,000 viable cells isolated 
from the medial portion of healthy pulmonary arteries from unused donor 
lungs. Each section of the artery was confirmed to have no vasculopathies by a 
pathologist before cells were harvested. All reagents were warmed to 37 °C in a 
pre- warmed water bath and sterile technique used throughout in a laminar air 
flow culture hood. The cells were maintained according to the manufacturer’s 
recommendations using basal Medium 231 (Gibco, Life Technologies), growth 
serum (catalogue number: S00725, Gibco, Life Technologies) and P/S. The 
growth serum contains basic fibroblast growth factor, insulin, epidermal 
growth factor, heparin, FCS and bovine serum albumin optimal for SMC growth. 
Each vial was used from passage 4 – 9 and each flask grown to 90 % confluence.  
Vials were removed from nitrogen storage and left to defrost in a water bath for 
30 secs. Once thawed the cells were immediately agitated using a sterile 1 ml 
pipette tip. Dye exclusion was used to check cell viability. Trypan blue (Sigma-
Aldrich Ltd) was used at a 1:10 ratio of trypan blue to cell suspension in media. 
The dye does not enter healthy cells but can enter dead and dying cells. The dye 
allows visualisation of blue dead and clear live cells under a light microscope.  
Viable cells were counted by haemocytometer and diluted to 1.25 x 10⁴ cells 
/ml in supplemented media. The cells were then seeded in 25 cm² flasks 
(SARSTEDT AG & Co.) at approximately 6.25 x 10⁴ and gently rocked to ensure 
even distribution of cells. Each flask was then incubated undisturbed for at least 
24 hours in 37 °C cell culture incubators conditioned with 5 % CO₂ and 95 % 
air. 
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2.3.2 GROWING IPAH PATIENT PULMONARY ARTERY SMOOTH MUSCLE CELLS 
 
Explant lung tissue was obtained from patients with confirmed IPAH diagnosis 
in accordance with Papworth Tissue Bank Ethics REC 08/H0304/56. SMCs were 
isolated from the medial portion of pulmonary arteries by micro-dissection. 
Following isolation, all samples were genotyped to identify BMPR2 or ALK1 
mutations. The vial of pulmonary artery SMCs corresponding to patient 74mps 
was a kind gift from Professor Nicholas Morrell, Cambridge University. The vial 
contained cells with a known mutation in BMPR2, the leucine at residue 401 
being replaced with a serine.  
The cells were grown as described above and maintained using DMEM (Gibco, 
Life Technologies) containing 10 % FCS and 1 % P/S. The vial was used from 
passage 4 – 9 and each flask grown to 90 % confluence at which time cells were 
either maintained in 75 cm² flasks at 0.8 x 10⁵ cell /ml or used in experiments. 
Flasks were incubated at 37 °C in incubators conditioned with 5 % CO₂ and 
room air. 
 
2.3.3 GROWING PRIMARY HUMAN AORTIC VASCULAR SMOOTH MUSCLE CELLS 
 
Cyropreserved human aortic vascular SMCs were obtained from Cambrex 
Bioscience at passage 4. The vial contained approx. 450,000 viable cells from a 
single donor. Before growing up the vial all reagents were left to warm to 37 °C 
in a heated water bath and sterile technique used throughout. Cells were 
maintained in Medium 231 containing SMC growth serum and P/S as above 
(2.3.1).  Cells were only used to passage 9 and each culture flask split once cells 
reached 90 % confluence.  
The vial was left to thaw in a water bath heated to 37 °C before manual agitation 
using a sterile 1 ml pipette tip. Trypan blue (Sigma-Aldrich Ltd) exclusion was 
used as above to calculate viable cell numbers and haemocytometer counts 
performed. Cells were diluted to 1.25 x 10⁴ cells /ml and seeded in 25 cm² 
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flasks with approximately 6.25 x 10⁴ cells /flask as above. Flasks were 
incubated undisturbed for 24 hours in 37 °C cell culture incubators conditioned 
with 5 % CO₂ and 95 % air before experimental use. 
 
2.3.4 MAINTAINING AND SUB CULTURING PRIMARY CELLS 
 
Primary cells were grown and maintained in 75 cm² flasks in Medium 231 
containing SMC growth serum and 1 % P/S or DMEM with 10 % FCS and 1 % 
P/S. Once cells were grown to approximately 90 % confluence, they were 
washed with Dulbecco’s PBS (Gibco, Invitrogen). Flasks were then incubated 
with 1 ml 0.25 % Trypsin /EDTA solution (Gibco, Invitrogen) /flask for 2 mins 
in 37 °C incubator. Fully supplemented media was used to stop the reaction (5 
ml /flask) and cell number determined by manual haemocytometer counts. 
Cells were then seeded in 75 cm² flasks at 0.8 x 10⁵ cell /ml or used in 
experiments. Flasks were incubated at 37 °C, sterile technique was used 
throughout. 
 
2.3.5 FREEZING DOWN CELLS  
 
Cryopreservation medium was made with basal medium DMEM containing 10 
% FCS and 10 % DMSO (Sigma-Aldrich Ltd). A manual cooling chamber (Mr. 
Frosty, Sigma-Aldrich Ltd) was filled with 200 ml clean isopropanol (Fisher 
Scientific) and vial holder placed on top. Cell suspensions were made by lifting 
adherent cells using 0.25 % trypsin /EDTA solution. Cell number was 
determined by haemocytometer counts and cells spun at 100 g for 5 minutes. 
Cells were resuspended at 1 x 106 /ml in cryopreservation medium and 1 ml 
placed in each 1.5 ml cryovial (SARSTEDT AG & Co.). Vials were left in a Mr. 
Frosty vial holder and lid tightened. Each Mr. Frosty was placed in -80 oC 
freezer overnight to cool -1 oC / min allowing dehydration before freezing 
before all vials were transferred to liquid nitrogen.  
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2.4 GROWING SMOOTH MUSCLE CELLS IN NORMOXIA AND HYPOXIA 
 
Prior to establishing PA-SMC and monocyte co-cultures, cell viability and 
number was defined in both hypoxic monoculture (3 kPa) and normoxic 
monoculture (19 kPa). Cell viability was measured by reduction of cell 
permeable alamarBlue® (Invitrogen), an indicator of metabolic activity (2.4.2). 
A Coulter counter (Z-1 series, Beckman Coulter Ltd.) was used to calculate total 
cell numbers (2.4.1).  
To determine the optimal seeding densities for co-culture experiments, 
pulmonary artery SMCs were seeded in 24 well Costar plates (Corning 
Incorporated) at 10,000 to 35,000 cells /well at 5,000 cell increments. Plates 
were then cultured for 24, 48 and 72 hours. After seeding, plates were left to 
equilibrate in either normoxia (19 kPa) or hypoxia (3 kPa) for 24 hours. All 
hypoxic experiments and incubations were carried out in a Ruskin InVivo₂ 400 
hypoxic workstation pre-set to supply 1 % O₂ and 5 % CO₂ and sterile technique 
used throughout. All hypoxic media was left to pre-equilibrate for at least 24 
hours prior to experimental use. All normoxic experiments were carried out in a 
laminar air flow culture hood. Normoxic incubations were carried out at 37 °C 
in incubators supplemented with 5 % CO₂ and 95 % air. 
After 24 hours of equilibration in each oxygen tension, plates were then serum 
starved in DMEM containing 0.2 % FCS and 1 % P/S for 48 hours. Plates were 
then washed in PBS and replaced with 500 µl RPMI with 10 % FCS and 1 % P/S 
for either 24, 48 or 72 hours.  
 
2.4.1 TOTAL CELL COUNTS IN SMOOTH MUSCLE CELL MONOCULTURES 
 
Total SMC number /well was calculated by use of a Coulter counter; each well 
was washed with PBS and cells lifted by incubation with 500 µl non enzymatic 
cell dissociation solution (Gibco, Invitrogen) for 5 mins to allow cell 
detachment. Detachment was confirmed visually under the microscope and the 
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lifted solution was added to 9.5 ml Isoton (BD Biosciences), an electrolyte 
solution, in a cell counter chamber (Becton Dickinson, Oxford). The counter 
works using the Coulter principle allowing small molecule number and size to 
be determined in a solution by electrolyte flux. Micro channels pass a small 
aliquot of the cell suspension through two charged chambers. Cells are non-
conducting causing a temporary drop in current, the size of the change is 
proportional to the size of the particle. The machine detects the changes in 
electrolyte flux indicating presence of non- conducting particles. Settings were 
altered to measure all items between 0.5 to 10 µm. The number of particles 
diluted in the Isoton are expressed on the machine and manually recorded. 
Total cell counts from each sample are then calculated and the mean for each 
used to establish the period of time and seeding density used for co-culture 
(Figure 2.4).  
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Figure 2.4 Growing pulmonary arterial smooth muscle cells in normoxia 
and hypoxia  
To establish the best baseline for our co-culture experiments, SMCs were seeded 
between 10,000 and 35,000 cells /well in 24 well plates. Cells were incubated in pre-
equilibrated RPMI containing 10 % FCS and 1 % P/S for a) 24, b) 48 and c) 72 hours in 
normoxia (19 kPa) (open bars) or hypoxia (3 kPa) (closed bars). Coulter counts were 
then performed and bars represent mean +/- SEM, *P<0.05, cells from 2 seperate vials 
studied n=8, two-way ANOVA with Bonferonni post test.  
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2.4.2 RELATIVE METABOLIC ACTIVITY IN SMOOTH MUSCLE CELL MONOCULTURES  
 
AlamarBlue® (Invitrogen) has a low redox potential allowing its non fluorescent 
blue compound called Resazurin to be readily reduced to its fluorescent red 
counterpart called Resorufin without disturbing respiration in living cells.  
Reduction of the dye is mediated by oxidative respiration so was used to show 
relative metabolic activity of SMCs thus indirectly showing viability. 
Cycloheximide (Sigma-Aldrich Ltd.) at a final concentration of 1 ng/ ml was 
used as a positive control. Cycloheximide is a protein synthesis inhibitor and 
acts specifically on the 60S subunit of ribosomes. SMCs were grown in 24 well 
Costar plates, left to oxygen equilibrate for 24 hours and serum starved for a 
further 48 hours in basal DMEM containing 0.2 % FCS and 1 % P/S. After 20 
hour culture in RPMI containing 10 % FCS and 1 % P/S wells were washed and 
replaced with fresh media. Each well was incubated for 4 hours with 50 µl 
alamarBlue® and positive controls with cycloheximide then cell free 
supernatants analysed in triplicate on 96 well Costar plates (Corning 
Incorporated) by flourecence plate reader set to excitation limit 544 nm and 
emission limit 590 nm. For each sample a fluorescence ratio (sample 
flourecence: cycloheximide killed sample fluorescence) was calculated: 
       
             Fluorescence ratio =                        χ fluorescence   
                                                                     killed χ fluorescence   
                                                                                       
         
Triplicate flourescnece ratios were averaged to give mean fluorescence ratios, 
also expressed as relative metabolic activity (Figure 2.5). Mean relative 
metabolic activity values were then normalised for cell number and used to 
determine the effects of oxygen tension on metabolic activity (Figure 2.6). 
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Figure 2.5 Calculating metabolic activity of normoxic and hypoxic smooth 
muscle cells 
To measure changes in metabolic activity SMCs were seeded from 10,000 to 35,000 
cells /well in 24 well plates. Cells were cultured in pre-equilibrated RPMI containing 10 
% FCS and 1 % P/S in normoxia (19 kPa) (open bars) or hypoxia (3 kPa) (closed bars) 
for a) 24, b) 48 and c) 72 hours. AlamarBlue® was added in the last 4 hours of culture 
with and without 1 µg/ ml cycloheximide. Graphs show relative metabolic activity 
when compared to matched cycloheximide killed controls. Bars represent mean +/- 
SEM, **P<0.01, ***P<0.001, cells from 2 seperate vials studied n=8, two-way ANOVA 
with Bonferonni post test. Please note scales bars for graph a) and b) are different from 
graph c).  
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Figure 2.6 Relative metabolic activity corrected for smooth muscle cell 
number 
Metabolic activity was measured at each SMC density from 10,000 to 35,000 cells /well 
in 24 well plates. Cells were cultured in pre-equilibrated RPMI containing 10 % FCS 
and 1 % P/S in normoxia (19 kPa) (open bars) or hypoxia (3 kPa) (closed bars) for a) 
24, b) 48 and c) 72 hours. AlamarBlue® was added in the last 4 hours of culture with 
and without 1 µg /ml cycloheximide and cell counts performed. Graphs show relative 
metabolic activity normalised to total cell number at each density. Bars represent mean 
+/- SEM, cells from 2 seperate vials studied n=8.  Please note scales for graph a) and b) 
are different from graph c). 
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2.5 CO-CULTURE MODELS 
 
A seeding density of 25,000 SMCs /well and an incubation period of 24 hours 
was selected because SMC metabolic activity was preserved and monocyte 
survival was unaffected over this time. Moreover, 24 hours allowed us to 
directly compare our co-culture system to the established model used in 
Professor Sabroe’s laboratory (Morris et al.) (Figure 2.7).  
To set up co-cultures of SMC and monocytes, 24 well Costar plates were seeded 
at 25,000 cells /well in an overall volume of 500 µl with SMC between passage 4 
and 9. All hypoxic media was allowed to equilibrate in hypoxia at least 24 hours 
prior to use and sterile technique used throughout. Plates were equilibrated in 
normoxia and hypoxia for 24 hours and serum starved for a further 48 hours in 
DMEM, 0.2 % FCS and 1 % P/S. Plates were washed in PBS and then fresh RPMI 
with 10 % FCS and 1 % P/S was added to each well with and without freshly 
isolated monocytes at a ratio of 1:5 monocytes to SMC (Figure 2.7). Monocytes 
were added either directly into wells or into transwell inserts (0.2 µm pore 
size) (Corning Incorporated) in an overall volume of 500 µl. At this point cells 
were stimulated with either 10 ng /ml LPS; 5 ng /ml or 10 ng /ml recombinant 
PDGF (Sigma-Aldrich Ltd.); 1 µM, 10 µM, 100 µM or 1 mM pan hydroxylase 
inhibitor DMOG (Sigma-Aldrich Ltd.); 0.75 ng /ml, 1.5 ng /ml, 3 ng /ml, 6 ng 
/ml, 12.5 ng /ml 25 ng /ml or 50 ng /ml IL- 1 receptor antagonist (Amgen Ltd.); 
3 ng /ml or 50 ng /ml IL-1 receptor antagonist placebo (Amgen Ltd.); 1 mM, 10 
mM, 100 mM or 1 M vitamin E analogue Trolox (Calbiochem, Merek Millipore). 
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Figure 2.7 Flow diagram illustrating co-culture model set up  
SMCs from passage 4-9 were grown in Medium 213 with full growth supplement and 
P/S in T75 cm2 flasks until 90 % confluence. Flasks were then washed with PBS, 
incubated with 0.25 % Trypsin/ EDTA and total cell number calculated by 
haemocytometer. Plates were seeded with 25,000 SMC /well. After 24 hour oxygen 
equilibration in either normoxia (19 kPa) or hypoxia (3 kPa) and serum starvation, 
purified monocytes were obtained from peripheral blood and added to each well at 
1000 monocytes /well. After 24 hour incubation, total cell countes were performed, 
relative metabolic activity calculated and cell free supernatants were obtained and 
stored at -80 oC for analysis by ELISA. 
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2.5.1. SUPERNATANT TRANSFER EXPERIMENTS 
 
Monocytes were cultured in normoxia (19 kPa) or hypoxia (3 kPa) in 24 well 
plates for 24 hours. Monocytes were cultured at 0.1 x 10⁶ cells /ml in pre- 
equilibrated RPMI containing 10 % FCS and 1 % P/S. All subsequent steps were 
carried out in sterile laminar flow hoods (normoxia) or Ruskin InVivo₂ 400 
chamber (hypoxia). Upon removal from sterile areas all tubes were kept on ice.  
Cell-free supernatants were collected by transferring media from monocyte 
wells into sterile 1.5 ml microcentrifuge tubes and spinning tubes at 2000 rpm 
for 2 mins in a microcentrifuge. Supernatants were then transferred to clean 1.5 
ml microcentrifuge tubes and stored at -80 °C until needed. Before use, 
supernatants were thawed on ice. SMCs were grown as above, seeded at 25,000 
cells /well in 24 well plates and left to equilibrate in normoxia (19 kPa) and 
hypoxia (3 kPa) for 24 hours. Following 48 hour serum starvation, cells were 
washed with PBS and wells replaced with either 500 µl pre- equilibrated RPMI 
containing 10 % FCS and 1 % P/S or 500 µl normoxic or hypoxic cell-free 
supernatant. Plates were incubated for a further 24 hours prior to total cell 
counts being performed.  
 
2.6 STAINING PROTOCOLS  
 
2.6.1 IMMUNOCYTOCHEMISTRY  
 
To ensure SMCs were maintaining their phenotype over our culture period and 
in each oxygen tension, SMCs were stained for beta- smooth muscle cell actin 
using the VECTASTAIN Elite ABC kit and DAB substrate kit (Vector Laboratories 
Ltd.). The VECTOR kits are used to amplify primary antibody signal by binding 
of biotinylated secondary antibody and subsequent binding of avidin 
/biotinylated enzyme complexes. Protocol dictates to be diluted in equal 
measure both avidin and biotinylated peroxidase which are left for 30 mins to 
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make complexes. After incubation and washing 3, 3’-diaminobenzidine (DAB) 
substrate was added where it was oxidised to give a brown colour.   
SMCs were grown in 4 well chamber slides (Lab-Tek, Thermo Scientific) at 0.2 x 
106 cells /chamber under the same conditions as 24 well Costar plates. After 
incubation the slides were washed in PBS and fixed with 1 % paraformaldehyde 
(Sigma-Aldrich Ltd.) on ice for 10 mins. Immediately following this slides were 
stained for beta- smooth muscle cell actin (AbCam ab5694), CD31 (AbCam 
ab24590) and Von Willebrand factor (AbCam ab6994). Desired SMC 
populations were positive for beta- smooth muscle cell actin but negative for 
the endothelial and differentiation markers CD31 and Von Willebrand factor. 
Chambers were removed and slides labelled in pencil then protocol was carried 
out as advised in data sheet. A 1 % solution of Marvel (Premier International 
Foods (UK) Ltd) in PBS was used to block and make up antibody solutions. Non- 
sterile PBS was used for all wash steps. Endogenous peroxidase activity was 
quenched by incubation in 1 % hydrogen peroxide solution (Fisher Scientific) in 
water for 30 mins at room temp before blocking. All other incubation steps 
were carried out in a humidified chamber for 1 hour. Primary antibodies were 
used at 1:200 dilution and secondary antibodies at 1:1000. After staining with 
DAB, slides were counterstained with nuclear dye haematoxylin (Reagena Oy 
Ltd) and fixed with coverslips (Thermo Scientific) using DPX (Fisher Scientific).  
 
2.7 APOPTOSIS ASSAYS 
 
2.7.1 DETERMINING CELL DEATH BY MORPHOLOGY 
 
Cells undergoing apoptosis have many distinct characteristics including cell 
shrinkage, membrane blebbing and chromatin condensation which can be 
observed morphologically. Monocytes and PBMC were lifted by gentle agitation 
and transferred to a clean 1.5 ml microcentrifuge tube. Samples were then spun 
at 2000 rpm for 2 mins in a microcentrifuge and the supernatants discarded. 
The pellets were resuspended in 100 µl RPMI and applied to a cytospin funnel 
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clamped to a slide and blotting paper (Thermo Scientific). The slides were spun 
at 3000 rpm for 3 mins in a cytospin machine (Thermo Shandon Cytospin 3) 
and clamps dismantled allowing slides to air dry. Once dried, slides were fixed 
by ice cold methanol (VWR International Ltd.). Fixed slides were then dual 
stained with the acidic cytoplasmic dye eosin (Reagena Oy Ltd.) and basic 
nuclear stain haematoxylin before covering with coverslips using the xylene 
containing fixative DPX. Ultraviolet (UV) killed PBMC and monocytes were used 
as positive controls. These were incubated under a UV cross linker (Hoefer 
Scientific Instruments) for 10 mins at 10 kJ prior to culturing. Apoptosis was 
calculated as a percentage by morphological change:  
 
                Number apoptotic cells    x   100 =   % Apoptotic cells 
                           Total cells  
 
 
2.7.2 QUANTIFYING CELL SURVIVAL BY FLOW CYTOMETRY  
 
To verify the obsevered survival phenotype of monocytes and PBMC, these cells 
were stained with the fluorescent necrosis indicator dye TO-PRO-3 iodide 
(Molecular Probes, Life technologies) and fluorescently conjugated annexin V 
(BD Pharmagen) and observed by flow cytometry. TO-PRO-3 is a very effective 
indicator of membrane integrity; as such it is used in a 1: 10000 dilution in 1 x 
annexin binding buffer (BD Pharmagen) to denote necrotic cells. Annexin binds 
negatively charged phosphotidyl serine which is externalised upon activation of 
apoptosis pathway. For use on flow cytometry, phycoerythrin (PE) conjugated 
annexin was used. Positive controls were made either by pre-incubating cells 
for 10 mins under a 10 kJ UV cross-linker or co-incubation with 100 ng /ml 
cycloheximide 1 hour prior to lifting cells.  
Monocytes and PBMCs were lifted by gentle agitation and transferred to a clean 
1.5 ml microcentrifuge tube, these were then spun at 2000 rpm for 2 mins in a 
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microcentrifuge and washed with ice cold PBS. Cell pellets were resuspended in 
50 µl 1 x annexin binding buffer and 2.5 µl annexin-PE added to relevant 
samples. These were then incubated in the dark for 10 mins on ice before 
addition of 250 µl TO-PRO-3 or 250 µl PBS. Before reading on the FACS Calibur 
flow cytometer, samples were transferred to clean labelled FACS tubes (Figure 
2.8).  FlowJo 8.7.1 software was used to analyse data from the FACS Calibur.  
PBMC populations were isolated according to size and granulation and then 
gated into four quadrants. This separation was then superimposed onto all 
samples and each quadrant analysed. Quadrant a showed a necrotic population 
(TO-PRO-3 positive only), quadrant b signifies late apoptotic and early necrotic 
population (TO-PRO-3 and annexin positive), quadrant d represents apoptotic 
populations (annexin positive only) and quadrant c is the viable population 
(annexin and TO-PRO-3 negative) (Figure 2.8). Results are expressed as the 
percentage necrotic and apoptotic cells. This was calculated by: 
 
 % Necrosis =   (Counts FL-2 –ve/ FL-4 +ve) x 100  
                                         Total event count 
 
 
% Apoptosis = (Counts FL-2 +ve/FL-4 –ve) + (Counts FL-2 +ve/FL-4 +ve) x 100 
                                                                  Total event count 
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Figure 2.8 Calculating PBMC survival by flow cytometry  
PBMCs were isolated and cultured in normoxia (19 kPa) (open bars) or hypoxia (3 kPa) 
(closed bars) for 24 hours with and without cycloheximide (1 µg /ml).  Cells were 
labelled with both the apoptosis label annexin and the necrosis indicator TO-PRO-3. 
Samples were then run on FACS Calibur to allow for analysis by FlowJo 8.7.1. software. 
The PBMC populations were identified by size and granulation. This was then gated 
into four quadrants and superimposed to all samples. Quadrant a is necrotic 
population, quadrant b signifies late apoptotic and early necrotic population, quadrant 
d represents apoptotic populations and quadrant c is the viable population. Graphs 
represent mean +/- SEM, **P<0.01, ns= not significant, n=8, two-way ANOVA with 
Bonferonni post test. 
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2.7.3 ASSAYING APOPTOSIS BY TUNEL 
 
A TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labelling) assay 
was used to determine apoptosis in cells by labelling DNA fragmentation. The 
principle behind this assay was first described by Garvrieli et al. (Garvrieli, 
1992). When cells undergo programmed cell death the genome becomes 
fragmented. In order to detect nuclear DNA fragmentation cells need to be 
permeabilised. Following this, both the enzyme terminal deoxynucleotidyl 
transferase and fluorescein conjugated dUTPs are added in excess to catalyse 
the reaction between the nick ends of fragmented DNA and the labelled dUTPs 
allowing direct detection of apoptotic cells by fluorescent microscopy.  
TUNEL kits were purchased (Millipore, Merck Millipore) and SMCs and 
monocytes were analysed as described by the manufacturer’s protocols. SMCs 
were cultured with or without monocytes in transwell inserts as described 
above. Cycloheximide (100 µM) killed cells were used as positive controls and 
all samples carried out in duplicate. Washes were carried out between each step 
using PBS for 5 mins on a plate rocker and repeated three times. All solutions 
were added drop wise across each well to ensure even coverage and incubation 
at room temperature unless stated otherwise. After 24 hour culture in both 
normoxia and hypoxia plates were removed from their sterile environment and 
were fixed using 4 % paraformaldehyde for 10 mins on the bench. 
Paraformaldehyde was the preferred fixative as its cross linking properties are 
thought to anchor chromatin in the cells. The fixative was then replaced with 
PBS, at this point plates were either stored at 4 °C or rest of staining protocol 
carried out.  
In order to permealize the cells a mix of ethanol and acetic acid (2:1) was used 
for 5 mins at -20 °C.  To optimise the sample pH levels, 13 µl equilibration buffer 
was added to each well for 10 secs. All excess was removed by pipette and cells 
incubated with 11 µl working strength TdT enzyme and reaction buffer mix 
containing digoxigenin labelled deoxynucleotides for 1 hour. The reaction was 
stopped by addition of 100 µl working strength stop wash buffer /well for 10 
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secs. Each well was then fluorescently labelled by addition of 8 µl anti-
digoxigenin fluorescein isothiocynate (FITC) conjugate for 30 mins in the dark.  
Samples were counterstained with cell permeable fluorescent DNA label 4’6-
diamino-2-phenylindole (DAPI) (Gibco, Life Technologies) and examined under 
a fluorescent microscope. Approximately 300 total cells were counted from 3 
different fields. The blue channel was counted first for DAPI positive cells then 
the FITC/ TUNEL positive green channel. Images were taken of each and then 
overlaid for dual fluorescent counts. Results were expressed as percentage 
TUNEL positive from total cell counts.  
 
2.8 ELISA ANALYSIS 
 
Cell free supernatants were prepared by centrifugation (2000 rpm, 2mins) 
following 24 hour culture and stored at -80 oC. For all samples cytokine 
generation was determined by DuoSet® sandwich enzyme-linked 
immunosorbent assay (ELISA) (DuoSet®, R&D Systems Inc.), the following 
factors were analysed:  
IL- 1β, IL- 1 receptor antagonist (IL-1ra), interleukin-8 (IL-8), interleukin-6 (IL-
6), interleukin-10 (IL-10), interferon- gamma (IFN-γ) and Regulated upon 
Activation, Normal T-cell Expressed and Secreted (RANTES), BMP4, OPG, 
endothelin-1, VEGF and soluble VEGF receptor (sFlt-1). 
The method was carried out according to the manufacturer’s specifications 
using 96-well Costar plates (Corning Incorporated) and standards diluted to 
recommendations in protocol (appendix I). Blocking was carried out using 5 % 
bovine serum albumin (BSA) (Sigma-Aldrich Ltd) in PBS while all washes and 
antibody dilutions using PBS and 0.05 % Tween-20 (Fisher Scientific). Plates 
were washed between each step until addition of colour substrate. To prevent 
desiccation, plates were wrapped in cling film until addition of streptavidin- 
horse radish peroxidase (HRP) (R&D Systems Inc.) where foil was used to avoid 
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cleavage of the light sensitive HRP conjugate. 100µl solution was added / well 
unless otherwise stated. 
Coating antibodies were added to plates and left overnight at room temperature 
on the bench before plates were blocked for 1 hour. After blocking, standards 
and samples were each applied in duplicate and plates incubated for 1 ½ hours 
on a rotating platform. Samples were diluted appropriately to fit within linear 
portions of a log (concentration) / linear (optical density) standard curve as 
recommended. Biotinylated antibodies were then applied to plates to be 
incubated for 1 ½ hours on a rotating platform and subsequent addition of 1:20 
HRP for 20 mins in the dark on a rotator. A 1:1 ratio of hydrogen peroxide and 
tetramethylbenzidine (R&D Systems Inc.) was then mixed and added to the 
plate. This solution undergoes a colour change when it interacts with 
peroxidase on the plate. The reaction was stopped by the addition of 50 µl 1 M 
sulphuric acid (Fisher Scientific), turning the solution yellow which was then 
analysed on a 96 well plate reader by reading absorbance at 450 nm. Values 
were calculated from linear values of standard curves (Figure 2.9).  
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Figure 2.9 ELISA standard curves  
Representative standard curves created for ELISA analysis of a) IL-8, b) IL-6, c) IL-1 β, 
d) RANTES, e) VEGF and f) VEGFR1 as calculated by transformation of standard 
concentrations by x = log (x). 
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2.9 RNA ANALYSIS 
 
2.9.1 RNA PRODUCTION 
 
TRI reagent is a commercially available solution used for RNA isolation. 
Guanidinium thiocynate- phenol- chloroform isolation was used as previously 
described (Chomcynski, 1987). Cells were spun in 1.5 ml microcentrifuge tubes 
and lysed using 1 ml TRI Reagent (Sigma-Aldrich Ltd.). TRI Reagent is a 
guanidinium thiocynate and phenol denaturing solution which is used with 
chloroform to produce three separate phases of organic protein, DNA and RNA 
according to the manufacturer’s protocol.  
 
2.9.2 RNA ISOLATION 
 
SMCs and monocytes were lifted, transferred to 1.5 ml microcentrifuge tubes 
and spun at 2000 rpm for 2 mins. Supernatants were discarded and for every 10 
million monocytes or 35,000 SMCs, 1 ml of TRI Reagent was added. Throughout 
all RNA preparations RNase and DNase free pipette tips (ART, Sigma-Aldrich 
Ltd.), water and microcentrifuge tubes were used and all surfaces and 
equipment carefully cleaned with 10 % IMS to reduce RNase or DNase 
contamination. Pellets were dislodged by vigorous pippetting and then inverted 
to mix. At this point samples could be stored at -80 °C or progressed to RNA 
isolation. 
To each microcentrifuge tube 200 μl chloroform (VWR International) was 
added, mixed by inversion and left to settle at room temperature for 5 mins. 
Water saturated phenol is insoluble in chloroform leading to separation into 2 
phases. Samples were spun at 14,000 rcf for 15 mins at 4 °C giving an upper 
clear aqueous phase, a white precipitate and a lower pink aqueous phase. The 
upper clear phase contains soluble RNA, a DNA precipitate in the inter-phase 
and the lower pink organic phase with dissolved lipids. The aqueous clear layer 
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was transferred to a clean labelled 1.5 ml microcentrifuge tube and the 
remainder discarded in the fume hood. Aqueous RNA was left to form a 
precipitate by the addition of 500 µl sterile isopropanol (Fisher Scientific) to 
each tube. Samples were inverted to mix and then incubated at room 
temperature for 10 mins before spinning at 14000 rcf for 8 mins at 4 °C. Small 
RNA pellets were purified by carefully removing supernatants and addition of 1 
ml 75 % ethanol without mixing. Tubes were spun at 9000 rcf for 5 mins at 4 °C 
and supernatants carefully removed. Air dried pellets were then resuspended in 
10 µl RNase-free water (B. Braun, Melsungen) before quantifying on a ND-1000 
spectrophotometer (Nanodrop, Thermo Scientific).  
 
2.9.3 RNA PURIFICATION BY DNA DIGESTION 
 
DNA contamination was removed by treatment with DNase I enzyme (Ambion, 
Invitrogen). Throughout RNase and DNase free pipette tips, water and 
microcentrifuge tubes were used and all surfaces and equipment carefully 
cleaned with 10 % IMS. Each sample was diluted with RNase-free water to give 
an overall concentration of 200 ng /µl nucleic acid and for every 200 ng /µl 
nucleic acid, 1 µl 1 x DNase I buffer was added. To each microcentrifuge tube 1 
µl DNase I enzyme was added and samples mixed by gently shaking on a vortex. 
Samples were subsequently incubated for 30 mins at 37 °C prior to removal of 
divalent cations and inactivation of the DNase enzyme by addition of 2 µl DNase 
Inactivation reagent at a 1: 10 dilution. In order to pellet the inactivation beads, 
tubes were spun at 10,000 rcf for 90 secs at 4 °C. Without disturbing the beads, 
tubes were taken to a ND-1000 spectrophotometer to quantify RNA suspended 
in the supernatant. Samples were then stored at -80 °C or converted to cDNA 
immediately. 
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2.9.4 CDNA SYNTHESIS BY PROMEGA AMV-REVERSE TRANSCRIPTASE 
 
Avian myeloblastosis virus (AMV) reverse transcriptase transcribes single 
stranded RNA to single stranded complementary DNA sequence (cDNA). This 
property was manipulated to obtain stable cDNA sequences from instable RNA 
solutions. All reagents used were purchased from Promega and thawed on ice 
prior to use. 
Aliquots of 1 µg RNA were made up to 12.4 µl with RNase free water in clean 
labelled 0.5 ml microcentrifuge tubes. To each 1 µg RNA: 8 µl 5 x AMV buffer 
containing 50mM Tris-HCl (pH 8.3), 40mM KCl, 8.75mM MgCl2, 10mM DTT and 
0.1 mg/ml acetylated BSA; 1.6 µl 100 mM deoxycytosine triphosphate (dCTP); 
1.6 µl 100 mM deoxythymidine triphosphate (dTTP); 1.6 µl 100 mM 
deoxyadenosine triphosphate (dATP); 1.6 µl 100 mM deoxyguanine 
triphosphate (dGTP); 1.2 µl recombinant ribonuclease inhibitor (RNasin); 1.2 µl 
random primers; 1.2 µl AMV- reverse transcriptase and  9.6 µl RNase and DNase 
free water was added.  Samples were vortexed to mix, centrifuged at 2000 rpm 
for 2 mins in a microcentrifuge and then run on a thermal cycler with heated lid 
(GS1, G-Storm). Samples were run at 23 °C for 5 mins, 42 °C for 2 hours and 
heated to 99 °C to deactivate the enzyme before cooling to 4 °C until manually 
stopped. Samples were then stored at -20 °C until needed. 
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2.9.5 MEASURING RNA QUANTITY AND INTEGRITY BY NANODROP ND-1000 
SPECTROPHOTOMETER 
 
Quantification of RNA solutions was needed to establish protocols for DNase 
treatment and generation of cDNA. Samples were kept on ice and taken to a 
Nanodrop ND-1000 spectrophotometer. The machine measures 1 µl aliquots of 
samples using surface tension to hold the sample in place. It reads between 220 
and 750 nm so can be used to measure both concentration and integrity of 
nucleic acids. 
The sampler was cleaned with alcohol wipes (AZO wipes, Cravenmount Ltd.) 
and Nanodrop software opened on the computer. To initiate the programme 1 
µl of RNase-free water was loaded onto the pedestal. After each reading the 
pedestal was wiped with clean laboratory tissue. Blank measurements were 
made using 1 µl RNase free water and RNase free tips (ART, Sigma-Aldrich Ltd.) 
used throughout. Each reading measured DNA contamination using 260:280 nm 
ratios, chemical contamination using 260:230 nm ratios and concentration as 
ng /µl.  
 
2.10 PCR AMPLIFICATION PROTOCOL 
 
Polymerase chain reaction (PCR) is a technique for amplifying DNA using Taq 
DNA polymerase to amplify samples. Specific primers can be used to amplify a 
gene of interest or random hexamer primers to amplify all DNA. Samples are fed 
through a cycle of temperatures; 95 °C to denature cDNA complexes to single 
stranded structures, 40-60 °C to allow annealing of primers to the DNA, 72 °C 
the optimum temperature for the Taq DNA polymerase to work and then cooled 
to 4 °C to stop the reaction. The PCR products can then be run on agarose 
electrophoresis gels for visualisation. All samples and reagents were incubated 
on ice when not used. RNase and DNase free tips, microcentrifuge tubes and 
water were used throughout. All PCR reagents were purchased from Promega 
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unless stated otherwise. Each reagent was vortexed thoroughly and spun in a 
microcentrifuge at 2000 rpm for 2 mins prior to use. All primers were created 
by request from Eurogentec.   
 
2.10.1 PCR AMPLIFICATION AND VISUALISATION 
 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is an ubiquitiously 
enzyme which catalyses the convertion of glyceraldehydes-3-phosphate to D-
glycerate 1,3-bisphosphate in glycolysis. Integrity of cDNA was established by 
polymerase chain reaction (PCR) using primers for GAPDH (Figure 2.10). Also, 
in order to optimise the protocol for siRNA transfection of SMCs, cyclophilin B 
siRNA was used. Transfection efficiency was determined by PCR using primers 
to cyclophilin B compared to GAPDH loading controls. The primer sequences for 
GAPDH and cyclophilin B were: 
 
GAPDH forward primer: 5’- ACTTTGGTATCGTGGAAGGAC- 3’,  
GAPDH reverse primer: 5’- TGGTCGTTGAGGGCAATC- 3’. 
 
Cyclophilin B forward primer: 5’- CTTCCCCGATGAGAACTTCA- 3’, 
Cyclophilin B reverse primer: 5’- CTGTGGAATGTGAGGGGAGT- 3’. 
 
To each 2 µl aliquot of cDNA, 23 µl of PCR master mix was added. The master 
mix was made up of: 5 µl 5 x green GoTaq Flexi buffer; 1.5 µl 25 mM magnesium 
chloride solution; 1 µl 10 mM dNTP mix; 13.85 µl RNase and DNase free water; 
0.7 µl forward primer; 0.7 µl reverse primer and 0.25 µl 5 U /µl GoTaq Flexi 
DNA polymerase /sample.  A thermal cycler (GS1, G-Storm) was used to 
perform the PCR on each sample using the following settings: 1 cycle of 92 °C 
for 2 mins; 25 cycles of 94 °C for 30 secs, 60 °C for 1 min, 72 °C for 30 secs; 1 
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cycle of 72 °C for 2 mins and then hold at 4 °C until manually stopped. Samples 
were then stored at -20 °C until ran on an agarose electrophoresis gel.  
Both GAPDH and cyclophilin B PCR products were in the region of 400 bp so 
were run on a 1.5 % agarose (Sigma-Aldrich Ltd.) gel made in 1 x TAE buffer 
with a 1000 bp ladder (Bioline). Ethidium bromide (VWR International) was 
added for visualisation at 1 µl /100 mls 1.5 % agarose in 1 x TAE buffer. 
Samples were run at 100 V for 40 mins after which gels were exposed on 
ChemiDoc MP imaging system (Si Laboratories Ltd.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
69 
 
 
 
 
 
 
 
 
Figure 2.10 GAPDH PCR blots to confirm cDNA integrity  
PCR gel electrophoresis was performed on amplified cDNA samples from primary 
human pulmonary artery SMCs. 1 µl of each 1 µg sample was amplified with primers to 
GAPDH to confirm cDNA integrity. PCR gels were run as hyperladder IV, 12 different 
SMC cDNA samples and hyperladder IV. Blots a) and b) are from two separate dates 
where RNA from human SMCs was isolated and converted to cDNA. Both blots show 
maintained GADDH expression across all samples which suggests good cDNA quality.  
 
 
 
 
70 
 
2.10.2 REAL-TIME PCR BY TAQMAN 
 
Real time PCR allows the reaction to be monitored as it progresses using 
TaqMan hydrolysis probes enabling relative quantification. Specific cyclers with 
fluorescent resonance energy transfer (FRET) light source are used to excite 
flourophores. The method relies on Taq polymerase to cleave dual-labelled 
TaqMan probes which bind at a specific site in the primer amplification region. 
The probes have 6-carboxyﬂuorescein (FAM) fluorescent reporters covalently 
bound to the 5’- end of the probe and a non- fluorescent 6-
carboxytetramethylrhodamine (TAMRA) quencher at the 3’- end. As the Taq 
polymerase extends the 5’- primer it degrades the probe releasing the reporter 
from the quencher. Hence fluorescence is detected as the reaction progresses 
and is proportional to the amount of DNA.    
All samples and reagents were incubated on ice when not used. RNase and 
DNase free tips, microcentrifuge tube and water were used throughout. All 
probes were purchased from Applied Biosystems unless stated otherwise. Each 
reagent was vortexed thoroughly and spun in a microcentrifuge at 2000 rpm for 
2 mins prior to use. New standard curves were generated for each primer probe 
set measured using seven  1 in 4 or 1 in 2 serial dilutions of time 0 commercial 
SMC cDNA in water. Before use all samples were diluted 1 in 4 and each 
standard and sample was applied to 384 well plates (Greiner Bio-One GmbH) in 
duplicate. Plates were covered with Microseal ‘B’ adhesive seals (Bio-Rad 
Laboratories) and agitated before spinning at 1200 rpm for 2 mins to remove 
air bubbles and ensure all solutions are in the bottom of the wells. Each 
experiment was run on ABI 7900HT Real-time PCR system (Applied 
Biosystems, Life Technologies) using 384 well plate block. Total reaction 
volumes of 20 µl /well were used containing 1 µl cDNA and 19 µl reaction 
master mix.  
Commercially available TaqMan primer probe sets (Applied Biosystems, Life 
Technologies) were used against β actin, HIF-1, HIF-2 and BMPR2. The assay ID 
for each was hs01060665_g1, hs00153153_m1, hs01026149_m1 and 
hs00176148_m1 respectively. The reaction master mix consisted of: 1 µl 
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TaqMan primer probe containing both forward and reverse primers as well as 
the TaqMan probes; 10 µl 2 x qRT-PCR Master Mix (Eurogentec) containing 
HotGoldStar Taq enzyme, dNTPs, MgCl₂, and ROX passive reference which is a 
fluorescent dye which maintains its intensity used to eliminate well to well 
variations; 8 µl water. Once completed data was analysed by SDS 2.2.1. 
Software.  
 
2.10.3 ANALYSIS OF REAL-TIME PCR 
 
All standards were labelled and given an arbitrary value corresponding with the 
dilution series. Undiluted cDNA was given the value of 10,000 and water was 
used as the negative control. From these standards, amplification plots were 
generated and Ct values assigned. Standard curve plots and amplification plots 
were generated for samples as well as standards (Figure 2.11). Threshold 
values were decided upon by determining the linear portion of each standard 
and sample amplification plot. The point at which each amplification plot 
crossed the threshold (Ct value) was compared between duplicates. Duplicates 
with large variation in Ct values were discarded. Ct values for each sample were 
read off the amplification plot and arbitrary values generated by comparing to 
the standard curve. Ratios of gene of interest compared to actin were generated 
in Microsoft Office 7 EXCEL (Microsoft):  
 
Ratio gene of interest to actin =         mean quantity gene of interest 
                                                                mean quantity actin for each sample 
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Figure 2.11 Representative amplification plots obtained from real-time PCR 
standards 
Representative amplification plots for human SMC a) actin standards diluted 1 in 4, b) 
HIF-1 α standard diluted 1 in 4, c) HIF-2 α standard diluted 1 in 2 and d) BMPR2 
standard diluted 1 in 4. 
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2.11 PROTEIN LYSIS 
 
Plates were seeded at 25,000 cells /well and monocytes incubated at 0.1 x 10⁶ 
cells /ml at a ratio of 5 SMCs: 1 monocyte. After 24 hour culture in normoxia (19 
kPa) or hypoxia (3 kPa), cells were lysed using sodium orthovanadate lysis 
buffer. All plates were incubated on ice when removed from sterile culture 
environments. 
 
2.11.1 SODIUM ORTHOVANADATE LYSIS METHOD 
 
Aliquots of sodium orthovanadate lysis buffer (appendix II) were boiled at 95 °C 
in a heat block (Unitek HBS-130, Life systems designs) for 10 mins. SMC wells 
were washed with pre-equilibrated PBS and all excess PBS removed with a 
sterile P1000 pipette tip. Plates were removed from sterile conditions on ice 
and 50 µl of hot lysis buffer added to each well for 5 mins. Cells were scraped 
using a blunt P200 tip and lysate transferred to a clean labelled 1.5 ml 
microcentrifuge tube. Lysates were boiled at 95 °C in a heat block for 5 mins 
before being spun at 14,000 rpm for 10 mins at 4 °C. Supernatants were 
transferred to clean labelled 1.5 ml microcentrifuge tubes and stored at -80 °C 
to be run on SDS-PAGE gels. 
 
2.12 QUANTIFYING PROTEIN 
 
2.12.1 DC ASSAY 
 
DC assay (Bio-Rad Laboratories) is a colorimetric assay used to quantify 
proteins and is readily compatible with detergents as well as EDTA and Tris. 
The DC reagents contain alkaline copper tartrate solution and folin reagent 
which react with proteins to give a colour change.  
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Samples and standards were run on a clear bottom 96 well plates to be read on 
an absorbance plate reader. Assay reagents were prepared by addition of 20 µl 
reagent S to every 1 ml reagent A in a clean bijoux tube (BD Biosciences). This 
solution was called reagent A’ and 25 µl added to each well containing 
standards or samples. Standard curves were generated based on readings from 
BSA diluted in sodium orthovanadate lysis buffer. BSA was diluted from 16 µg 
/ml to 0 µg /ml by 1 in 2 serial dilutions and 20 µl of each standard loaded onto 
the plate in triplicate. Samples were run in duplicate and 20 µl of sample was 
used in each duplicate. To all wells 200 µl reagent B was added before plates 
were left to develop for 15 mins on the bench. After incubation plates were 
agitated and absorbance at 630 nm read on an absorbance plate reader. Values 
were expressed as µg /ml and volumes needed to load 30 µg or 50 µg protein/ 
lane on SDS-PAGE gels calculated. 
 
2.13 WESTERN BLOT ANALYSIS OF PROTEIN EXPRESSION 
 
Protein samples were heated to 95 °C for 10 mins prior to running on 8 % SDS-
PAGE gels (appendix III) and separated by electrophoresis. Geneflow 
electrophoresis kits were assembled (Geneflow Ltd.), plates secured and 
structure lowered into western tank. Gaskets were filled to the top with 1 x SDS 
Running buffer (appendix IV) and rest of tank filled halfway. Combs were 
removed and wells cleared with a 0.7 gauge needle (BD Microlance) attached to 
1 ml syringe (BD Plastipak). Either 30 µg or 50 µg protein from each sample was 
loaded into wells along with 5 µl ColourPlus Protein ladder (New England 
Biolabs). Gels were run at 120 V for 20 mins (Bio-Rad Laboratories) or until the 
dye front passed through the stacking gel after which voltage was raised to 200 
V. Power packs were stopped when the dye front ran off the bottom of the gel.   
Separated proteins were then transferred to PVDF membranes (Millipore, 
Merck Millipore) pre activated with methanol. Transfer tanks were filled with 1 
x transfer buffer (appendix V) then sponges (Geneflow Ltd.) and blotting paper 
(Scientific Laboratory Supplies) submerged in 1 x transfer buffer. Cassettes 
75 
 
were opened and assembled as: 2 x sponges, 1 x blotting paper, SDS-PAGE gel, 
PVDF membrane, 1 x blotting paper and 2 x sponges. Careful layering to avoid 
air bubbles was carried out before cassettes were re-assembled. Tanks were 
kept in ice and transfers were run at 180 V for 90 mins. The transfer efficiency 
was checked by soaking membranes in 1 in 10 Ponceau S (Sigma-Aldrich Ltd.). 
After membranes were rinsed in water, blots were blocked with 5 % Marvel in 1 
x TBS for 1 hour at room temperature on a rocker. Membranes were then 
incubated overnight at 4 °C on a rotating platform in primary antibodies 
(appendix VI), washed 3 x 15 min in TBS and 0.1 % Tween-20 before incubating 
for 1 hour with filtered HRP- conjugated secondary antibody at room 
temperature on a rotating platform. Membranes were washed again as above 
and developed with Enhanced Chemilluminescent Reagent, EZ-ECL (Geneflow 
Ltd.) and visualised either in the dark room using photographic film (GE 
Healthcare Ltd.) or read on the ChemiDoc MP imaging system (Bio-Rad 
Laboratories). 
 
2.13.1 DENSITOMETRY 
 
All western images and films were scanned using Canon scanner (Canon (UK) 
Ltd.) and saved as a new .TIFF file. Images were opened using Image J and boxes 
transformed across bands. The programme can then be used to calculate the 
optical density across the area and values expressed as a histogram. The area 
under the graph was recorded for each sample and all values were normalised 
to corresponding actin densitometry values.  
 
2.14 SIRNA TRANSFECTION OF PULMONARY ARTERY SMOOTH MUSCLE CELLS 
 
Small interfering RNAs can be used in cell culture to knock down expression of 
target genes. This technique manipulates eukaryotic cells’ RNAi pathway. To do 
this specifically designed 20-25 base pair complementary sequences with 2-3 
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nucleotide overhangs are introduced into a cell. Once entered, the double 
stranded RNA unwinds and is incorporated into RNAi induced silencing 
complex (RISC). The RISC containing the antisense sequence is then active to 
target its complimentary mRNA leading to its degradation.  
Designed siRNA sequences against cyclophilin B, HIF- 1 α, HIF- 2 α and BMPR2 
mRNA were transfected into primary pulmonary artery SMCs using the 
chemical agent DharmaFECT2 (Dharmacon, Thermo Scientific). For each 
transfection 1 µl DharmaFECT2 was used with OptiMEM I (Gibco, Life 
Technologies) to transfect 2 µM siRNA for every 35,000 SMCs.  
After transfection total cell counts were performed and transfection efficiency 
measured by PCR electrophoresis or real-time PCR. Sterile technique was used 
throughout.  
Each siRNA was bought from Dharmacon (Thermo Scientific). Cyclophilin B 
siRNA sequences were pre designed targeting accession number NM_000942 
(siSTABLE Cyclophilin B siRNA, D-001710-02-05) whereas HIF-1 α, HIF-2 α and 
BMPR2 sequences were custom designed: 
 
HIF-1 α:                sense 5’- CUGAUGACCAGCAACUUGAdTdT -3’ 
                        antisense 5’- UCAAGUUGCUGGUCAUCAGdTdT -3’ 
 
HIF-2 α:                sense 5’- CAGCAUCUUUGAUAGCAGUdTdT -3’ 
                        antisense 5’- ACUGCUAUCAAAGAUGCUGdTdT -3’ 
 
BMPR2:                sense 5’- CAUGUAUGCUCUUGGACUAUUdTdT -3’ 
                        antisense 5’- UAGUCCAAGAGCAUACAUGUUdTdT -3’ 
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The day before transfection, SMCs were seeded into 24 well plates at a 
concentration of 70 million cells /ml in a total well volume of 500 µl. Plates 
were incubated overnight at 37 °C in a normoxic (19 kPa) incubator 
supplemented with 5 % CO₂. On the day of transfection 2 µM siRNA solutions 
were made up in RNase free water from 20 µM reconstituted stocks. For each 
well two tubes of solutions were created: 
 
Tube 1- 25 µl 2 µM siRNA + 25 µl OptiMEM I 
Tube 2- 1 µl DharmaFECT2 + 49 µl OptiMEM I 
 
For mock infected controls 25 µl OptiMEM I was used instead of 2 µM siRNA. 
Each tube was mixed and incubated for 5 mins at room temperature. Both tubes 
were then combined and mixed by carefully pipetting up and down before 
incubating for 30 mins at room temperature to allow formation of chemical 
complexes containing siRNA sequences. During the incubation media was 
removed from each well, cells washed with PBS and 400 µl OptiMEM I without 
antibiotics or supplements added. After incubation 100 µl siRNA complexes 
were applied to each well for a total transfection time of 12 hours at 37 °C in 
normoxic incubators supplemented with 5 % CO₂. 
After incubation complexes were removed by gentle pipetting and cells washed 
with PBS. Media was then replaced with DMEM containing 0.2 % FCS and 1 % 
P/S. Immediately following cells left to recover for a further 12 hours at 37 °C as 
above. After recovery plates were washed with PBS and media replaced with 
fresh DMEM containing 0.2 % FCS and 1 % P/S. Plates were incubated for a 
further 24 hours either in normoxia as above or a Ruskin InVivo₂ 400 hypoxic 
workstation pre-set with 1 % O₂ and 5 % CO₂. Following this wells were 
washed with PBS and either lifted by the addition of 500 µl 0.25 % Trypsin/ 
EDTA solution for Coulter counts to be performed or lysed with 1 ml TRI 
Reagent.   
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This protocol was first optimised using siRNA to cyclophillin B, which is an 
abundantly expressed mRNA (Figure 2.12). Knock down of cyclophilin B does 
not affect cell viability so it is often used as a positive control. Initially cells and 
complexes were incubated for 6 hours leading to inefficient knockdown of 
cyclophillin B (Figure 2.12a). However, a transfection time of 12 hours was both 
effective and reproducible (Figure 2.12b).   
 
2.15 STATISTICS 
 
All statistics were performed using GraphPad Prism 5.0 (GraphPad Software 
Inc.). All data is expressed as mean +/- standard error of mean (SEM) of a 
number of independent experiments (n). Parametric statistical tests were 
chosen when normal distribution of data was observed. One-way analysis of 
variance (ANOVA) was used when comparing several samples with Bonferonni 
post test to compare means of all samples. Two-way ANOVA was used when 
comparing two variables such as oxygen tension and culture conditions with 
Bonferonni post test to compare interactions of each variable. Where only two 
samples were being compared a students’ t-test was used. Data was considered 
significant if P<0.05. 
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Figure 2.12 Confirming knock-down of cyclophillin B in smooth muscle cells 
using PCR gel electrophoresis 
In brief SMCs were either mock infected (mock), transfected with 0.5 µM scrambled 
siRNA (scram) or with 0.5 µM siRNA targeting cyclophilin B (cycB siRNA) by chemical 
transfection for a) 6 hours or b) 12 hours. Samples were washed and incubated in 
either normoxia (Nx) (19 kPa) or hypoxia (Hx) (3 kPa) for a further 24 hours. Samples 
were lysed using TRI Reagent and RNA converted to cDNA. Samples were amplified 
with cyclophilin B primers and run on 1 % agarose gels with ethidium bromide for 
visualisation. Representative blots of n=3. 
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3. MONOCYTE REGULATION OF HYPOXIC SMOOTH MUSCLE 
CELL PROLIFERATION 
 
3.1 INTRODUCTION 
 
The vascular remodelling events which occur in the pulmonary artery leading 
to disease progression are driven by excessive SMC proliferation. SMC 
deposition is characteristic of concentric lesion formation and a dysregulated 
media is also seen in plexiform lesions. An important property of SMCs leading 
to vascular remodelling is the pleotrophic nature of the cell type. In healthy 
pulmonary arteries, small non-muscularised vessels are composed of fully 
differentiated contractile SMC whereas during vascular remodelling the cells 
switch to a synthetic phenotype (Dempsey et al., 1998). It is still unknown how 
this switch is initiated, however, the two distinct sub-types each play a role in 
the development of PAH. Both SMC types can be defined by their differential 
growth and cell surface expression as identified by isolating both cell types 
from pulmonary arteries and examining there growth and expression in vitro. 
Synthetic SMC were shown to have a more proliferative phenotype in 
comparison to their contractile counterparts which resembled a senescent 
population (Frid et al., 1997). The differential cell surface expression patterns 
were exemplified by co-culture of SMC and tumour necrosis factor-α stimulated 
vascular endothelial cells. Synthetic SMC and endothelial cell co-culture caused 
increased ICAM-1 and VCAM-1 expression and NF-κB translocation but 
senescent contractile SMC and endothelial cell co-culture had the converse 
effect (Wallace and Truskey, 2010).  Primary SMCs isolated from pulmonary 
arteries of neonatal calves with hypoxia induced pulmonary hypertension 
displayed increased motility associated with upregulation of the Ca²⁺ binding 
protein S100A4 compared to healthy controls. With prolonged hypoxic 
exposure these SMC dedifferentiated to a more synthetic phenotype where they 
expressed the myofibroblast maker α- smooth muscle cell actin and showed 
increased [³H]-thymidine and BrdU incorporation. More work is needed to 
identify why SMC change phenotype, however, this work by Stenmark et al 
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suggests hypoxia may be a contributing factor (Frid et al., 2009). Although some 
data suggest the contrary, the main body of data suggests hypoxia is a 
proliferative stimulus. For example within the same paper, Cooper et al show 
SMCs cultured in 5 % 02 and 10 % FCS proliferate after 24 hours as determined 
by BrdU incorporation and total cell counts. However, when these cells were 
cultured in 1 % 02 for 24 hours no proliferation was seen by the same detection 
methods (Cooper and Beasley, 1999). 10 % hypoxia has also been used as a 
secondary stimulus to stabilise a PAH phenotype in a variety of mouse models 
(Eddahibi et al., 2000) (Beppu et al., 2004) (Lui et al., 2005) (Steiner et al., 
2009). A more reliable rat model of PAH uses 10 % hypoxia and Sugen 5416 
injected rats to induce vascular remodelling which has traditionally been 
difficult to replicate in animal models  but it is important to note that there is a 
significant difference in directly cellular exposure of oxygen between 10 % 
inhaled oxygen and 10 % oxygen in vitro (Abe et al., 2010).  
The exact oxygen tensions of diseased vessels are unknown, however, indirect 
evidence that these lesions are hypoxic was provided by lungs from patients 
presenting with severe PAH. These patients expressed the hypoxia inducible 
transcription factor (HIF) both at the protein and mRNA level in both plexiform 
and concentric lesions (Tuder et al., 2001). HIF is a heterodimeric transcription 
factor composed of constitutively expressed β subunit and one of three oxygen 
sensitive α subunits. During oxygen availability, hydroxylated HIF- α is 
ubiquitinated and degraded by the E3 ubiquitin ligase complex containing the 
tumor suppressor protein Von Hippel- Lindau (VHL). Its presence therefore is 
an indirect marker of regional hypoxia. Another murine model for PAH is the 
VHLR/R mouse, these mice are homozygous for a specific mutation R200W 
affecting HIF degradation and have been shown to develop spontaneous PAH as 
determined by elevated systolic PA pressures of >25 mmHg. Moreover, the 
VHLR/R mice have increased mRNA expression of many HIF target genes specific 
to the HIF-2α subunit e.g. endothelin-1 (ET-1) thus a role for HIF-2α in the 
development of IPAH has been postulated (Hickey et al., 2010). In humans this 
specific mutation is associated with developing Chuvash Polycythemia. Patients 
with this disease are susceptible to developing spontaneous PAH making these 
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mice a potentially strong animal model for PAH and strengthening the link 
between HIF activity and PAH progression.  
The presence of monocytes have also been shown in lung sections of patients 
with PAH (Hall et al., 2009) (Tuder et al., 1994) (Dorfmuller et al., 2003) (Frid et 
al., 2006) and in various animal models (Ikeda et al., 2002) (Voelkel and Tuder, 
1994) (Dorfmuller et al., 2011), however, the role of these cell infiltrates is yet 
to be determined. Moreover, at sites of inflammation in the pulmonary 
vasculature there is evidence of neutophils invading tissue by extravating the 
endothelium of blood vessels. An essential leukocyte in facilitating neutrophil 
margination is the monocyte (Maus et al., 2003). Monocytes are circulating 
phagocytes with a patrolling role in tissues. Once in tissues they have the 
potential to differentiate into either tissue resident macrophages or dentritic 
cells. The importance of monocytes is strengthened by the fact that these cells 
are a major source of cytokines and very few cells can lead to a large biological 
effect (Morris et al., 2005). These are key cells in driving the inflammatory 
process, not only do they induce ROS production but this in turn increases pro-
inflammatory cytokine release in plasma and further leukocyte recruitment to 
the pulmonary artery thus the association of inflammation and progression of 
PAH is strengthened. 
Another inflammatory artefact which has been shown to be altered in 
pulmonary hypertension is systemic cytokine expression with the pro-
inflammatory cytokines IL- 1β and IL-6 been shown to be increased 40 fold and 
4 fold respectively in serum from patients with severe PPH, now known as PAH, 
compared with healthy control serum or those with pulmonary hypertension 
secondary to chronic obstructive pulmonary disease (Martin et al., 2002) (Hall 
et al., 2009). Circulating plasma levels of monocyte chemokines tumour necrosis 
factor-α (TNF-α) and MCP-1 have also been shown to be increased in the early 
stages of IPAH when compared to plasma of healthy controls (Itoh et al., 2006). 
Not only is IL- 1 been found to be increased in disease but also it is known that 
IL- 1β and IL- 1α are potent SMC proliferative stimuli (Ikeda et al., 1990), 
however, the mechanism by which they act is still under investigation. There is 
evidence that NF-κB pathway activation is needed for IL- 1β to exert its 
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proliferative effects on SMC. When exposed to 1 ng/ ml IL- 1β, SMC showed 
more nuclear translocation of the NK-κB pathway member p65 in cells 
expressing the proliferative marker Ki67 compared to non proliferating SMC 
(Sasu and Beasley, 2000). Furthermore, SMC transfection with dominant active 
IL- 1α precursor or full length protein transcript displayed enhanced SMC 
proliferation as measured by BrdU incorporation (Beasley, 1999). IL- 1 type 1 
receptor (IL- 1R1) transduction involves the adaptor protein MyD88. Although 
not shown in pulmonary hypertension, the interaction of IL- 1 and the MyD88 
pathway is evident in many other cardiovascular diseases such as 
atherosclerosis. Homozygous MyD88 deficient mice (MyD88-/-) show 
significantly less neointima formation in response to vascular injury. This was 
reduced further by administration of an IL- 1R1 blocking antibody (Saxena et 
al., 2011) implicating a role for innate signalling in vascular repair. Taken 
together these data show an important role of the IL- 1 pathway in SMC 
proliferation. 
The IL- 1 pathway also interacts with PAH diseased linked factors such as PDGF. 
PDGF is a potent proliferative stimulus for SMCs and induces proliferation via 
PI3K and Akt phosphorylation. Antibodies against PDGF inhibit IL-1 induced 
proliferation in smooth SMC as detected in mice by decreased tritiated leucine 
incorporation (Ikeda et al., 1990). Moreover, in vitro migration assays showed 
PDGF antibodies can inhibit IL-1 induced mitogenesis (Raines et al., 1989). The 
interaction of both these pathways is supported by work from Jiang et al who 
found SMC co-stimulated with 10 ng/ ml IL-1 β and 25 ng/ ml PDGF 
upregulating contractile markers such as myosin heavy chain and calponin at 
the protein level after 24 hours causing proliferation (Jiang et al., 2002). 
Membrane fractions from SMC stimulated with either PDGF or IL-1 β have 
shown an interaction of both PDGF receptor and IL-1R1 by co-
immunoprecipitation. This interaction was explored further showing PDGF 
receptor β phosphorylation is inhibited by the addition of 10 ng/ ml IL-1 
receptor antagonist (IL-1ra) (Cho et al., 2013). 
A further growth factor associated with SMC proliferation and vascular 
remodelling in disease is VEGF. This cytokine is a HIF target gene and has been 
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demonstrated to be important in angiogenesis during embryonic development 
in particular. Evidence for this has been provided in vivo by homozygous and 
heterozygous VEGF knock out mice being embryonic lethal with abnormal 
blood vessel formation (Carmeliet et al., 1996) (Ferrara et al., 1996). VEGF is 
also known to be a potent pro survival and proliferation stimulus for 
endothelial cells and has more recently been shown to be upregulated in PAH 
vascular lesions (Geiger et al., 2000). Moreover, recent work also links soluble 
VEGF receptor secretion to stimulated monocytes. The group found HIF-2α 
mediated soluble VEGF receptor (Flt-1) production was increased in monocytes 
cultured in 0.5 % O₂ with GM-CSF stimulation (Eubank et al., 2011). The levels 
of Flt-1 in my co-culture supernatants will be investigated in my work. 
I propose to study the interactions of vascular SMCs and monocytes using co-
culture models with particular regard to total cell counts. I will investigate the 
potential role of local hypoxia on SMC proliferation and I want to establish both 
a normoxic (19 kPa) and hypoxic (3 kPa) comparative co-culture model with 
and without direct cell contact. Furthermore, due to changes in circulating 
levels of IL-6, IL-1, TNF- α, MCP-1, MIP-1 cytokines in patients with pulmonary 
hypertension and in monocrotaline rat models of the disease it will be 
important to establish whether cytokine profiles are modified with hypoxic 
stimulation and/ or the addition of monocytes.  
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3.2 RESULTS 
 
3.2.1 PULMONARY ARTERY SMOOTH MUSCLE CELL NUMBER IS INCREASED IN 
HYPOXIA COMPARED TO NORMOXIA BUT METABOLIC ACTIVITY IS PRESERVED 
 
Due to the controversy surrounding the effect of hypoxia on pulmonary arterial 
SMC proliferation it was important to establish the effect of hypoxia on SMC 
number in my model. Based on preliminary experiments investigating non 
diseased SMC numbers over a range of seeding densities (Chapter 2.4.1), a 
seeding density of 25,000 SMCs /well was selected. Moreover, to attempt to 
resemble physiological oxygen tensions 3 kPa of oxygen in the media was also 
selected. To ensure all findings were robust each experiment was carried out 
using at least 2 separate vials of cells over different passage numbers. 
Commercially available healthy pulmonary arterial SMCs were grown alone in 
hypoxia (3 kPa) or normoxia (19 kPa) for 24 hours after 48 hours quiescence. 
Post-culture, cells were lifted and total cell counts were calculated by Coulter 
counter. SMC numbers were significantly increased in hypoxia compared to 
normoxia (n=16) (Figure 3.1 a).  
To eliminate the possibility of the difference in SMC number at each oxygen 
tension being due to a change in cell viability in either culture condition, 
reduction of alamarBlue® was used as an indirect measure of cell viability. 
AlamarBlue® acts as a terminal electron acceptor in the electron transport chain 
in viable cells. Reduction of alamarBlue® leads to a colour change in the 
compound, this can then be read on a spectrophotometer. The results were 
compared to matched killed controls using 1 μg/ ml, protein synthesis inhibitor, 
cycloheximide. Cell free supernatant samples of healthy SMC cultured in 
hypoxia or normoxia were compared with cell free supernatants of matched 
killed controls. Results are expressed as arbitrary units /10,000 SMC (Figure 3.1 
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b). When corrected for cell number there was no significant difference in 
relative metabolic activity in either oxygen tension (n=8). 
 
 
 
Figure 3.1 Pulmonary artery smooth muscle cell number is increased in 
hypoxia compared to normoxia but metabolic activity is preserved 
SMCs were seeded in 24 well plates at 25,000 cells /well for 24 hours in normoxia (19 
kPa) (open bars) and hypoxia (3 kPa) (closed bars) following 24 hours oxygen 
equilibration and 48 hours in low serum. a) Total cell numbers were calculated by 
Coulter counter. Bars represent mean +/- SEM, **P<0.01, cells from 6 seperate vials 
studied n=16, one-way ANOVA with Bonferonni post test. b) Relative metabolic activity 
a) 
b) 
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was measured by alamarBlue® reduction and expressed as arbitrary units /10,000 
cells. Bars represent mean +/- SEM, cells from 2 seperate vials studied n=8.   
 
3.2.2 PULMONARY ARTERY SMOOTH MUSCLE CELLS RETAIN THEIR PHENOTYPE IN 
HYPOXIA COMPARED TO NORMOXIA 
 
Synthetic SMCs have been shown to de-differentiate when undergoing cell 
stress. The de-differentiated state has been shown to express more endothelial-
like markers in comparison to the contractile SMCs (Dempsey et al., 1999). To 
ensure both hypoxic (3 kPa) and normoxic (19 kPa) SMC preserved their 
phenotype in the experimental model, they were fixed post- oxygen 
equilibration, serum starvation and 24 hour culture with 4 % 
paraformaldehyde for immunocytochemistry (ICC) to be performed. To ensure 
all findings were robust each experiment was carried out using at least 2 
separate vials of cells over different passage numbers. Cells were analysed for 
smooth muscle cell β actin (a SMC marker), CD31 and Von Willebrand factor 
(both endothelial cell markers) using standard ICC protocols (Chapter 2.6.1).  
Both normoxic and hypoxic SMCs were positive for smooth muscle cell β actin 
and negative for Von Willebrand factor and CD31. Secondary antibody only 
controls were negative for all three labels showing SMCs were maintaining their 
phenotype in the culture conditions (Figure 3.2).  
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Figure 3.2 Smooth muscle cells retain their phenotype in hypoxia compared 
to normoxia 
To establish if commercial SMCs were maintaining their phenotype in the culture 
system, cells were stained for the SMC marker, smooth muscle cell β actin and 
endothelial markers CD31 and Von Willebrand factor. Both normoxic and hypoxic SMC 
were positive for smooth muscle cell β actin. These cells were also negative for CD31 in 
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  2° 
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each oxygen tension. Secondary antibody only controls were negative for all three 
labels. Images were taken using the x 100 objective. 
3.2.3 MONOCYTES HAVE INCREASED SURVIVAL AND MAINTAINED METABOLIC 
ACTIVITY IN HYPOXIA 
 
Having found a difference in SMC behaviour in each oxygen tension, the effect of 
hypoxia (3 kPa) on monocytes was investigated. It has been shown in 
neutrophils that hypoxia acts as an anti-apoptotic stimulus (Walmsley et al., 
2005), however, it is unknown whether this is true of other myeloid cells 
therefore survival was measured in each oxygen tension. Monocytes were 
obtained from healthy volunteers by OptiPrep™ density gradient separation. 
Only suspensions of purity 85 % or higher were used for experiments. 
Monocytes were cultured in both normoxia and hypoxia for 24 hours in pre-
equilibrated RPMI containing 10 % FCS and 1 % P/S.  
To investigate if hypoxia regulates monocyte survival, apoptosis was assessed 
by annexin-PE positivity seen on the FL-2 parameter on a FACS Calibur flow 
cytometer (Figure 3. 3 a). Monocytes alone showed a significant increase 
apoptosis at 24 hours in normoxia compared to hypoxia (n=4). The protein 
synthesis inhibitor cycloheximide (1 µg /ml) was used as a positive control, 
treated samples had significantly higher apoptosis compared to untreated 
samples (n =4). Membrane integrity was used to indicate necrosis. In these data 
necrosis is described as ToPro-3 positive, annexin -PE negative cells as detected 
on the FL-4 parameter of the FACS Calibur flow cytometer. There was no 
difference between rates of necrosis in either normoxia or hypoxia (n=4) or 
killed controls (n=4) (Figure 3.3 b). 
Having shown that relative metabolic activity was unaffected in SMCs in either 
oxygen tension, the effect of hypoxia on relative metabolic activity of monocytes 
was subsequently investigated (Figure 3.3 d). Results are expressed as relative 
metabolic activity per 1000 monocytes. Metabolic activity was preserved in 
normoxia (19 kPa) versus hypoxia (3 kPa) (n=6). Cells were also stimulated 
with 10 ng /ml LPS to mimic an inflammatory insult as it is a potent TLR4 
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agonist, however, it had no additive effect on relative metabolic activity (n=6) 
(Figure3.3 c). 
 
 
 
Figure 3.3 Monocytes have increased survival and preserved metabolic 
activity in hypoxia compared to normoxia 
Monocytes were isolated from venous blood and cultured in normoxia (19 kPa) (open 
bars) or hypoxia (3 kPa) (closed bars) in parallel for 24 hours. a) Percentage apoptosis 
was calculated by annexin-PE positivity and b) necrosis by ToPro-3 positivity. 
Monocytes were directly compared to matched killed controls using 1 µg/ ml 
cycloheximide. Bars represent mean +/- SEM, *P<0.05, **P<0.01, n=4, two-way ANOVA 
with Bonferonni post test. c) Relative metabolic activity was measured in monocytes 
cultured for 24 hours with and without 10 ng /ml LPS by reduction of alamarBlue®. 
a
) 
b
) 
c) 
91 
 
Results are expressed as arbitrary units and normalised for monocyte cell number. 
Bars represent mean +/- SEM. Results shown as relative metabolic activity /1000 
monocytes, n=6. 
3.2.4 MONOCYTES CAN ABOLISH HYPOXIC SMOOTH MUSCLE CELL INCREASE IN CELL 
NUMBER 
 
Having defined each cell type independently in normoxia and hypoxia a co-
culture model was established. SMCs were seeded at 25,000 cell /well in each 
oxygen tension. In order to reflect physiological conditions a ratio of 1 
monocyte: 5 SMCs was selected based on previous work on aortic SMC and 
monocyte co-cultures by Professor Sabroe’s group (Morris et al., 2005). Plates 
were cultured for 24 hours with or without the addition of monocytes (5000 
/well). The experiment was carried out using at least 4 separate vials of cells 
over different passages. Total cell counts were obtained by Coulter counter as 
previously shown (2.4.1). Total cell counts for SMCs in hypoxia were 
significantly higher than in normoxia (n=10). Our key finding was that the 
addition of monocytes (1:5) to SMC had no effect on normoxic SMC number but 
inhibited hypoxic increase in SMC number (n=10) (Figure 3. 4).  
 
3.2.5 MONOCYTE INHIBITION OF HYPOXIC SMOOTH MUSCLE CELL PROLIFERATION 
IS NOT DUE TO INCREASED SMOOTH MUSCLE CELL APOPTOSIS 
 
Monocyte induced reduction in hypoxic SMC number could be mediated by 
inhibition of SMC proliferation or increased SMC death. The latter was 
investigated using fluorescent TUNEL SMC labelling following mono- and co-
culture. The fluorescent nuclear dye DAPI was used to focus samples and 
overlays with FITC positive TUNEL used for manual counts (Figure 3. 5).  
Results are expressed as percentage apoptotic from total cells with at least 
three hundred cells from three different fields counted. Hypoxic and normoxic 
SMC alone showed less than 5 % apoptosis after 24 hours (n=3). The addition of 
monocytes had no effect on apoptosis rates in either oxygen tension (n=3). 
Unstained negative controls showed only DAPI positivity. Positive controls 
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were carried out by pre-incubation with 1 µg /ml cycloheximide. Cycloheximide 
significantly increased apoptosis in both normoxic and hypoxic SMC alone 
compared to their untreated counterparts (n=3).  
 
 
 
 
 
Figure 3.4 Monocytes can abolish hypoxic smooth muscle cell increase in cell 
number 
SMCs were grown in both normoxia (19 kPa) (open bars) and hypoxia (3 kPa) (closed 
bars) for 24 hours after serum starvation and oxygen equilibration with and without 
monocytes purified from venous blood. Monocytes were co-cultured at a ratio of 1 
monocyte: 5 SMC. Bars represent mean +/- SEM, ***P<0.001, cells from 2 seperate vials 
studied n=10, one-way ANOVA with Bonferonni post test. 
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Figure 3.5 Monocyte inhibition of hypoxic smooth muscle cell proliferation is 
not due to increased apoptosis 
SMCs were cultured with and without monocytes for 24 hours in either normoxia (19 
kPa) (open bars) or hypoxia (3 kPa) (closed bars). TUNEL assay flourescin labelled 
apoptotic nuclei. Positive controls were pre-incubated with 1 µg/ ml cycloheximide. a) 
Percentage apoptotic cells from total cell population in at least 300 cells from 3 
different fields. Bars represent mean +/- SEM, **P<0.01, ***P<0.001, n=3, one-way 
ANOVA with Bonferonni post test. b) Representative FITC positive TUNEL images of 
normoxic and hypoxic monoculture, co-culture and cycloheximide treated SMC and 
DAPI positive images. Images were magnified x1000.  
a) 
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3.2.6 AORTIC VASCULAR SMOOTH MUSCLE CELLS HAVE ALTERED GROWTH 
RESPONSES COMPARED TO PULMONARY ARTERIAL SMOOTH MUSCLE CELLS  
 
The pulmonary vasculature is thought to be unique and possess different 
properties to the systemic vasculature. Not only due to it being a high pressure 
and high resistance system but it has also been shown to express different 
adhesion molecules in comparison to the rest of the circulation. Bearing this in 
mind both pulmonary artery SMCs and aortic vascular SMCs were compared in 
the same culture system. Aortic vascular SMCs were seeded at 25,000 cells 
/well prior to 24 hour oxygen equilibration in either normoxia (19 kPa) or 
hypoxia (3 kPa) and 48 hour serum starvation. Cells were cultured for a further 
24 hours with and without the addition of monocytes at a ratio of 1 monocyte: 5 
SMCs as above (Figure 3.6). Instead of finding hypoxic induced proliferation of 
aortic SMCs, hypoxia had no effect on total cell numbers compared to their 
normoxic counterparts (n=4). Moreover no change in cell number was observed 
by the addition of monocytes in either oxygen tension compared to 
monoculture baseline numbers (n=4). These data suggest hypoxic uplift in SMC 
number and monocyte inhibition of SMC proliferation is specific to pulmonary 
artery SMCs.                                          
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Figure 3.6 Aortic vascular smooth muscle cells have altered growth 
responses compared to pulmonary arterial smooth muscle cells 
Aortic SMCs were seeded at 25,000 cells/ well and left to oxygen equilibrate for 24 
hours then left in quiescent media for 48 hours. Cells were then cultured with and 
without monocytes (1 monocyte: 5 SMC) for 24 hours in both normoxia (19 kPa) (open 
bars) and hypoxia (3 kPa) (closed bars). Post culture washed trypsinised wells were 
counted by Coulter counter. Bars represent mean +/- SEM, n=4. 
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3.2.7 MONOCYTE INHIBITION OF HYPOXIC SMOOTH MUSCLE CELL PROLIFERATION 
IS INDEPENDANT OF DIRECT CELL CONTACT AND TRANSFERABLE 
 
Having shown that pulmonary artery SMC and monocyte co-culture can 
modulate SMC proliferation, the importance of direct cell contact was 
investigated. To do this, co-cultures were carried out as above using 0.4 µm 
pore transwells to separate monocytes from SMC. To ensure all findings were 
robust each experiment was carried out using at least 2 separate vials of cells 
over different passage numbers. Total cell counts were measured by Coulter 
counter after 24 hour culture. Again hypoxia significantly increased SMC 
number compared to normoxia (n=6) and addition of monocytes in transwells 
significantly reduced hypoxic increase in total cell number (n=6) (Figure 3.7 a).  
To further explore the importance of direct cell contact, monocytes were 
cultured for 24 hours in normoxia and hypoxia and cell free supernatants (SN) 
saved. Total SMC counts were calculated by Coulter counter after 24 hour 
incubation with monocyte SN. Both normoxic and hypoxic monocyte SN had no 
effect on normoxic total SMC counts (n=4). However, hypoxic SMC proliferation 
was significantly inhibited not only by normoxic monocyte supernatants but 
also by hypoxic monocyte SN to a similar order of magnitude (n=4) (Figure 3.7 
b). This experiment shows that monocyte inhibition of hypoxic SMC 
proliferation is a transferable effect and it is independent of monocyte hypoxia.  
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Figure 3.7 Monocyte inhibition of hypoxic smooth muscle cell proliferation is 
independent of direct cell contact and transferable  
SMCs were seeded at 25,000 cells /well in normoxia (19 kPa) (open bars) and hypoxia 
(3 kPa) (closed bars) for 24 hours. a) Monocytes were added to co-culture wells in 0.4 
µm transwells. Total cell counts were carried out on the washed and trypsinised SMC 
using a Coulter counter. Bars represent mean +/- SEM, ***P<0.001, cells from 2 
seperate vials studied n=6, one-way ANOVA or two-way ANOVA with Bonferonni post 
test. b) Cell free supernatants from normoxic and hypoxic monocytes were added to 
SMC and cultured for 24 hours. Total cell counts were analysed as above. Bars 
represent mean +/- SEM, ***P<0.001, n=4, one-way ANOVA with Bonferonni post test.  
 
a) 
b) 
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3.2.8 LIPOPOLYSACCHARRIDE HAS NO EFFECT ON THE ABILITY OF MONOCYTES TO 
INHIBIT HYPOXIC SMOOTH MUSCLE CELL PROLIFERATION 
 
In pulmonary hypertension monocytes will be recruited to an acutely 
inflammatory pulmonary artery and thus be activated. To ensure that the co-
culture model was representative of this, lipopolysaccharide (LPS), a potent 
TLR 4 agonist was used. LPS is known to activate the pro-inflammatory MyD88 
pathway in monocytes leading to cytokine production and cell activation. LPS 
was used at 10 ng /ml which is the gold standard concentration when working 
with monocytes to activate a pro-inflammatory response (Figure 3.8). The 
experiment was carried out using at least 2 separate vials of cells over different 
passage numbers.  
SMCs were seeded at 25,000 cells /well and cultured for 24 hours with and 
without monocytes and /or LPS following 24 hour oxygen equilibration and 48 
hour serum starvation. Following 24 hour culture total cell counts were 
measured by Coulter counter. Monocytes stimulated with LPS were equally able 
to inhibit hypoxic SMC number as unstimulated monocytes (n=8).   
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Figure 3.8 Lipopolysaccharide has no effect on the ability of monocytes to 
inhibit hypoxic smooth muscle cell proliferation 
SMCs were seeded in 24 well plates at 25,000 cells /well and cultured in normoxia (19 
kPa) (open bars) and hypoxia (3 kPa) (closed bars) for 24 hours prior to serum 
starvation. Plates were then maintained with and without monocytes (1 monocyte: 5 
SMC) or LPS (10 ng/ml) stimulation. Total cell counts were calculated by Coulter 
counter. Bars represent mean +/- SEM, ***P<0.001, ns= not significant, cells from 2 
seperate vials studied n=8, two-way ANOVA with Bonferonni post test. 
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3.2.9 SMOOTH MUSCLE CELL AND MONOCYTE CO-CULTURE PRO-INFLAMMATORY 
CYTOKINE EXPRESSION PROFILES  
 
With the knowledge that hypoxic SMC proliferation can be modulated by 
monocyte supernatant, cell free supernatants were obtained from SMC and 
monocyte monocultures and co-cultures. Differences in expression between 
mono- and co-culture samples would give key insights into potential factors 
which could be eliciting inhibition of hypoxic SMC proliferation. Supernatant 
samples were then analysed by enzyme-linked immunosorbent assay (ELISA) 
for factors which monocytes were known to release such as IL- 1β, IL-1ra, IL-8, 
IL-6, IL-10, IFN-γ and RANTES. LPS at 10 ng /ml was used to create more 
physiologically relevant conditions and maximise monocyte activation and 
cytokine profiles.  
Monocytes alone released undetectable levels of IL-8, this was unaffected by 
LPS stimulation or hypoxia. Interestingly, neither LPS stimulation nor hypoxia 
had any effect on IL-8 release from SMC alone (Figure 3.9 a). LPS stimulation 
almost doubled the expression of IL-8 from co-cultures compared to 
unstimulated co-cultures in each oxygen tension (n=6).  
IL-6 release followed a similar pattern, stimulated co-cultures significantly 
increased IL-6 compared to unstimulated counterparts (n=6) (Figure 3.9 b). 
Under all conditions IL-1 β levels were below the limit of detection. This was 
also true of the TLR 3 downstream target IFN- γ, IL-1ra and the anti- 
inflammatory cytokine IL-10. The chemokine CCL5 also known as RANTES 
followed a similar pattern to the other pro-inflammatory cytokines and LPS 
stimulated co-cultures had significantly increased expression compared to 
unstimulated counterparts (n=6) (Figure 3.9 c). 
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Figure 3.9 Pro-inflammatory cytokine profiles of smooth muscle cell and 
monocyte monoculture and co-cultures 
Monocytes and SMC monocultures and co-cultures (1 monocyte: 5 SMC) were set up in 
normoxia (19 kPa) (open bars) and hypoxia (3 kPa) (closed bars). Cell free 
supernatants were collected from each condition with and without 10 ng/ ml LPS 
stimulation and analysed by sandwich ELSIA by the manufacturer’s instructions. 
Values were calculated using log transformation and linear regression analysis for 
secreted expression of a) IL-8, b) IL-6 and c) RANTES. Bars represent mean +/- SEM, 
*P<0.05, **P<0.01, ***P<0.001, n=6, two-way ANOVA with Bonferonni post test.   
 
a) 
b) 
c) 
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3.2.10 EXPRESSION PROFILES OF DISEASE RELATED FACTORS 
 
Being unable to find any pro-inflammatory cytokines or chemokines 
responsible for causing monocyte inhibition of SMC proliferation, disease linked 
factors were then examined. OPG, BMP4 and endothelin-1 are all factors shown 
to be increased in serum of patients with PAH. Each of the proteins has been 
shown to contribute to vascular remodelling and thus disease progression. 
Monocytes alone did not produce any OPG but SMC alone in both oxygen 
tensions produced the factor to similar levels (n=2). Stimulation had no effect 
on OPG release in either oxygen tension (Figure 3.10 a). Endothelin-1 and BMP4 
were expressed below the limit of detection suggesting none of these factors 
could be responsible for monocyte inhibition of hypoxic SMC proliferation.  
Another factor which has been shown to upregulated in remodelled pulmonary 
arteries and a known angiogenic factor is VEGF. This growth factor is also a HIF 
target gene so was used as a positive control for hypoxic samples. Hypoxia 
significantly increased VEGF levels compared to normoxic levels in SMC alone 
(n=6) and in SMC and monocyte co-cultures (n=6) providing indirect evidence 
of HIF activation in the culture system. LPS stimulation had no effect on VEGF 
expression (Figure 3.10 b). Monocytes stimulated with granulocyte macrophage 
colony stimulating factor (GM-CSF) were found to increase expression of the 
soluble VEGF receptor-1 also known as sFlt-1 (Eubank et al., 2012). It was 
postulated that in the culture system monocytes were activated and releasing 
sFlt-1 which was binding to the hypoxic induced VEGF from hypoxic SMCs 
preventing increase in cell number from co-culture samples. I went on to 
measure LPS stimulated monocyte release of sFlt-1 as well as in SMC alone and 
in monocyte and SMC co-culture. Normoxic monocytes alone produced no sFlt-
1, hypoxia increased sFlt-1 levels and LPS further increased release but all 
values are below 150 pg/ ml which is the limit of detection (n=3) (Figure 3.10 
c).   
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Figure 3.10 Expression profiles of disease related factors 
SMCs and monocytes were grown in normoxia (19 kPa) (open bars) or hypoxia (3 kPa) 
(closed bars) for 24 hours as well as co-cultures of both cell types (1 monocyte: 5 SMC). 
Cell free supernatants were obtained from cultures with and without LPS (10 ng/ml) 
and analysed by ELISA according to the manufacturer's instructions. Values were 
calculated using log transformation and linear regression analysis for a) OPG (n=2), b) 
VEGF (n=6) and c) Flt-1 (n=3). Bars represent mean +/- SEM, ***P<0.001, two-way 
ANOVA with Bonferonni post test. 
a) 
b) 
c) 
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3.2.11 AORTIC SMOOTH MUSCLE CELL PRO-INFLAMMATORY CYTOKINE PROFILES 
 
As the above results were contradictory to comparative data using aortic 
vascular SMCs (Morris et al., 2005), the validity of the results was investigated 
using aortic vascular SMCs in the same culture system. Cell free supernatants 
were obtained from human aortic vascular SMC and monocyte monocultures 
and co-cultures. Secreted IL-1 β, IL-6, IL-8 and VEGF were analysed by ELISA. As 
with pulmonary arterial SMC culture, LPS was used as an inflammatory 
stimulus to maximise the activation of the MyD88 pathway leading to increased 
pro-inflammatory cytokine release. There was no detectable IL-8 from 
monocytes alone in either oxygen tension with or without LPS stimulation. 
Neither LPS stimulation nor hypoxia had any effect on IL-8 release from SMC 
alone (Figure 3.11 a). Hypoxia significantly increased unstimulated co-culture 
IL-8 release compared with its normoxic counterpart (n=4). Stimulation further 
increased monocyte and SMC co-culture IL-8 release in hypoxia compared to 
normoxia (n=4). Monocytes alone produced no IL-6 while SMC alone in 
normoxia and hypoxia released equivalent levels of IL-6 (n=3). Stimulation had 
no effect on SMC monoculture release of IL-6 (n=4). Unstimulated co-culture IL-
6 release was significantly increased compared to stimulated co-culture in 
normoxia (n=4) and hypoxia (n=4) (Figure 3.11 b). IL-1 β was detectable but 
limitations of the assay meant values were both low and variable (Figure 3.11 
c). Again hypoxic secretion of VEGF was increased in hypoxia compared with 
normoxia. This was significant for hypoxic LPS stimulated co-culture compared 
to its normoxic counterpart (n=4) (Figure 3.11 d). These data closely resembled 
data previously published (Morris et al., 2005) suggesting that there is a real 
detectable difference in responsiveness between pulmonary artery SMCs and 
aortic vascular SMCs.           
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Figure 3.11 Aortic vascular smooth muscle cell pro-inflammatory cytokine 
profiles 
Commercial aortic SMCs were cultured in normoxia (19 kPa) (open bars) and hypoxia 
(3 kPa) (closed bars) for 24 hours with and without monocytes (1 monocyte: 5 SMC). 
Cell free supernatants were obtained with and without LPS (10 ng/ml) stimulation and 
analysed by ELISA according to the manufacturer's instructions. Values were calculated 
using log transformation and linear regression analysis for a) IL-8 (n=4), b) IL-6 (n=4), 
c) IL-1 β (n=3) and d) VEGF (n=4). Bars represent mean +/- SEM, *P<0.05, **P<0.01, 
two-way ANOVA with Bonferonni post test. 
 
 
a) b) 
c) d) 
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3.2.12 INTERLEUKIN-1 RECEPTOR ANTAGONIST CAN INHIBIT HYPOXIC STIMULATED 
SMOOTH MUSCLE CELL PROLIFERATION 
 
Although IL- 1 was undetectable in culture supernatants by ELISA, the IL- 1 
pathway may still have a role in monocyte inhibition of hypoxic SMC 
proliferation. IL- 1 is known t be difficult to detect by ELISA owing to the fact 
that it has both a short half life and is released early on during inflammation. 
Work by Professor Sabroe’s group found that although they were unable to 
detect IL- 1 itself in culture supernatants they were able to modulate their 
phenotype by the addition of exogenous IL- 1ra showing a role for the IL- 1 
pathway in their model. Therefore, to further investigate a role of the IL-1 
pathway in the culture system above, SMC and monocyte cultures were pre-
incubated with increase concentrations of a) exogenous human IL- 1ra 
(Anakinra) and b) its matched placebo (carrier fluid alone). This experiment 
was carried out using at least two different vials of pulmonary artery SMCs at 
different passages.  
Hypoxic SMCs alone had significantly higher total cell counts than both their 
normoxic counterparts and hypoxic SMCs with monocytes (n=6) (Figure 3.12 
a). Exogenous IL- 1ra at 0.75 ng/ ml led to a small reduction in hypoxic SMC 
number when cultured alone compared to hypoxic co-culture values and 
normoxic SMC number (n=4). Hypoxic SMC number was reduced further with 
addition of 1.5 ng/ ml IL- 1ra when compared to both hypoxia co-culture and 
normoxia alone (n=4). At 3 ng/ ml IL- 1ra hypoxic SMC number dropped to 
numbers similar to normoxic SMC alone and of hypoxic co-culture (n=6). 
Cultures incubated with IL-1ra at concentrations of more than 3 ng/ ml had a 
reduced hypoxic SMC number comparable to hypoxia co-culture and normoxia 
alone values. 
To ensure the IL- 1ra carrier had no effect in the culture system, SMCs were 
grown both in normoxia and hypoxia with and without monocytes and either 3 
ng/ ml or 50 ng/ ml Anakinra IL-1ra placebo. Exogenous placebo had no effect 
on total cell counts and in each condition, cell number in hypoxia alone was 
significantly higher than in either normoxia alone or hypoxia co-culture, (n=4).  
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Figure 3.12 Exogenous IL-1ra can inhibit hypoxic stimulated smooth muscle 
cell proliferation 
SMCs were cultured in normoxia (19 kPa) alone (black) and hypoxia (3 kPa) with (red) 
or without (blue) addition of monocytes (1 monocyte: 5 SMC). Each condition was pre 
incubated with increasing concentrations of a) IL-1ra or b) placebo for 30 mins prior to 
24 hour culture. Total cell counts were performed by Coulter counter. Points represent 
mean +/- SEM a) *P<0.05, **P<0.01, ***P<0.001, cells from 2 seperate vials studied n=4 
0.75 ng/ ml and 1.5 ng/ ml, n=6 other values, two-way ANOVA with Bonferonni post 
test. b)  ***P<0.001, n=4, two-way ANOVA with Bonferonni post test. 
 
 
 
a) 
b) 
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3.2.13 INDIRECT EVIDENCE OF INTERLEUKIN- 1 ACTIVITY AS MEASEURED BY 
INTERLEUKIN- 8 EXPRESSION 
 
Addition of exogenous IL- 1ra had a biological effect in the culture system but it 
was not known if this was due to interruption of the IL- 1 pathway. As we were 
unable to detect IL- 1 by ELISA, IL- 8 expression was used as an indirect 
measure of IL- 1 pathway activation. Both IL- 1β and IL- 8 release are induced 
by activation of the MyD88 pathway thus reduced activation of this pathway by 
IL- 1ra should mediate a reduction in IL-8..  
SMC were grown in normoxia (19 kPa) and hypoxia (3 kPa) for 24 hours with or 
without pre-incubation with increase concentrations of exogenous IL- 1ra or 
placebo for 30 mins and with or without monocytes (1 monocyte: 5 SMC). Cell-
free supernatants were then collected and analysed by ELISA for IL- 8 release.  
Cell-free supernatants from a) SMC in normoxia alone (n=4), b) SMC in hypoxia 
alone (n=4) and c) SMC in hypoxia co-cultured with monocytes (n=4) had 
similar expression patterns of IL-8 (Figure 3.13). Each condition had a 
reduction in IL-8 with incubation of IL-1ra at concentrations of 3 ng/ ml or 
higher compared with no IL-1ra (n=4). 
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Figure 3.13 Indirect evidence of IL- 1 activity as measured by IL-8 expression  
SMCs were seeded at 25,000 cells /well and plates left to equilibrate in normoxia (19 
kPa) and hypoxia (3 kPa) for 24 hours. Following 48 hours serum starvation, plates 
were pre-incubated with increasing concentrations of exogenous IL-1ra for 30 mins 
prior to 24 hour culture with and without monocytes (1 monocyte: 5 SMC). Cell free 
supernatants were saved from samples cultured in a) normoxia alone, b) hypoxia alone 
and c) hypoxia with monocytes to be analysed by ELISA. Concentrations of interleukin-
8 pg/ ml were calculated using log transformation and linear regression analysis. Bars 
represent mean +/- SEM, *P<0.05, n=4, one-way ANOVA with Bonferonni post test.  
a) 
b) 
c) 
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3.2.14 MONOCYTES CANNOT INHIBIT GROWTH FACTOR INDUCED SMOOTH MUSCLE 
CELL PROLIFERATION  
 
Monocytes can inhibit hypoxic induced SMC proliferation but I was yet to 
determine if this is specific to hypoxia. To address this, the effect of monocytes 
on growth factor induced SMC proliferation was determined. The pro-
angiogenic growth factor PDGF was used at increased concentrations to 
stimulate SMC proliferation.  
SMCs were seeded at 25,000 cells /well with or without monocytes (1 
monocyte: 5 SMC) and increase concentrations of PDGF following 48 hour 
serum starvation. After 24 hour culture total cell counts were performed by 
Coulter counter. SMC number significantly increased with addition of 3 ng/ ml 
PDGF in monoculture (n=4) and in co-culture (n=4) (Figure 3.14). This increase 
in cell number was maintained at 10 ng/ ml PDGF. Addition of monocytes had 
no effect on total cell counts at either concentration of PDGF.     
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Figure 3.14 Monocytes cannot inhibit growth factor induced smooth muscle 
cell proliferation 
SMCs were seeded at 25,000 cells /well before quiescence. Plates were then co-
incubated with (blue) and without (green) monocytes (1 monocyte: 5 SMCs) and 
increasing concentrations of platelet derived growth factor (PDGF) for 24 hours. Total 
cell counts were performed by Coulter counter. Points represent mean +/- SEM, 
***P<0.001, n=6, two-way ANOVA with Bonferonni post test. 
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3.3 DISCUSSION 
 
In PAH, extracellular matrix deposition, endothelial dysfunction and aberrant 
channel formation lead to increase right ventricular pressure, poor oxygenation 
of the pulmonary vessels and eventually heart failure (Voelkel et al., 1995). 
Thickened medial layers underlie the vascular remodelling process however the 
trigger for this is still unknown. Much descriptive work has been done 
regarding phenotyping vascular changes associated with IPAH vessel 
remodelling but less is known about the role of the inflammatory component. It 
has been shown that these areas express the hypoxic inducible transcription 
factor HIF (Tuder et al., 2001) suggesting these areas may have localised 
hypoxia. With this in mind I was using physiological oxygen tensions of 3 kPa to 
gain a more reliable model for human conditions. Based on preliminary work in 
my methods a time frame of 24 hours was also selected (Chapter 2.4).  
I found hypoxia significantly increases pulmonary arterial SMC total cell 
number. The effect of hypoxia on pulmonary arterial SMC is a source of much 
contention (Tamm et al., 1998) (Dempsey et al., 1991) (Eddahibi et al., 1999) 
(Cooper et al., 1999). Previous data from the Glasgow group has shown that 
SMC cultured in 1 % O₂ total cell numbers went up after 48 hours (Dempsey, 
1991). Tamm et al have shown a significant increase in pulmonary arterial SMC 
proliferation after 48 hours in 3 % O₂ with 5 % FCS supplemented basal media 
(Tamm et al., 1998). This phenotype was mirrored using 5 % O₂ in serum 
starved conditions and in 1 % O₂ but 10 % FCS (Stotz et al., 2004) (Yang et al., 
2002). These results seem to strengthen the observed phenotype, however, 
there is a body of data to suggest hypoxia leads to decreased or no change in 
pulmonary arterial SMC proliferation. These studies largely involved either 
serum starvation or complete anoxia (Eddahibi et al., 1999) (Cooper et al., 
1999). Das’s group have attributed the pro-proliferative SMC phenotype seen in 
PAH plexiform lesions to fibroblasts which potentiate the differentiation of SMC 
from a non-proliferating contractile phenotype to a proliferative synthetic one 
using in vitro cell culture models (Stenmark et al., 2002). Perhaps fibroblast 
contamination could account for some of the discrepancies in the data sets.  
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Cultured primary SMCs isolated by the Cambridge group showed the 
pleuripotency of pulmonary arterial SMC when in hypoxia. Initial exposure of 
SMCs from passage 1-3 to 3-4 kPa O2 in media revealed inhibition of SMC 
proliferation as determined by [H³]-thymidine incorporation. However, when 
these cells were maintained at low density in hypoxia for 1-2 weeks a hypoxic 
stimulated subpopulation was revealed (Yang et al., 2002). Similar to healthy 
pulmonary arterial SMCs obtained from commercial companies, these cells had 
a proliferative phenotype in hypoxia (5 % O2) when in maintained culture. 
Unfortunately hypoxic growth rates of freshly isolated cells from commercial 
sources are unknown as each vial is received at passage 3. Reassuringly rates of 
proliferation as determined by total cell counts were similar for hypoxic 
commercial SMCs and hypoxic selected SMC subpopulations. Despite the 
different findings my robust data set supports the argument that hypoxia 
induces pulmonary artery SMC proliferation. These data may be useful to 
determine if local hypoxia is a trigger to SMC proliferation and thus vascular 
remodelling in disease.  
Regardless of the difference in SMC number in either oxygen tension, I found 
that metabolic activity was preserved. I used the redox indicator alamarBlue® 
which is commonly used to confirm cell viability. With a high redox potential 
alamarBlue® can be preferentially reduced by cytochromes and electron 
acceptors in the electron transport chain without disturbing the pathway. 
Aerobic mitochondrial respiration requires high oxygen tensions for generation 
of ATP. Oxygen is essential to convert electron acceptors to their oxidised state 
therefore adequate oxygen concentrations are essential for efficient 
mitochondrial function. Hypoxia results in the build-up of electron acceptors in 
their reduced state, without re-oxidation production of ATP is decreased so 
cells revert to anaerobic glycolytic respiration. The direct affect to 
mitochondrial respiration caused by hypoxia may not only affect alamarBlue® 
reduction but also may mean the dye is not a reliable indicator of viability under 
conditions of oxygen limitation. I instead used the dye to indicate the relative 
metabolic activity when compared to killed controls and normalised for SMC 
number. The preserved metabolic activity in hypoxic SMCs compared to 
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normoxia despite an increase in hypoxic cell number may be due to the 
metabolic shift in SMCs as they revert to anaerobic glycolysis rather than 
aerobic respiration in hypoxia. Although monocytes have the ability to utilise 
mitochondrial respiration, they are described as facultative anaerobes. Also 
another key myeloid cell, the neutrophil, has been shown to be predominantly 
glycolytic even in oxygen abundant conditions. Therefore I was reassured to see 
that monocytes also displayed preserved metabolic activity in either oxygen 
tension. Uniquely I have also shown that, like the neutrophil, the monocyte 
exhibits a pro-survival phenotype in hypoxia. 
As mentioned previously the medial layer of the pulmonary artery contains a 
heterogeneous population of SMCs. Frid et al have shown these consist of the 
non- proliferative ‘contractile’ state providing elasticity of vessels and 
extracellular matrix deposition the undifferentiated ‘synthetic’ state (Frid et al., 
1994). The latter has a motile and proliferative phenotype and has been 
described within plexiform lesions of PAH pulmonary arteries (Worth et al., 
2009). Due to the disparate nature of both these types of SMCs it was important 
to establish the type of SMCs used in my culture system and to ensure 
phenotypic switching was not occurring between oxygen tensions. I have 
successfully shown that both hypoxic and normoxic SMCs express the 
contractile SMC marker smooth muscle cell β actin and are negative for the 
synthetic SMC markers CD31 and Von Willebrand factor. These data not only 
suggest that the SMCs used are contractile but also that the cells are 
maintaining their phenotype in hypoxia.   
My most important finding came with monocyte and SMC co-culture using a 
physiologically relevant ration of 1 monocyte to 5 SMCs. I found that hypoxic 
increase in total SMC number after 24 hours was abrogated with addition of 
monocytes. This finding formed the basis of my PhD suggesting perhaps 
monocytes have a regulatory role in the pulmonary vascular system may have a 
protective role against vascular remodelling by aiding repair mechanisms when 
recruited to sites of inflammation. The potential for this key finding to be 
altered in the disease setting will be investigated further using monocytes 
isolated from IPAH patients cultured with healthy SMC in Chapter 4.  
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Reduction of hypoxic SMC number by monocytes could be mediated either by 
monocytes inducing SMC apoptosis or monocytes reducing SMC proliferation. 
The former was investigated by measuring SMC apoptosis with and without 
monocyte co-culture via TUNEL assays. I found that decrease in hypoxic SMC 
number in the presence of monocytes was not due to increased apoptosis 
suggesting monocytes play a role in preventing hypoxic pulmonary arterial SMC 
proliferation rather than inducing SMC death. Whether this was a contact 
dependant phenomenon was yet to be established so 0.4 µm transwell inserts 
were used to separate SMCs from monocytes and it was shown that monocyte 
inhibition of hypoxic SMC proliferation was contact independent suggesting 
monocytes are secreting something which is inhibiting hypoxic SMC 
proliferation. I then went on to identify if this secreted factor is transferable and 
found that not only hypoxic monocyte supernatant could inhibit hypoxic SMC 
number but also normoxic monocyte supernatant. This finding suggests that 
monocytes are constitutively releasing a factor which is inhibiting hypoxic SMC 
proliferation. Identification of this unknown factor became the aim of the next 
series of experiments.  
Monocytes are known to be a key source of cytokines and patient data from 
Humbert et al has shown that serum levels of IL- 6 and IL- 1 (both pro-
inflammatory cytokines) are significantly increased in IPAH when compared to 
healthy controls (Humbert et al., 1995). The MCT rat model also showed 
increased levels of IL-6 in the lungs upon pulmonary hypertension onset 
(Voelkel et al., 1994). Monocyte derived cytokines may be responsible for 
regulating hypoxic SMC proliferation. The alteration of systemic cytokine 
concentrations in disease may account for disease progression. Both IL- 8 and 
IL- 1β have both been shown to directly regulate SMC proliferation and 
adhesion molecule expression with IL- 8 reducing VCAM-1 expression in rat 
vascular SMCs (Zhang et al., 2011) and IL- 1β causing SMC proliferation in both 
rat derived cells (Wang et al., 2011) and human SMCs (Kim et al., 2010)a. With 
this in mind cell-free supernatants from SMCs alone, monocytes alone and 
monocyte and SMC co-cultures were analysed for pro-inflammatory cytokines 
by ELISA.  
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In order to closely resemble physiological conditions the TLR4 agonist was used 
to apply an inflammatory insult. Monocytes are recruited to the vasculature in 
areas of inflammation thus LPS was used as it is a well studied inflammatory 
stimulus with known robust effects. To ensure LPS did not effect SMC numbers 
in either oxygen tension or monocyte ability to inhibit hypoxic SMC number LPS 
was added to the culture system and cell counts performed. I found that 
addition of LPS did not alter SMC proliferation or monocyte ability to inhibit 
hypoxic SMC proliferation. With regards to cytokine production I found 
induction of IL-6, IL-8 and RANTES in co-culture, this was increased with LPS 
stimulation but IL-1 β proved difficult to detect. These data did not indicate a 
potential target factor responsible for monocyte inhibition of hypoxic SMC 
number but cytokine values were all much lower than anticipated from 
previous work looking at aortic vascular SMCs (Morris et al., 2005). In order to 
confirm my ability to detect cytokines, experiments were repeated using aortic 
vascular SMCs. Having found aortic cytokine responses to be the same as 
predicted values previously published (Morris et al., 2005) I found when 
compared to aortic cells, pulmonary arterial SMC were much less responsive 
with a marked reduction in expression of most cytokines. Moreover, in contrast 
to aortic vascular SMC, pulmonary arterial SMC were also poorly responsive to 
LPS. Work by Dr. Lawrie’s group identify further differences in lung versus 
systemic biology who found that whole body ApoE-/- /IL1-R1-/- double knock-
out mice had an alternate active transcript of IL-1R1 in pulmonary vascular 
cells compared to systemic vascular cells (Lawrie et al., 2011). The difference in 
both cell types was further illustrated when comparing total cell count values. 
Aortic vascular SMC numbers were overall higher after 24 hour culture 
compared to their pulmonary artery counterparts. Moreover, oxygen tension 
had no effect on aortic vascular SMC number suggesting both hypoxic SMC 
proliferation and monocyte inhibition of SMC proliferation is specific to the 
pulmonary artery.  
With the knowledge that patients with BMPRII mutations are more susceptible 
to developing PAH I looked at other members of the super family, namely TGF- 
β which is a known pro-proliferative cytokine. TGF- β has been shown by 
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Morrell’s group to cause proliferation of IPAH patient pulmonary arterial SMC. 
Conversely, he found TGF- β caused inhibition of pulmonary arterial SMC 
proliferation in healthy controls (Hansmann et al., 2008). I found TGF- β to be 
expressed at very low levels which remained unchanged with co-culture. 
Another profile which is increased in sera of patients with IPAH compared to 
healthy controls and patients from elective orthopaedic preadmission clinic is 
the glycoprotein OPG. The protein plays a role in vascular cells by binding TNF- 
related apoptosis inducing ligand (TRAIL) thus preventing TRAIL binding death 
receptors and activating apoptosis (Emery et al., 1998). It is known that OPG 
has been directly linked to inflammation via the IL-1 pathway with IL-1 α and β 
themselves inducing OPG production in human pulmonary arterial SMC 
(Hofbauer et al., 1999) (Lawrie et al., 2008). Therefore secreted OPG levels were 
determined in the culture system however, there was no change in OPG 
expression either by LPS stimulation or by oxygen tension in SMC alone or in 
SMC and monocyte co-cultures. 
Endothelin-1 expression is not only linked to PAH as a SMC pro-proliferative 
agent but it is also a HIF-2 α target gene which has been found in PAH plexiform 
lesions (Hickey et al., 2010). Surprisingly, ET-1 expression was maintained at 
very low levels in each oxygen tension and with co-culture. Despite the 
knowledge that SMC proliferate with response to ET-1, this phenomenon may 
be attributed to pulmonary artery endothelial cell production of ET-1. Further 
work surrounding this would be to carry out parallel co-cultures using the co-
culture model with pulmonary arterial endothelial cells and monocytes. 
Reassuringly I saw up regulation of the HIF target gene VEGF in hypoxia 
compared to normoxia in each condition. This provided strong evidence that 
culture conditions were reliably hypoxic with increased HIF stabilisation and 
activity. Seeing as VEGF is a key SMC proliferative stimulus it was hypothesised 
that hypoxia was inducing SMC proliferation in a VEGF dependant manner and 
monocytes were able to inhibit this by releasing soluble VEGF receptor- 1 (sFlt-
1) mopping up unbound VEGF. To test this hypothesis sFlt- 1 expression was 
measured in culture supernatants however sFlt- 1 could not be detected in 
either culture condition. Modulation of VEGF expression and the other growth 
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factors investigated may occur in disease suggesting an area of further work 
using cells from IPAH patients. 
Although IL- 1 was undetectable by ELISA I cannot conclude that the pathway is 
not involved in monocyte inhibition of hypoxic SMC proliferation. Co-culture 
work from Morris et al. using aortic SMC and monocytes found no detectable IL- 
1β, however, indirect evidence of IL -1β activation was detected. Addition of IL- 
1 receptor antagonist (IL- 1ra) caused dose dependant reduction of IL- 8 release 
which is a downstream target of IL- 1 (Morris et al., 2005). I was unable to 
detect IL- 1 and saw no change in secreted levels of IL- 1ra, although, I am yet to 
define the intracellular concentrations of IL- 1ra. Copper and Beasley suggested 
the IL- 1 pathway played a role in hypoxic SMC proliferation by similar 
mechanisms to IL- 1α associated hypoxic fibroblast proliferation (Cooper et al., 
1999). Work looking at healthy human vascular SMC from explants could not 
detect IL- 1α in supernatants but did find the cell-associated form was 
significantly increased in hypoxia. This increase in IL- 1α corresponded to an 
increase in vascular SMC proliferation. It is known that increased intracellular 
IL- 1α production can induce SMC migration and proliferation (Beasley et al., 
1992). Moreover, hypoxia has been shown to increase IL- 1α protein and mRNA 
in both monocytes and endothelial cells (Koga et al., 1992) (Shreeniwas et al., 
1992). However, the effect of hypoxia on SMC levels of IL- 1α is yet to be 
established. 
In order to further elucidate a role for the IL- 1 pathway and IL- 1ra itself in 
SMC proliferation I used exogenous IL- 1ra and found dose dependant 
inhibition of hypoxic SMC proliferation. Reassuringly I found a reduction in IL- 8 
release which was evident with IL- 1ra concentrations as low as 3 ng /ml 
indicating that addition of IL- 1ra in my model was having a biological effect. 
This may translate to disease progression as systemic administration of 10 μg 
/ml IL- 1ra by osmotic mini-pump to fat fed ApoE-/- /IL-1R1-/- double knock out 
mice significantly reduced development of PAH measured haemodynamically 
(Lawrie et al., 2011). IL- 1ra has previously been used as a protective agent for 
inflammatory PAH models. Work by Voelkel has shown that subcutaneous 
administration of 2 mg /kg IL- 1ra can significantly reduce MCT induced 
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increased mean pulmonary artery pressures but is unable to inhibit hypoxic 
induced increased mean pulmonary artery pressures in these same rats 
(Voelkel et al., 1993). He also shows induction of both IL- 1α and β mRNA and 
protein in pulmonary vessels from MCT PAH rats compared to chronic hypoxic 
rats (Voelkel et al., 1994). This work suggests that IL- 1α, β and receptor 
antagonist have no role in hypoxic vascular remodelling but does not address 
the selectivity of IL-1ra to the hypoxic proliferation response and forms the 
basis of a set of experiments in Chapter 4.  
To address the specificity of monocyte inhibition of hypoxic SMC proliferation I 
used PDGF to induce SMC proliferation. PDGF is a potent SMC proliferative 
stimulus with reproducible predicable results (Ikeda et al., 1990) (Raines et al., 
1989) (Tamm et al., 1998). I found monocytes were unable to inhibit PDGF 
induced SMC proliferation suggesting that monocyte inhibition of SMC 
proliferation only occurs for hypoxic induced SMC proliferation. 
In conclusion I found that hypoxia significantly reduced apoptosis rates of 
monocytes and induced pulmonary artery SMC proliferation after 24 hour 
culture. My key finding came after co-culture of both cell types. Monocytes were 
able to inhibit hypoxic SMC proliferation and this inhibition was independent of 
both monocyte hypoxia and direct cell contact.  This phenotype was specific to 
the pulmonary vasculature as aortic SMC had a different growth profile. 
Although I was unable to identify any pro-inflammatory cytokine or disease 
linked factor which may be mediating monocyte inhibition of hypoxic SMC 
proliferation, I found exogenous IL- 1ra could inhibit hypoxic SMC proliferation. 
However, selectivity of IL- 1ra for hypoxic proliferation is yet to be established. 
Furthermore, monocytes are unable to inhibit growth factor induced 
proliferation suggestion monocyte inhibition of SMC proliferation is specific to 
hypoxic induced proliferation. 
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4 MECHANISM OF HYPOXIC INHIBITION OF SMOOTH 
MUSCLE CELL PROLIFERATION 
 
4.1 INTRODUCTION 
 
The purpose of this chapter is to try and understand the potential mechanisms 
by which monocytes are inhibiting hypoxic SMC proliferation and the disease 
relevance of this finding. A very important pathway in PAH is the BMPR2 
pathway with heterozygous mutations in BMPR2 found in about 60 % of 
patients with hereditary PAH patients (Chida et al., 2012) and in 27 % of 
sporadic cases of idiopathic disease (Rosenzweig et al., 2008). BMPR2 is a 
member of the TGF-β superfamily. It is already known that the cytokine TGF-β 
can induce proliferation in SMCs obtained from IPAH patient lung explants but 
has no effect on SMCs obtained from unused donor lungs with no vasculopathy 
(commercial SMC) proliferation (Morrell et al., 2001). The TGF-β pathway 
elicits it proliferative effects via the SMAD proteins SMAD 2 and SMAD 3. These 
proteins are phosphorylated upon TGF-β receptor activation and bind the co-
SMAD protein, SMAD 4. Binding of the co-SMAD protein allows the complex to 
translocate to the nucleus leading to increase gene expression of proliferative 
mediators such as cyclin D (Chen et al., 2004) (Figure 4.1). 
Immunohistochemistry carried out on lung sections from patients with PAH 
compared to patients with secondary pulmonary hypertension or healthy 
unused donor lungs showed IPAH patient lung had decreased BMPR2 
expression. Interactions between the TGF-β receptor and BMPR2 was suggested 
in these lung sections due to co-localisation of both these receptors, however, 
TGF-β receptor expression was preserved in each of the conditions (Atkinson et 
al., 2002). Like the TGF-β receptor, the BMPR2 pathway also elicits its effects via 
SMAD proteins, using SMAD 1, 5 and 8 to increase gene expression of anti-
proliferative and apoptotic genes such as the DNA-binding protein inhibitor (Id-
1) and Bcl-2 (Nakao et al., 1997) (Tamaki et al., 1998) (Figure 4.1).  
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Figure 4.1 Cell signalling by the TGF- beta and BMPR2 pathway 
Transforming growth factor- beta receptor 2 (TGF-βR2) and bone morphogenetic 
protein receptor 2 (BMPR2) dimerisation with activin receptor-like kinase 5 (ALK5) 
also known as transforming growth factor- beta receptor 1 (TGF-βR1) or ALK 1 /2 /3 
respectively occurs upon ligand binding. Dimerisation leads to a phosphorylation 
cascade culminating in activation of receptor regulated SMAD 2 /3 with regards to 
TGF-β ligand binding and SMAD 1 /5 /8 with respect to BMP ligand activation. 
Phosphorylation of receptor regulated SMAD proteins allows binding of co-SMAD 4 and 
subsequent nuclear translocation. In the nucleus SMAD complexes bind CREB binding 
protein (CBP) allowing transcription of specific genes. TGF-β induces transcription of 
genes which contribute to cell cycle progression such as c-Myc whereas BMP results in 
anti-proliferative genes such as Id-1. Specific inhibitory SMADs regulate each pathway, 
SMAD 7 for TGF-β pathway and SMAD 6 for BMP pathway.   
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Both BMPR2 ligands, BMP 2 and 7 usually function to inhibit SMC proliferation. 
Previous work has shown that these ligands are ineffective in disease as this 
pathway is down regulated in PAH either by a dysfunctional receptor or 
dysregulation of the pathway members (Trembath et al., 2001) (Morrell et al., 
2001). To further understand the importance of mutations in this pathway on 
my phenotype I obtained IPAH patient SMCs from Dr. Morrell (Papworth, 
Cambridge, UK) with a specific mutation in BMPR2 where residue 401 is 
replaced by a serine residue. In parallel I isolated monocytes from patients with 
IPAH and systemic sclerosis associated PAH to investigate if the circulating 
myeloid cells are different from healthy donor monocytes.  
Chapter 3 showed that hypoxia leads to increased SMC numbers but it is still 
unknown how hypoxia leads to SMC proliferation. A potential pathway which 
may be implicated in hypoxic SMC proliferation is the HIF pathway. Not only 
has both protein and mRNA expression of the transcription factor been 
identified within IPAH lesions after vascular remodelling (Tuder et al., 2001) 
but also I have shown in Chapter 3 indirect evidence of HIF activation through 
increased protein expression of the HIF target gene VEGF. HIF is a heterodimer 
consisting of the ubiquitously expressed beta subunit and the oxygen sensitive 
alpha subunit. The HIF alpha subunit contains an ODDD consisting of a 
conserved sequence containing two preserved proline residues. When oxygen is 
readily available, specific PHD enzymes hydroxylate HIF and target it for 
degradation (Wykoff et al., 2000). The pan-hydroxylase inhibitor 
dimethyloxalylglycine (DMOG) inhibits PHD enzymes and thus stabilises HIF 
allowing its translocation to the nucleus. Pulmonary artery SMCs treated with 
DMOG have been shown to display enhanced proliferation with growth factor 
stimulation both by cell number and fluorescent DNA incorporation (Schultz et 
al., 2009), thus mimicking hypoxic proliferative effects in SMCs. Another 
indirect role of HIF in the pathogenesis of pulmonary hypertension was 
provided by work in the chronic hypoxia rat model. When these animals were 
administered 30 mg /kg dehydroepiandrosterone (DHEA), reduced vascular 
remodelling was observed compared to control rats administered PBS (Bonnet 
et al., 2003). Further work by Dessouroux et al found DHEA directly reduced 
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expression of HIF-1 alpha at the protein level in human pulmonary artery SMC 
suggesting a possible role of HIF in regulation of hypoxic induced pulmonary 
hypertension (Dessouroux et al., 2008).  
During cellular hypoxia most cells switch from aerobic respiration to anaerobic 
glycolysis because oxygen is needed as the terminal electron acceptor in 
mitochondrial respiration. In aerobic respiration electrons are shunted through 
the mitochondrial membrane via Complex I, Complex II, coenzyme Q, Complex 
III, cytochrome c and Complex IV until being transferred to molecular oxygen 
allowing protons to be transferred across the mitochondrial membrane 
resulting in synthesis of 26-30 molecules of adenosine tri-phosphate (ATP) 
(Berg et al., 2006). In IPAH patient pulmonary artery endothelial cells, oxygen 
consumption was reduced when compared to healthy controls as measured by 
5300A biological oxygen monitors and adapted polarographic oxygen 
electrodes. This was attributed to both a reduction in Complex IV activity seen 
spectrophotometrically, by MTT reduction and a reduction in total 
mitochondria numbers. With preserved ATP generation, a cellular switch to 
glycolysis was hypothesised (Xu et al., 2007). Myeloid cells are primarily 
glycolytic and are dependant on the HIF pathway for functional competence 
(Levene, 1912) (Kempner, 1939) (Walmsley et al., 2005) (Cramer et al., 2003). 
In order for all cells to function under oxidative stress and generate ATP the HIF 
pathway aids the switch to glycolysis with many glycolytic enzymes containing 
hypoxia response elements (HRE) in their promoter regions. 
The metabolic switch from aerobic to anaerobic respiration also coincides with 
a change in redox potential. Hypoxic wild type mice have been found by using 
lucigen enhanced chemiluminescence technique to have an increase in 
superoxide activity (Liu et al., 2005). This is paralleled by an increase in 
hydroeicosatetraenoic acid (HETE) in patients with severe PAH (Bowers et al., 
2004) and a decrease in antioxidant protein expression in IPAH patient lungs 
compared to unused donor lung (Masri et al., 2008). It is hypothesised that a 
reduction in antioxidant bioavailability coupled with changes in redox potential 
induced by hypoxia lead to the increase in ROS. Interestingly, inhibition of ROS 
by exogenous thrombin has been shown to reduce HIF-1 alpha protein levels in 
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vascular SMCs. This pathway may address why both mice with a whole body 
heterozygous deletion in HIF-1 and mice which have a deletion in one of the 
HIF-2 alpha alleles are protected from development of hypoxia induced 
pulmonary hypertension (Yu et al., 1999) (Brusselmans et al., 2003). 
I propose to further investigate the role of the HIF pathway in both hypoxic SMC 
proliferation and monocyte inhibition of hypoxic SMC proliferation. Using 
monocytes obtained from PAH patients compared to healthy controls I will 
establish the disease specificity of monocyte inhibition of SMC proliferation. 
Monocytes will be isolated from both IPAH patients, patients with an 
inflammatory associated form of the disease (systemic sclerosis associated 
PAH) and healthy volunteers. I will also establish differences between IPAH 
patient SMCs and healthy commercial SMCs in the established co-culture model. 
Seeing as IPAH SMCs have a known BMPR2 mutation, I will investigate if 
knocking down BMPR2 will recapitulate IPAH SMC phenotypes in commercial 
SMCs. Moreover with the knowledge that hypoxia significantly increases ROS 
generation and that ROS confers SMC proliferation, I will identify if monocytes 
are eliciting their hypoxic inhibition of SMC proliferation by antioxidant release. 
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4.2 RESULTS 
 
4.2.1 IPAH PATIENT MONOCYTES CANNOT INHIBIT HYPOXIC SMOOTH MUSCLE CELL 
PROLIFERATION 
 
Having found that healthy monocytes can inhibit hypoxic SMC proliferation, the 
next question was is this altered in the disease setting? To establish if 
monocytes from patients with PAH can inhibit hypoxic SMC proliferation to the 
same order of magnitude as monocytes from healthy controls, monocytes were 
isolated from healthy controls, IPAH patients and patients with scleroderma 
associated PAH (another inflammatory form of the disease used as a control).  
Healthy control SMCs were grown alone in hypoxia (3 kPa) or normoxia (19 
kPa) for 24 hours prior to 48 hours quiescence. SMCs were cultured for a 
further 24 hours with or without monocytes isolated from peripheral blood at a 
ratio of 1 monocyte: 5 SMCs. Post-culture, cells were lifted and total cell counts 
were calculated by Coulter counter (Figure 4.2). Commercial healthy SMC 
number increased in hypoxia compared to normoxia (n=8). This increase in cell 
number was significantly reduced with co-culture of SMCs and healthy donor 
monocytes (n=8) (Figure 4.2.a). 
In all conditions hypoxic monoculture caused a significant increase in total SMC 
number compared to normoxic monoculture. Monocytes isolated from patients 
with scleroderma associated PAH were also able to inhibit hypoxic SMC 
proliferation (n=12) (Figure 4.2.b).  Our key finding was that monocytes 
isolated from IPAH patients were unable to inhibit hypoxic SMC proliferation 
(n=10) (Figure 4.2.c). 
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Figure 4.2 IPAH patient monocytes cannot inhibit hypoxic smooth muscle 
cell proliferation 
SMCs were seeded at 25,000 cells /well and cultured in normoxia (19 kPa) (open bars) 
or hypoxia (3 kPa) (closed bars) for 24 hours prior to serum starvation. Plates were 
cultured for a further 24 hours in the presence and absence of monocytes isolated from 
peripheral blood of a) healthy volunteers, b) systemic sclerosis associated pulmonary 
artery hypertension patients (SSc-PAH) or c) IPAH at a ratio of 1 monocyte: 5 SMCs. 
Total cell counts were carried out by Coulter counter. Bars represent mean +/- SEM, 
*P<0.05, **P<0.01, ***P<0.001, ns= not significant, n=6 healthy volunteers, n=4 SSc-
PAH, n=3 IPAH, one-way ANOVA with Bonferonni post test. 
a) 
b) 
c) 
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4.2.2 IPAH PATIENT SMOOTH MUSCLE CELLS HAVE AN INCREASED PROLIFERATIVE 
PHENOTYPE INDEPENDENT OF HYPOXIA AND MAINTAINED METABOLIC ACTIVITY 
 
To establish if SMCs from patients have different growth profiles from SMCs 
obtained commercially from unused donor lungs with no known vasculopathy, 
SMCs obtained from a patient with IPAH were grown in normoxia (19 kPa) and 
hypoxia (3 kPa) with and without healthy donor monocytes. After 24 hour 
oxygen equilibration and 48 hour serum starvation cells are cultured for a 
further 24 hours with and without healthy donor monocytes.  
Post-culture, SMCs were lifted and total cell counts were calculated by Coulter 
counter. Initial findings showed that IPAH patient SMC number after oxygen 
equilibration and quiescence was increased showing these SMC were 
proliferating during serum starvation. To control for this cells were recovered 
both before and after 24 hour mono- or co-culture. Therefore all results are 
expressed as % recovery i.e. (number of SMC after 24 hour culture /number of 
SMC before 24 hour culture) x 100. When recovery was taken into account for 
commercial healthy SMCs, hypoxia significantly increased SMC recovery but this 
was significantly reduced with co-culture with monocytes (n=5) (Figure 4.3.a). 
There was no change in % recovery for IPAH patient SMC in each culture 
condition (n=6) (Figure 4.3.b). 
Reduction of alamarBlue® was used to measure metabolic activity and as an 
indirect measure of cell viability as described previously (Chapter 2.4.2). Cell 
free supernatants from IPAH patient SMC pre-incubated with the dye were 
compared with supernatants from 1 μg/ ml cycloheximide killed controls. 
Results are expressed as arbitrary units per 10,000 SMCs (Figure 4.3 c). When 
corrected for cell number there was no significant difference in relative 
metabolic activity in either oxygen tension (n=6). 
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Figure 4.3 IPAH patient smooth muscle cells have an increased proliferative 
phenotype independent of hypoxia and preserved metabolic activity 
SMCs obtained from an IPAH patient were seeded at 25,000 cells /well. Plates were 
cultured for 24 hours in normoxia (19 kPa) (open bars) or hypoxia (3 kPa) (closed 
bars) before serum starvation.  Plates were cultured for a further 24 hours with and 
without the addition of monocytes (1 monocyte: 5 SMCs). After quiescence and after 24 
hour culture cells were lifted and total cell counts were performed by Coulter counter. 
Cell numbers were expressed as % recovered after 24 hour culture for a) commercial 
SMC, n=5 and b) IPAH patient SMC, n=6. Bars represent mean +/- SEM, ***P<0.001, 
one-way ANOVA with Bonferonni post test. c) Relative metabolic activity was 
calculated by reduction of the redox indicator alamarBlue®. Results are normalised to 
cell number and bars represent mean +/- SEM, n=6. 
b) 
a) 
c) 
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4.2.3 IPAH PATIENT SMOOTH MUSCLE CELL VEGF EXPRESSION PROFILE 
 
To account for the increased proliferative phenotype of IPAH patient SMCs 
compared to their healthy counterparts it was postulated that patient cells had 
increased HIF pathway activity. It was possible to use expression of the HIF 
target gene VEGF as an indirect indicator of HIF activity. 
SMCs from IPAH patients were seeded at 25,000 cells /well and established in 
the co-culture model with and without the addition of 1 monocyte: 5 SMCs and 
/or LPS stimulation (10 ng /ml). Cell free supernatants were saved and 
analysed by ELISA for release of VEGF. SMCs from IPAH patients alone released 
approx. 1 1/2 times more VEGF than SMCs obtained commercially from 
explants donor lungs with no known vascular dysregulation (Figure 3.10). 
Contradictory to VEGF release from healthy commercial cells, VEGF release 
from IPAH SMCs was unaffected by oxygen tension or LPS stimulation (n=3). 
Co-culture with monocytes increased IPAH SMC VEGF release but this increase 
was not significantly different in either oxygen tension with or without LPS 
stimulation (Figure 4.4).  
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Figure 4.4 IPAH patient smooth muscle cell VEGF expression 
IPAH patient SMCs were seeded at 25,000 cells /well and left to equilibrate in 
normoxia (19 kPa) (open bars) or hypoxia (3 kPa) (closed bars) for 24 hours before 
inducing senescence. Patient SMCs and healthy volunteer monocytes were then 
cultured alone for 24 hours as well as both cell types co-cultured together (1 monocyte: 
5 SMCs). Cell free supernatants were obtained from cultures with and without LPS (10 
ng /ml) stimulation and analysed by ELISA. Values were calculated using log 
transformation and linear regression analysis. All Bars represent mean +/- SEM, n=6.  
 
 
 
131 
 
4.2.4 THE PAN-HYDROXYLASE INHIBITOR DMOG CAUSES SMOOTH MUSCLE CELL 
PROLIFERATION WHICH IS NOT INHIBITED BY MONOCYTES  
 
The mechanism by which monocytes can inhibit hypoxic SMC proliferation is 
unknown. However, it is known that SMCs must be hypoxic to reveal the 
phenotype therefore the mechanism may be HIF dependant. DMOG is a pan 
hydroxylase inhibitor thus inhibits activity of the prolyl hydroxylase enzymes 
which target HIF α subunits for degradation during abundant oxygen 
availability and stabilising HIF α protein expression. By determining whether 
monocytes can inhibit DMOG induced SMC proliferation we may be able to 
determine the hydroxylase dependence of monocyte inhibition of hypoxic SMC 
proliferation.  
Healthy SMCs obtained commercially from unused donor lungs were seeded at 
25,000 cells /well and placed in normoxia (19 kPa) for 24 hours prior to serum 
starvation. Cells were cultured for a further 24 hours with and without 
monocytes and increase concentrations of DMOG. Monocytes were isolated 
from peripheral blood of healthy volunteers and added at a ratio of 1 monocyte: 
5 SMCs. After culture total cell counts were performed by Coulter counter. SMC 
number increased with increase concentrations of DMOG but monocytes had no 
effect on increase in cell number (n=10) (Figure 4.5). 
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Figure 4.5 Monocytes cannot inhibit DMOG induced smooth muscle cell 
proliferation 
Commercial SMCs were seeded at 25,000 cells /well and placed in normoxia (19 kPa) 
for 24 hours prior to serum starvation. Cells were then incubated with increase 
concentrations of DMOG for a further 24 hours with and without 1 monocyte: 5 SMCs. 
After culture, cells were washed and counted by Coulter counter. Graph shows SMC 
monoculture in blue and SMC and monocyte co-culture in red. Data points show mean 
+/- SEM, n=6. 
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4.2.5 MONOCYTE SUPERNATANTS PRE-INCUBATED WITH DMOG MAINTAIN THE 
ABILITY TO INHIBIT HYPOXIC SMOOTH MUSCLE CELL PROLIFERATION 
 
Knowing that monocytes could not inhibit DMOG induced proliferation did not 
mean that monocyte inhibition of hypoxic SMC proliferation was HIF 
independent. DMOG may be adversely affecting the monocytes’ ability to inhibit 
hypoxic proliferation. To investigate this further, cell free normoxic monocyte 
supernatants were obtained after 24 hour culture with and without 100 µM 
DMOG.  
Meanwhile SMCs were seeded at 25,000 cells /well and were grown in 
normoxia (19 kPa) or hypoxia (3 kPa) for 24 hours before serum starvation. 
After quiescence cells were incubated for 24 hours with and without cell free 
supernatants. After culture, total cell counts were performed by Coulter 
counter. As shown previously (Figure 3.1) hypoxia significantly increased SMC 
number compared to normoxia. DMOG increased normoxic cell number (n=7) 
but hypoxia with DMOG significantly increased total cell counts compared to 
normoxic DMOG stimulation (n=7) (Figure 4.6). Monocyte supernatant 
inhibited hypoxic increase in cell number to normoxic levels (n=7). This was 
also true of DMOG treated monocyte supernatants (n=7) suggesting DMOG is 
not affecting monocytes’ ability to inhibit SMC proliferation.  
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Figure 4.6 Monocyte supernatants pre-incubated with DMOG maintain the 
ability to inhibit hypoxic smooth muscle cell proliferation 
Monocytes were resuspended at 0.1 x 106 /ml and incubated with and without DMOG 
(100 µM) for 24 hours before cell free supernatants were saved. SMCs were seeded at 
25,000 cells /well and grown in normoxia (19 kPa) (open bars) or hypoxia (3 kPa) 
(closed bars) for 24 hour prior to serum starvation. SMCs were then cultured for a 
further 24 hours with and without supernatants. Total cell counts were calculated by 
Coulter counter. Bars represent mean +/- SEM, ***P<0.001, n=7, two-way ANOVA with 
Bonferonni post test, †††P<0.001, n=7 one-way ANOVA with Bonferonni post test. 
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4.2.6 EXOGENOUS INTERLEUKIN- 1 RECEPTOR ANTAGONIST CAN INHIBIT DMOG 
INDUCED SMOOTH MUSCLE CELL PROLIFERATION 
 
Having found that IL- 1ra could inhibit SMC proliferation I went on to try and 
establish the specificity of IL- 1ra to hypoxia by using DMOG. If IL- 1ra can 
inhibit DMOG induced SMC proliferation then it is likely that the IL- 1 pathway 
is not important in monocyte inhibition of hypoxic SMC proliferation as 
monocytes themselves cannot inhibit DMOG induced SMC proliferation. To 
ensure results were robust at least 2 different vials of healthy commercial SMCs 
were used at different passages. 
SMCs were seeded at 25,000 cells /well and grown in normoxia for 24 hours 
prior to serum starvation. Plates were then cultured for a further 24 hours with 
and without 100 μM DMOG alone or with 10 ng /ml IL-1ra or 10 ng /ml IL-1ra 
placebo (IL-1ra carrier fluid alone). Total cell counts were performed after 
culture using a Coulter counter. A significant increase in cell number was 
observed with DMOG incubation compared to SMCs grown alone (n=12). This 
increase in cell number was significantly reduced with pre-incubation with 10 
ng /ml IL-1ra but not its placebo (n=12) (Figure 4.7). These data suggest IL-1ra 
inhibition of SMC proliferation is not specific to monocyte inhibition of hypoxic 
SMC proliferation.  
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Figure 4.7 Exogenous IL-1ra can block DMOG induced smooth muscle cell 
proliferation 
SMCs were seeded at 25,000 cells /well and following senescence, cells were incubated 
with and without 100 μM DMOG alone or with 10 ng/ ml IL-1ra or 10 ng/ ml IL-1ra 
placebo. Post-culture cells were washed and counted by Coulter counter. Bars 
represent mean +/- SEM, **P<0.01, ***P<0.001, n=12, one-way ANOVA with 
Bonferonni post test. 
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4.2.7 HIF-1 AND HIF-2 ALPHA PROTEIN REGULATION IN COMMERCIAL SMOOTH 
MUSCLE CELL AND MONOCYTE CO-CULTURES 
 
Although monocytes were unable to inhibit DMOG induced SMC proliferation, 
due to DMOG being a non-specific pan-hydroxylase, the HIF independency of 
monocytes ability to inhibit SMC proliferation could not be confirmed.  To 
further determine a role for the HIF pathway in both SMC proliferation and 
monocyte inhibition of hypoxic proliferation western blots were carried out on 
culture lysates for both HIF- 1 and HIF- 2α. 
Commercial SMCs obtained from unused donor lungs with no known 
vasculopathies were cultured in normoxia (19 kPa) and hypoxia (3 kPa) for 24 
hours with and without monocytes (1 monocyte: 5 SMCs) and /or DMOG (100 
μM). Samples were then lysed and probed for both HIF- 1 and HIF- 2α protein 
expression on western blots. Blots were then analysed by densitometry 
normalising to corresponding actin expression.  
SMCs alone had no HIF- 1α expression in normoxia however, both DMOG and 
hypoxia increased protein expression to similar levels (n=5) but monocytes had 
no inhibitory effect (n=5) (Figure 4.8). HIF- 1α has a predicted weight of 120 
kDa and actin of 40 kDa. With regards to HIF- 2α expression which has a 
predicted weight of 120 kDa, normoxic SMCs alone expressed little HIF- 2α but 
this was increased with monocyte co-culture (n=5) this was also true in hypoxia 
(n=5). DMOG treatment significantly increased HIF- 2α expression in SMC alone 
(n=5) (Figure 4.9).  
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Figure 4.8 HIF- 1α expression is increased in commercial smooth muscle 
cells by hypoxia and DMOG 
Commercial SMCs were seeded at 25,000 cells /well and cultured in normoxia (19 kPa) 
(open bars) or hypoxia (3 kPa) (closed bars) for 24 hours with and without monocytes 
(1 monocyte: 5 SMCs) and 100 μM DMOG. Post culture, cells were lysed and frozen at 
-80 °C before analysis by western blot. Graph represents densitometry results from five 
HIF- 1α (120 kDa) probed blots normalised to corresponding actin (40 kDa) 
expression. Bars represent mean +/- SEM, ***P<0.001, ns= not significant, students’ t-
test, n=5. Below shows representative western blot for HIF- 1α and actin loading 
control.   
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Figure 4.9 Expression of HIF- 2α is increased with co-culture in each oxygen 
tension and with DMOG stimulation 
Commercial SMCs were seeded at 25,000 cells /well and cultured in normoxia (19 kPa) 
(open bars) or hypoxia (3 kPa) (closed bars) for 24 hours with and without monocytes 
(1 monocyte: 5 SMCs) and 100 μM DMOG. Post culture, cells were lysed and frozen at 
-80 °C before analysis by western blot. Graph represents densitometry results from five 
HIF- 2α (120 kDa) probed blots normalised to corresponding actin (40 kDa) 
expression. Bars represent mean +/- SEM, *P<0.05, n=5, students’ t-test. Below shows 
representative western blot for HIF- 2α and actin loading control.   
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4.2.8 HIF-1 AND HIF-2 ALPHA PROTEIN EXPRESSION IN IPAH PATIENT SMOOTH 
MUSCLE CELL AND MONOCYTE CO-CULTURES 
 
Having seen a difference in HIF- 2 protein expression with and without the 
addition of monocytes I went on to determine if SMCs from patients with IPAH 
showed any difference in HIF expression with and without monocyte co- 
culture. IPAH patient SMCs were cultured alone or with monocytes (1 
monocyte: 5 SMCs) in normoxia (19 kPa) and hypoxia (3 kPa) with and without 
DMOG (100 μM). Samples were lysed and analysed by western blot for both 
HIF- 1 and HIF- 2α protein expression. Densitometry was used to quantify 
protein expression and results are normalised to corresponding actin 
expression. The predicted weights of both HIF α subunits are 120 kDa and actin 
is 40 kDa.  
HIF- 1α expression was present at low levels in patient SMCs at low passages 
(from passage 4-5), however, the later passages (from passage 6-8) this was not 
seen. Taken together, the data showed little HIF- 1α protein expression in 
normoxia with and without monocytes. Hypoxia and DMOG significantly 
increased HIF- 1α protein levels in SMC alone when compared to normoxic SMC 
alone (n=6). Both hypoxia and DMOG significantly increased HIF- 1 expression 
in SMC and monocyte co-cultures compared to normoxic co-cultures (n=6) 
(Figure 4.10). Oxygen tension or DMOG stimulation had little effect on SMC 
expression of HIF- 2α. However there was a trend of increased HIF- 2α 
expression in SMC and monocyte co-culture compared to SMCs alone which was 
significant in normoxia (n=4) (Figure 4.11). 
 
 
 
 
 
141 
 
 
 
                                          
                             
Figure 4.10 HIF-1 α expression is increased in hypoxia and with DMOG in 
IPAH patient smooth muscle cells 
IPAH patient SMCs were seeded at 25,000 cells /well and cultured in normoxia (19 
kPa) (open bars) or hypoxia (3 kPa) (closed bars) for 24 hours with and without 
monocytes (1 monocyte: 5 SMCs) and 100 μM DMOG. Post culture, cells were lysed and 
frozen at -80 °C before analysis by western blot. Graph represents densitometry results 
from six HIF- 1α probed blots normalised to corresponding actin expression. Bars 
represent mean +/- SEM, *P<0.05, **P<0.01, n=6, students’ t-test. Below shows 
representative western blot for HIF- 1α and actin loading control. 
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Figure 4.11 HIF- 2α expression in IPAH patient smooth muscle cells is 
preserved in each oxygen tension but increased with monocyte co-culture  
IPAH patient SMCs were seeded at 25,000 cells /well and cultured in normoxia (19 
kPa) (open bars) or hypoxia (3 kPa) (closed bars) for 24 hours with and without 
monocytes (1 monocyte: 5 SMCs) and 100 μM DMOG. Post culture, cells were lysed and 
frozen at -80 °C before analysis by western blot. Graph represents densitometry results 
from four HIF- 2α probed blots normalised to corresponding actin expression. Bars 
represent mean +/- SEM, *P<0.05, n=4, students’ t-test. Below shows representative 
western blot for HIF- 2α and actin loading control.   
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4.2.9 HIF-1 ALPHA SIRNA TRANSFECTION IN COMMERCIAL AND IPAH PATIENT 
SMOOTH MUSCLE CELLS 
 
The different effects of monocyte co-culture on commercial and IPAH patient 
hypoxic SMC HIF-1 expression was explored using siRNA targeting HIF- 1α to 
transfect both commercial and IPAH patient SMCs. These experiments would 
help identify any HIF- 1 dependence of monocyte inhibition of hypoxic SMC 
proliferation. Cells were seeded at 35,000 cells /well and either mock 
transfected, transfected with 2 µM scrambled siRNA or with HIF- 1α siRNA after 
which cells were incubated for 24 hours in normoxia (19 kPa) or hypoxia (3 
kPa). Cell counts were performed by Coulter counter and lysates made for RNA 
isolation.  
Commercial SMCs obtained from unused donor lungs displayed significantly 
increased cell number in hypoxic mock and scrambled siRNA transfected 
samples compared to normoxic counterparts (n=9) (Figure 4.12a). There was 
no significant difference in cell number in each oxygen tension when 
transfected with HIF- 1 siRNA. There was an increase in normoxic HIF- 1 siRNA 
transfected cell number compared to normoxic mock infected. While hypoxic 
HIF- 1 transfected cell numbers were unchanged when compared to hypoxic 
mock infected numbers. 
This increase may be due to inefficient HIF- 1α knockdown. To establish 
transfection efficiency, real-time TaqMan PCR was used to quantify HIF- 1 RNA 
expression normalised to actin for each sample. For each experiment values 
were normalised to mock infected samples and expressed as % change from 
mock infected. In both normoxia  and hypoxia HIF- 1α transfected samples had 
significantly less HIF- 1α expression when compared to scrambled controls 
(n=9) (Figure 4.12b) (n=9) (Figure 4.12c). HIF-2 siRNA had no effect on HIF-1 
mRNA expression in each oxygen tension. 
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IPAH patient SMC number was maintained in hypoxia and normoxia for mock 
infected, scrambled siRNA transfected and HIF-1 α transfected samples (n=7) 
(Figure 4.13a). Transfection efficiency for all normoxic (Figure 4.13b) and 
hypoxic (Figure 4.13c) samples was determined by TaqMan real-time PCR. All 
samples were normalised to actin and each experiment normalised to mock 
infected samples. Data is expressed as % change from mock infected samples. In 
normoxia HIF- 1α expression was significantly reduced compared with 
scrambled siRNA transfected samples, this was also found in hypoxia (n=7). 
HIF-2 siRNA had no significant effect on HIF-1 mRNA in either oxygen tension. 
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Figure 4.12 HIF- 1α knockdown increased normoxic commercial smooth 
muscle cell number but had no effect in hypoxia  
Commercial SMCs were seeded at 35,000 cells /well and transfected with 2 µM siRNA 
targeting HIF- 1α. After transfection and 24 hour culture in normoxia (open bars) (19 
kPa) and hypoxia (3 kPa) (closed bars) a) total cell counts were performed for mock 
infected, scrambled siRNA transfected and HIF- 1α siRNA transfected samples by 
Coulter counter. Bars represent mean +/- SEM, ***P<0.001, ns= not significant, cells 
from two separate vials studied n=9, two-way ANOVA with Bonferonni post test, 
†††P<0.001, ns= not significant, cells from two separate vials studied n=9, one-way 
ANOVA with Bonferonni post test. RNA expression of HIF- 1α normalised to actin as 
shown as % change from mock infected samples are shown for b) normoxic samples 
and c) hypoxic samples. Bars represent mean +/- SEM, **P<0.01, ***P<0.001, ns= not 
significant, n=9, students’ t-test.  
b) 
c) 
a) 
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Figure 4.13 HIF- 1α did not change total IPAH smooth muscle cell number in 
either oxygen tension  
IPAH patient SMCs were seeded at 35,000 cells /well and transfected with 2 µM siRNA 
targeting HIF- 1α. After transfection and 24 hour culture in normoxia (open bars) (19 
kPa) and hypoxia (3 kPa) (closed bars) a) total cell counts were performed for mock 
infected, scrambled siRNA transfected and HIF- 1α siRNA transfected samples by 
Coulter counter. Bars represent mean +/- SEM, ***P<0.001, ns= not significant, n=7, 
two-way ANOVA with Bonferonni post test. RNA expression of HIF- 1α normalised to 
actin as shown as % change from mock infected samples are shown for b) normoxic 
samples and c) hypoxic samples. Bars represent mean +/- SEM, *P<0.05, ***P<0.001, 
ns= not significant, n=7, students’ t-test. 
a) 
b) 
c) 
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4.2.10 HIF-2 ALPHA KNOCK-DOWN IN COMMERCIAL AND IPAH SMOOTH MUSCLE 
CELLS 
 
Having observed a difference in HIF- 2 expression in both commercial and IPAH 
patient SMCs with and without monocytes I used siRNA targeting HIF- 2α in 
both commercial and IPAH patient SMCs to investigate the importance of HIF- 
2α in SMC proliferation. Before transfection, cells were seeded at 35,000 cells 
/well and then mock transfected or transfected with 2 µM scrambled siRNA or 
with HIF- 2α siRNA. Plates were then incubated for 24 hours in normoxia (19 
kPa) or hypoxia (3 kPa) after which cell counts were then performed by Coulter 
counter and lysates made for RNA isolation.  
Commercial cells obtained from unused donor lungs with no vascular 
irregularities have a significantly increased cell number in hypoxia compared to 
normoxia in each transfection condition (n=7) (Figure 4.14a). Transfection 
efficiency was established at the RNA level by TaqMan PCR normalising to actin. 
For each experiment samples were normalised to mock infected samples and 
expressed as % change from mock infected. HIF- 2 siRNA significantly reduced 
normoxic and hypoxic HIF- 2 expression compared to scrambled controls (n=7) 
(Figure 4.14b), (n=7) (Figure 4.14c). HIF- 1 siRNA had no effect on HIF- 2 mRNA 
expression in either normoxia or hypoxia. 
Cell numbers from IPAH patient SMC were unaffected by oxygen tension or 
transfection with HIF- 2α siRNA (n=7) (Figure 4.15a). TaqMan PCR was used to 
determine transfection efficiency of normoxic (Figure 4.15b) and hypoxic 
(Figure 4.15c) samples. Samples were normalised to actin and each 
experimental data point to mock infected sample. Data is expressed as % 
change from mock infected. HIF- 2α expression was significantly reduced in 
normoxic HIF- 2α transfected samples compared to samples transfected with 
scrambled siRNA (n=7). Hypoxic samples transfected with HIF- 2 siRNA had 
significantly reduced HIF- 2 mRNA expression compared to scrambled controls 
(n=7). HIF- 1 siRNA had no effect on HIF- 2 expression in either oxygen tension. 
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Figure 4.14 Knockdown of HIF- 2α in commercial smooth muscle cells did 
not change total cell counts 
Commercial SMCs were seeded at 35,000 cells /well and transfected with 2 µM siRNA 
targeting HIF- 2α. After transfection and 24 hour culture in normoxia (open bars) (19 
kPa) and hypoxia (3 kPa) (closed bars) a) total cell counts were performed for mock 
infected, scrambled siRNA transfected and HIF- 2α siRNA transfected samples by 
Coulter counter. Bars represent mean +/- SEM, *P<0.05, ***P<0.001, cells from two 
separate vials studied n=7, two-way ANOVA with Bonferonni post test. RNA expression 
of HIF- 2α normalised to actin as shown as % change from mock infected samples are 
shown for b) normoxic samples and c) hypoxic samples. Bars represent mean +/- SEM, 
**P<0.01, ns= not significant, n=7, students’ t-test. 
a) 
b) 
c) 
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Figure 4.15 IPAH patient smooth muscle cell number was preserved with 
HIF- 2α knockdown 
IPAH patient SMCs were seeded at 35,000 cells /well and transfected with 2 µM siRNA 
targeting HIF- 2α. After transfection and 24 hour culture in normoxia (open bars) (19 
kPa) and hypoxia (3 kPa) (closed bars) a) total cell counts were performed for mock 
infected, scrambled siRNA transfected and HIF- 2α siRNA transfected samples by 
Coulter counter. Bars represent mean +/- SEM, ns= not significant, n=7, two-way 
ANOVA with Bonferonni post test. RNA expression of HIF- 2α normalised to actin as 
shown as % change from mock infected samples are shown for b) normoxic samples 
and c) hypoxic samples. Bars represent mean +/- SEM, *P<0.05, ns= not significant, 
n=7, students’ t-test. 
a) 
b) 
c) 
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4.2.11 HIF-1 AND HIF-2 ALPHA DOUBLE KNOCK-DOWN IN PRIMARY SMOOTH 
MUSCLE CELLS 
 
Having found differential roles for both HIF- 1 and HIF- 2α in normoxic 
commercial SMC proliferation and IPAH patient SMC proliferation I went on to 
transfect both commercial and IPAH patient SMCs with a mix of HIF- 1 and HIF- 
2α siRNA at ratio of 1:1. The day before transfection, SMCs were seeded at 
35,000 cells /well. The next day cells were either, mock transfected, transfected 
with 2 µM scrambled siRNA or transfected with a 1:1 mix of HIF- 1 and HIF- 2α 
siRNAs. After transfection cells were incubated for a further 24 hours in 
normoxia (19 kPa) or hypoxia (3 kPa). Post-culture total cell counts were then 
performed by Coulter counter and lysates made for RNA isolation.  
In each condition hypoxia significantly increased commercial SMC number 
compared to normoxia. Co-transfection with both HIF- 1 and HIF- 2α siRNA had 
no effect on cell number in each oxygen tension (n=6) (Figure 4.16a). Relative 
HIF- 1 RNA expression was determined by TaqMan PCR to show transfection 
efficiency.  TaqMan data showed a significant reduction in HIF- 1 and HIF- 2 
expression in both normoxia and hypoxia for HIF- 1 and HIF- 2α siRNA co-
transfected samples compared to scrambled siRNA transfected samples. All 
samples are normalised to actin and expressed as % change from mock infected 
(n=6) (Figure 4.16b) (n=6) (Figure 4.16c). 
IPAH patient SMC total cell numbers were equivalent for both normoxic and 
hypoxic SMCs which were either mock transfected or transfected with non-
targeting scrambled siRNA. Co-transfection with both HIF- 1 and HIF- 2α siRNA 
had no effect on total cell counts in either normoxia or hypoxia (Figure 4.17a). 
To determine efficiency of HIF- 1α knockdown TaqMan PCR was used. In both 
normoxia and hypoxia HIF- 1α expression was significantly reduced in co-
transfected samples in normoxia and hypoxia compared to mock infected 
samples. Samples were normalised to actin and data from each experiment 
normalised to mock infected samples. Data is expressed as % change from mock 
infected (n=6) (Figure 4.17b). The expression of HIF- 2α was also determined 
by TaqMan real-time PCR. Data shows that co-transfection with both HIF- 1 and 
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HIF- 2α siRNAs significantly reduce HIF- 2α expression in both normoxia and 
hypoxia. Data is normalised to actin and expressed as % change from mock 
transfected samples (n=6) (Figure 4.17c). 
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Figure 4.16 HIF- 1 and HIF- 2α co-transfection did not change total cell 
numbers in commercial smooth muscle cells 
Commercial SMCs were seeded at 35,000 cells /well and transfected with 2 µM siRNA 
targeting both HIF- 1 and HIF- 2α. After transfection and 24 hour culture in normoxia 
(open bars) (19 kPa) and hypoxia (3 kPa) (closed bars) a) total cell counts were 
performed for mock infected, scrambled siRNA transfected and HIF siRNA transfected 
samples by Coulter counter. Bars represent mean +/- SEM, ***P<0.001, cells from two 
separate vials studied n=6, two-way ANOVA with Bonferonni post test. RNA expression 
of b) HIF- 1α and c) HIF- 2α normalised to actin as shown as % change from mock 
infected samples are shown for normoxic and hypoxic samples. Bars represent mean 
+/- SEM, *P<0.05, ***P<0.001, students’ t-test. 
HIF- 1 expression HIF- 2 expression 
a) 
b) c) 
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Figure 4.17 IPAH patient smooth muscle cell number was preserved with 
HIF-1 and HIF-2 α co-transfection  
IPAH patient SMCs were seeded at 35,000 cells /well and transfected with 2 µM siRNA 
targeting both HIF- 1 and HIF- 2α. After transfection and 24 hour culture in normoxia 
(open bars) (19 kPa) and hypoxia (3 kPa) (closed bars) a) total cell counts were 
performed for mock infected, scrambled siRNA transfected and HIF siRNA transfected 
samples by Coulter counter. Bars represent mean +/- SEM, ***P<0.001, n=6, two-way 
ANOVA with Bonferonni post test. RNA expression of b) HIF- 1α and c) HIF- 2α 
normalised to actin as shown as % change from mock infected samples are shown for 
normoxic and hypoxic samples. Bars represent mean +/- SEM, *P<0.05, ***P<0.001, 
students’ t-test. 
a) 
HIF- 1 expression HIF- 2 expression b) c) 
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4.2.12 PROTEIN EXPRESSION OF HIF-1 AND HIF-2 ALPHA IN TRANSFECTED 
COMMERCIAL SMOOTH MUSCLE CELLS 
 
Transfection efficiency at the RNA level has been shown to be effective. I then 
wanted to determine the consequence of RNA knockdown with regards to 
protein expression. SMCs obtained commercially as healthy cells with no 
vascular abnormalities were seeded at 35,000 cells /well and either mock 
infected or transfected with 2 µM siRNA. After transfection and 24 hour culture 
in either normoxia (19 kPa) or hypoxia (3 kPa) protein lysates were made for 
analysis by western blot. Blots were then analysed by densitometry normalising 
to corresponding actin expression.  
SMCs had no HIF- 1α expression in normoxia so transfection had no effect on 
normoxic HIF- 1α expression. Hypoxia increased HIF- 1α expression in both 
mock and scrambled siRNA transfected cells. Transfection with HIF- 1α siRNA 
significantly reduced HIF-1 protein expression (n=4) (Figure 4.18). HIF- 2α 
protein expression was more stable in normoxia and HIF- 2 siRNA significantly 
reduced expression compared to mock and scrambled siRNA transfected 
samples (n=4). HIF- 2α protein was expressed highly in both hypoxic mock and 
scrambled siRNA samples but this was dramatically reduced in HIF- 2α siRNA 
transfected samples (n=4) (Figure 4.19).  
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Figure 4.18 HIF- 1α siRNA transfection in commercial smooth muscle cells 
reduced HIF- 1α protein expression in hypoxia  
Commercial SMCs were seeded at 35,000 cells /well and either mock transfected or 
transfected with 2 µM siRNA targeting HIF- 1 or non-targeting siRNA. After 
transfection and 24 hour culture in normoxia (open bars) (19 kPa) and hypoxia (3 kPa) 
(closed bars) cells were lysed. Graph represents densitometry results from four HIF- 
1α probed blots normalised to corresponding actin expression. Bars represent mean 
+/- SEM, *P<0.05, **P<0.01, n=4, students’ t-test. Below shows a representative 
western blot for HIF- 1 and actin loading control. HIF- 1α has a predicted weight of 120 
kDa and actin of 40 kDa.  
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Figure 4.19 Protein expression of HIF- 2α was reduced in commercial 
smooth muscle cells with HIF - 2α siRNA transfection 
Commercial SMCs were seeded at 35,000 cells /well and either mock transfected or 
transfected with 2 µM siRNA targeting HIF- 2α or non-targeting siRNA. After 
transfection and 24 hour culture in normoxia (open bars) (19 kPa) and hypoxia (3 kPa) 
(closed bars) cells were lysed. Graph represents densitometry results from four HIF- 
2α probed blots normalised to corresponding actin expression. Bars represent mean 
+/- SEM, *P<0.05, n=4, students’ t-test. Below shows a representative western blot for 
HIF- 2 and actin loading control. HIF- 2α has a predicted weight of 120 kDa and actin of 
40 kDa. 
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4.2.13 PROTEIN EXPRESSION OF HIF-1 AND HIF-2 ALPHA IN HIF- 1 AND HIF- 2 
ALPHA SIRNA TRANSFECTED IPAH PATIENT SMOOTH MUSCLE CELLS  
 
IPAH patient SMC transfection efficiency at the protein level was determined 
next. IPAH patient SMCs were seeded at 35,000 cells /well and either mock 
infected or transfected with 2 µM scambled siRNA or 2 µM siRNA targeting 
either HIF- 1α or HIF- 2α. After transfection and 24 hour culture in normoxia 
(19 kPa) or hypoxia (3 kPa), protein lysates were made for analysis by western 
blot. Blots were then analysed by densitometry normalising to corresponding 
actin expression.  
Patient SMC HIF-1 protein expression was very low in normoxia so transfection 
with HIF-1 siRNA had no effect. Hypoxia increased HIF- 1α protein expression 
and this was significantly reduced with HIF- 1α transfection (n=4) (Figure 
4.20). HIF- 2α protein expression was present at similar levels in normoxia and 
hypoxia. HIF- 2 siRNA significantly reduced HIF-2 protein compared to mock 
and scrambled siRNA counterparts in normoxia (n=4) and hypoxia (n=4) 
(Figure 4.21).  
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Figure 4.20 Hypoxic increase in IPAH patient smooth muscle cell HIF- 1α 
expression was lost with HIF- 1α siRNA transfection 
IPAH patient SMCs were seeded at 35,000 cells /well and transfected with 2 µM siRNA 
targeting HIF- 1 or non-targeting scrambled siRNA. After transfection and 24 hour 
culture in normoxia (open bars) (19 kPa) and hypoxia (3 kPa) (closed bars) cells were 
lysed. Graph represents densitometry results from four HIF- 1α probed blots 
normalised to corresponding actin expression. Bars represent mean +/- SEM, *P<0.05, 
**P<0.01, n=4, students’ t-test. Below shows a representative western blot for HIF- 1 
and actin loading control. HIF- 1α has a predicted weight of 120 kDa and actin of 40 
kDa.  
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Figure 4.21 Protein expression of HIF-2α was abolished in both oxygen 
tensions with HIF-2α siRNA transfection in IPAH patient smooth muscle cells  
IPAH patient SMCs were seeded at 35,000 cells /well and transfected with 2 µM siRNA 
targeting HIF- 2 or non-targeting scrambled siRNA. After transfection and 24 hour 
culture in normoxia (open bars) (19 kPa) and hypoxia (3 kPa) (closed bars) cells were 
lysed. Graph represents densitometry results from four HIF- 2α probed blots 
normalised to corresponding actin expression. Bars represent mean +/- SEM, *P<0.05, 
**P<0.01, n=4, students’ t-test. Below shows a representative western blot for HIF- 2 
and actin loading control. HIF- 2α has a predicted weight of 120 kDa and actin of 40 
kDa.  
Nx Hx m
o
ck
 
scram
 
H
IF 2
 
m
o
ck
 
scram
 
H
IF 2
 
150 kDa 
100 kDa 
 40 kDa Actin 
HIF-2α 
160 
 
4.2.14 BMPR2 KNOCKDOWN IN COMMERCIAL SMOOTH MUSCLE CELLS 
RECAPITULATED THE IPAH PATIENT SMOOTH MUSCLE CELL PHENOTYPE 
 
The vial of IPAH patient SMCs I used had a known mutation in BMPR2. This 
mutation has a serine substitution from the leucine at residue 401 in the kinase 
domain of the protein making it functionally inactive. The inactive BMPR2 
protein is thought to be responsible for the SMC hyperproliferative phenotype 
therefore siRNA transfection of healthy commercial SMCs targeting BMPR2 
should induce an IPAH patient SMC phenotype.  
To test this hypothesis, commercially available healthy SMCs with no known 
vascular abnormalities were transfected with siRNA targeting BMPR2. 
Commercial SMCs were seeded at 35,000 cells /well and were either, mock 
transfected, transfected with 2 µM scrambled siRNA or 2 µM siRNA targeting 
BMPR2. Post-transfection plates were cultured for 24 hours in normoxia (19 
kPa) or hypoxia (3 kPa) and total cell counts performed.  
Transfection with BMPR2 significantly increased normoxic cell number when 
compared to mock infected samples. This increase was unaffected by co-culture 
with monocytes (n=6) (Figure 4.22a). Transfection efficiency was calculated by 
TaqMan PCR. Samples were normalised to actin and expressed as % change 
from mock infected. BMPR2 siRNA significantly reduced BMPR2 expression 
when compared to scrambled siRNA transfected samples (n=6) (Figure 4.22b).  
Total cell counts of transfected SMCs in hypoxia were unaffected by either 
transfection condition or co-culture with monocytes (n=6) (Figure 4.23a). 
Efficiency of transfection was calculated by real-time TaqMan PCR and 
normalised to actin. All data is expressed as % change from mock transfected. 
BMPR2 transfection significantly reduced BMPR2 expression compared to 
scrambled siRNA transfection (n=6) (Figure 4.23b). 
 
 
161 
 
 
Figure 4.22 BMPR2 siRNA transfection increased normoxic smooth muscle 
cell number and monocyte co-culture did not inhibit this increase 
Commercial SMCs were seeded at 35,000 cells /well and transfected with 2 µM siRNA 
targeting BMPR2. After transfection and 24 hour culture in normoxia (19 kPa) a) total 
cell counts were performed for mock infected, scrambled siRNA transfected and 
BMPR2 siRNA transfected samples by Coulter counter. Bars represent mean +/- SEM, 
**P<0.01, n=6 experiments, one-way ANOVA with Bonferonni post test. b) RNA 
expression of BMPR2 normalised to actin as shown as % change from mock infected. 
Bars represent mean +/- SEM, *P<0.05, students’ t-test. 
 
 
a)  
b)  
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Figure 4.23 Hypoxic smooth muscle cell number was preserved with and 
without BMPR2 siRNA transfection 
Commercial SMCs were seeded at 35,000 cells /well and transfected with 2 µM siRNA 
targeting BMPR2. After transfection and 24 hour culture in hypoxia (3 kPa) a) total cell 
counts were performed for mock infected, scrambled siRNA transfected and BMPR2 
siRNA transfected samples by Coulter counter. Bars represent mean +/- SEM. b) RNA 
expression of BMPR2 normalised to actin as shown as % change from mock infected. 
Bars represent mean +/- SEM, **P<0.01, students’ t-test. 
a)  
b)  
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4.2.15 SMOOTH MUSCLE CELL NUMBER IS PRESERVED WITH CO-INCUBATION WITH 
TROLOX 
 
With the discovery that hypoxic SMC proliferation was HIF independent other 
hypoxic regulated pathways which were able to affect SMC proliferation were 
investigated. One possibility was that hypoxic induced ROS was driving 
proliferation and monocyte derived antioxidants were able to neutralise ROS 
dependant SMC proliferation. To test the hypothesis that ROS were inducing 
hypoxic SMC proliferation I used the vitamin E analogue and antioxidant Trolox 
in the hope that this would reduce hypoxic SMC number by preventing 
oxidation.  
Healthy commercial SMCs were seeded at 25,000 cells /well and cultured in 
normoxia (Nx) (19 kPa) and hypoxia (Hx) (3 kPa) prior to serum starvation. 
Plates were cultured for a further 24 hours with increase concentrations of 
Trolox. Total cell counts were then performed by Coulter counter. Total cell 
numbers were significantly increased in hypoxia compared to normoxia (n=3). 
Increase concentrations of Trolox had no additive effect on total cell numbers 
(Figure 4.24).  
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Figure 4.24 Smooth muscle cell numbers are unchanged by incubation with 
increase concentrations of Trolox 
SMCs were seeded at 25,000 cells /well and cultured in normoxia (Nx) (19 kPa) and 
hypoxia (Hx) (3 kPa) prior to serum starvation. Cells were then cultured for a further 
24 hours with increase concentrations of Trolox. After culture, cells were washed and 
counted by Coulter counter. Graph shows normoxic cultures in blue and hypoxic 
cultures in red. Data points show mean +/- SEM, *P<0.05, n=3, one-way ANOVA with 
Bonferonni post test. 
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4.3 DISCUSSION 
 
Despite the discovery of mutations in BMPR2 predisposing to PAH, the specific 
triggers of PAH and the cause of BMPR2 mutation independent cases are 
unknown. However, immune cell infiltration is often found surrounding both 
concentric and plexiform lesions formed in developed PAH. Despite the 
presence of these cells being increased in areas of vascular remodelling and 
monocytes being found to extravate diseased endothelium the exact role of 
these cells in PAH disease progression is yet to be established. I have shown 
that monocytes isolated from peripheral blood of patients with IPAH are unable 
to inhibit hypoxic SMC proliferation. This is not true of monocytes obtained 
from patients with an inflammatory associated form of the disease. Systemic 
sclerosis is an autoimmune disease characterised by increased inflammation 
and collagen deposition. Systemic sclerosis associated PAH has many 
similarities to IPAH both with its vascular remodelling and inflammatory 
component. Similar to IPAH, in many cases of systemic sclerosis associated PAH, 
an increase in TGF-β pathway activation is observed. However, monocytes from 
systemic sclerosis associated PAH patients were able to inhibit hypoxic SMC 
proliferation showing that monocyte inability to inhibit hypoxic SMC 
proliferation is specific to sporadic forms of the disease. Moreover, the inability 
of IPAH monocytes to inhibit hypoxic SMC proliferation suggests that the 
circulating myeloid cells display an altered phenotype to myeloid cells from 
healthy controls.  
This is supported by work from Bull et al. who found differences in gene 
expression for PBMCs obtained from IPAH patients and associated forms of the 
disease compared to healthy controls. The group analysed PBMCs obtained 
from IPAH patients, associated PAH patients and healthy volunteers. Using 
Affymetrix array chips a microarray was carried out on lysates of each cohort 
analysing about 6,000 genes. After analysis approximately 3,000 genes were 
identified to be comparable in all subjects. Unsurprisingly, cluster analysis 
showed a strong linkage in gene expression of IPAH and associated PAH 
samples compared to the healthy controls. This was validated in a second set of 
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samples; excitingly this second validation led to discovery of a key difference 
between IPAH patient PBMCs and associated PAH PBMCs. IPAH patient PBMC 
expression of the herpes virus entry mediator encoding gene HVEM was 
dramatically increased compared to diseased and healthy volunteer controls 
further suggesting circulating IPAH mononuclear cells are uniquely changed in 
disease (Bull et al., 2004). Despite PBMCs being studied monocytes in isolation 
have not been studied in PAH with regards to number, function and phenotype, 
monocytes have been shown to be altered in other cardiovascular diseases. For 
example monocytes isolated from patients with atherosclerosis presented with 
increased migration compared to monocytes from healthy controls (Bath et al., 
1991). With the knowledge that the pulmonary vasculature is very different 
from the systemic vasculature as illustrated in my work in Chapter 3, it is 
unlikely that processes in atherlerosclerosis are the same in PAH development. 
However, data from other cardiovascular diseases could give important 
mechanistic insights into potential pathways involved in PAH progression.  
There is little data phenotyping monocytes with regards to IPAH, however, by 
using data from other closely related cell types we may gain key insights to 
mechanisms which support the theory that monocytes may have an altered 
phenotype in IPAH compared to healthy. Another circulating cell type derived 
from the same hematopoietic stem cell as the monocyte is the CD34+CD133+ 
endothelial progenitor cell. Isolation of these cells from IPAH patient PBMCs 
showed an increase in circulating CD34+CD133+ cell number when compared to 
healthy controls (Farha et al., 2011). Evidence that these endothelial 
progenitors derive from a common cell lineage to monocytes and macrophages 
was provided in 2000. It was found that plate purified macrophages isolated 
from healthy volunteer blood could de-differentiate into endothelial like cells. 
With growth factor stimulation these cells could form tubes in Matrigel™ like 
mature endothelial cells as well as expressing endothelial cell markers such as 
von Willebrand Factor suggesting that endothelial cell progenitors could be 
derived from myeloid lineage (Schmeisser et al., 2001). A later publication 
isolated PBMCs from healthy volunteer buffy coats and successfully propagated 
pleuripotent stem cells. These stem cells had the ability to differentiate into 
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colony forming endothelial cells identifying a potential origin for endothelial 
cell progenitors (Zhao et al., 2003). Not only have circulating CD34+CD133+ 
endothelial cell progenitor numbers been shown to be increased in IPAH 
patients when compared to healthy controls but also despite similar baseline 
haematological profiles, CD34+CD133+ endothelial cell progenitor cells were 
more proliferative in IPAH patients when compared to controls (Farha et al., 
2011) (Toshner et al., 2009). Severe combined immunodeficiency mice on a 
non-obese diabetic background (NOD SCID) injected with endothelial 
progenitor cells isolated from patients with IPAH produced vascular lesions and 
showed an increased proliferative phenotype (Asosingh et al., 2008). The 
increase in endothelial progenitor cell number has been postulated to be used 
as a biomarker for cardiovascular disease as peripheral blood from patients at 
different cardiovascular disease states with no history of cardiovascular disease 
compared to healthy controls had an increase in CD34+CD133+ cell number (Hill 
et al., 2003). Monocytes themselves although maintained in number between 
IPAH and healthy cohorts may have an altered phenotype which is yet to be 
established with regards to functional competence and protein or gene 
expression. 
In addition to showing monocytes cells are altered in disease, I have shown that 
IPAH patient SMCs have an altered phenotype. I have found that SMCs from 
IPAH patients had a hyper-proliferative phenotype in normoxia to 5 % serum. 
Hypoxia had no additive effect on SMC proliferation with both oxygen tensions 
giving similar total cell counts. Unlike with commercial SMC, monocytes are 
unable to inhibit patient SMC proliferation. Previous work on IPAH patient 
SMCs found them to proliferate to hypoxia in serum starved conditions (Yang et 
al., 2002). Although I didn’t observe this, I think that my cells were already at 
maximum proliferation after 24 hours in 5 % serum so I was unable to see uplift 
in hypoxia. With a known BMPR2 mutation in IPAH SMCs, the inability of 
monocytes to inhibit patient SMC proliferation may mean that monocyte 
inhibition of hypoxic proliferation is independent of the BMPR2 and SMAD 
1/5/8 pathway. Combining both IPAH patient monocytes and SMCs will be 
important to further understand the disease phenotype. 
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To ensure my culture system was hypoxic I measured the pO2 of my culture 
supernatants but also secreted VEGF expression was used as a positive control. 
As a HIF target gene its expression was reassuringly increased in healthy 
hypoxic SMC supernatant samples compared to their normoxic counterparts. 
However, in my patient samples both normoxic and hypoxic expression of VEGF 
was equivalent. Moreover, in each culture condition VEGF expression was at 
least 2 fold higher then in healthy cells. One possible explanation for the 
differential growth phenotypes of diseased and healthy cells could be attributed 
to this difference in HIF pathway activation. In order to understand the role of 
the HIF pathway in hypoxic SMC proliferation the pan-hydroxylase enzyme 
DMOG was used to stabilise the oxygen sensitive domain of HIF- 1α. I found that 
HIF stabilisation with DMOG increased SMC proliferation and healthy 
monocytes were unable to inhibit DMOG- induced SMC proliferation. Work by 
Schultz, et al. found that DMOG inhibited growth factor induced proliferation in 
pulmonary artery SMC as shown by a reduction in [H]+ thymidine 
incorporation. Contradictory to my findings, in control cells treated with 100 
µM DMOG there was no increase in SMC proliferation. However, SMC 
proliferation is very sensitive to serum availability and these cultures were in 1 
% FCS which can reduce proliferation with regards to cell number and cyclin A 
expression (Schultz et al., 2009). Taken together, these findings suggested that 
HIF stability is important for SMC proliferation but monocyte inhibition of 
proliferation is independent of the HIF stability. However perhaps the chemical 
was adversely affecting monocytes’ ability to inhibit hypoxic SMC proliferation, 
to address this I pre-treated the monocytes with DMOG and cell-free 
supernatants applied to both normoxic and hypoxic SMCs. I proved that cell-
free supernatants from monocytes pre-treated with DMOG were still able to 
inhibit hypoxic SMC proliferation. Despite these data, the non-specific nature of 
DMOG means I cannot conclusively show that monocyte inhibition of hypoxic 
SMC proliferation is HIF independent. Moreover they may be DMOG carryover 
in the supernatant samples. What I can conclude from my experiments using 
DMOG as a proliferative stimulus is that IL- 1ra inhibition of SMC proliferation 
is not specific for hypoxia. Unlike monocytes, exogenous IL-1ra can inhibit both 
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hypoxic SMC proliferation and DMOG induced proliferation suggesting it is a 
more global regulator of SMC proliferation. 
To further address the HIF specificity of hypoxic SMC proliferation and 
inhibition of proliferation by monocyte co-culture I performed western blot 
analysis on SMC after 24 hour culture with and without monocytes. Although I 
found no change in HIF- 1α in SMC with or without monocytes, I did see an 
increase in HIF- 1α with hypoxia or DMOG. With regards to HIF- 2α, I found 
monocyte and SMC co-culture increased HIF- 2α expression compared to SMC 
monoculture in either oxygen tension but not with DMOG. This suggests that 
monocyte inhibition of SMC proliferation is HIF- 1α independent. However, it is 
still unknown if HIF- 2α has a role in monocyte inhibition of SMC proliferation 
or if HIF is important for hypoxic SMC proliferation. Using siRNA targeting both 
HIF- 1 and HIF- 2α I found that knockdown of HIF- 1α induced normoxic SMC 
proliferation but this was not so in IPAH patient SMC. Moreover, knockdown of 
HIF- 1α did not induce a compensatory increase in HIF- 2α. Knock down of HIF- 
2 had no effect on SMC proliferation in each oxygen tension for both commercial 
and IPAH patient SMC. Despite the increase in HIF- 2α protein seen in monocyte 
and SMC co-culture, HIF- 2α has no effect on SMC proliferation suggesting SMC 
increase in HIF- 2α protein is affecting SMCs in a proliferation independent 
manner. Given that both HIF- 1 and HIF- 2α have differential roles on cell cycle 
progression (Henze and Acker, 2010) (Schultz et al., 2005), an imbalance of 
either subunit may switch a senescent cell to progress through the cell cycle. 
This is illustrated by the fact that growth factor induced pulmonary artery SMC 
is inhibited with successful knockdown of HIF- 1α but siRNA targeting HIF- 2α 
has no effect on cell number in these same cells (Schultz et al., 2005). In human 
pulmonary artery SMCs, knockdown of HIF- 2α leads to a reduction in activity of 
the transcription factor forkhead box M1 (FoxM1). This reduction in turn leads 
to a reduction in the cell cycle mediators aurora A kinase and cyclin D1 
(Raghavan et al., 2012). This would suggest that HIF- 2 siRNA would reduce 
hypoxic SMC number but this is not seen in my work suggesting hypoxic SMC 
proliferation is driven by a different mechanism.  
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In relation to cancer there is evidence of a differential role for both HIF- 1 and 
HIF- 2α. Immunohistochemistry on non-small cell lung cancer tissues show a 
change in regulation and expression of HIF- 1 and HIF- 2α during tumour 
progression (Wu et al., 2011). In lung sections from patients undergoing 
surgery for emphysema the remodelled lung vessels showed increased HIF- 1 
stabilisation showing indirect evidence of the hypoxic microenvironment. These 
areas also showed an increase in proliferation cellular nuclear antigens as well 
as an increase in active caspase 3. These data were reproduced in vitro using 
CoCl2 as a HIF stabiliser on vascular SMCs. In different subpopulations of the 
vascular cells, proliferation, apoptosis and HIF expression was different, again 
suggesting differential roles for the HIFs in different cell populations (Howard 
et al., 2012).  
Hypoxia induces both HIF- 1 and HIF- 2 stabilisation and pulmonary artery SMC 
proliferation in male Sprague-dawley rats which then go on to develop 
pulmonary hypertension. This increase in both HIF subtypes also parallels and 
increase in ROS and intracellular Ca2+ (Zhang et al., 2012). The drug fluoxetine, a 
serotonin reuptake inhibitor, reduces hypoxic induction of HIF- 1α in MCT 
injected rats exposed to chronic hypoxia. This also leads to a reduction in ROS 
illustrating the close linkage between HIF- 1 expression and redox states of cells 
(Han et al., 2012). To determine whether hypoxia increased ROS in my culture 
system and thus induced hypoxic SMC proliferation, I used the antioxidant 
Trolox. Using increased concentrations of the vitamin E analogue Trolox I 
showed that monocyte inhibition of hypoxic proliferation was not due to 
monocytes release of an antioxidant by showing Trolox had no effect on hypoxic 
SMC proliferation.  
In conclusion I have shown that monocytes from IPAH patients are unable to 
inhibit hypoxic SMC proliferation and IPAH SMCs have an enhanced 
proliferative phenotype. I have shown that IL-1ra inhibition of SMC 
proliferation is not selective for hypoxia and the hypoxic SMC proliferation is 
HIF independent but there may be a role for the HIF pathway in monocyte 
inhibition of SMC proliferation. Further work would be to analyse the 
consequence of IPAH monocyte and IPAH SMC co-culture to further understand 
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the effect of disease on both vascular and circulating cells. In order to 
understand the mechanism of monocyte inhibition of hypoxic SMC proliferation 
I would like to explore other HIF independent pathways such as calcium 
channel regulation and iron bioavailability as explored in Chapter 5 and 
possibly investigate the inhibitory feedback effects of HIF- 3α in vascular SMCs 
(Augstein et al., 2011). It would also be interesting to investigate the role of the 
more mature CD16+ monocyte subset in PAH with regards to cell number and 
function. This monocyte subset is thought to have a more patrolling and 
regulatory role while CD14+ monocytes are first recruited to sites of 
inflammation and injury. However, no work has been done to investigate 
differential monocyte subset recruitment to vessels without inflammation so it 
is not known if either subset has a regulatory role in vessel homeostasis but an 
inflammatory role with stimulus.   
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5 GENERAL DISCUSSION 
 
PAH is a devastating vascular disease characterised by SMC hypertrophy and 
hyperplasia as well as endothelial cell dysregulation. Concentric lesion 
formation leads to narrowing and occlusion of the small pulmonary arteries 
leading to increased right ventricular pressure and eventually right heart 
failure. Endothelial aberrant growth can also lead to lesion development in the 
form of plexiform lesions. These have been found to have increased 
inflammatory cell infiltrates as well as inflammatory cytokines themselves 
being increased in serum from patients with the disease. The remodelled 
pulmonary vessels also stain positive for HIF which is a key mediator for 
myeloid cell function and an indirect indicator that these areas are hypoxic 
(although the exact oxygen tensions of the vessels are unknown). For these 
reasons I wanted to investigate SMC and monocyte co-cultures in normoxia and 
hypoxia with the hypothesis that monocytes can regulate SMC inhibition in a 
HIF dependant manner. Further to this to determine if IPAH patient monocytes 
and SMCs behave differentially to their healthy counterparts. 
My data showed that SMC number increased in hypoxia compared to normoxia 
and that this increase was specific to the pulmonary vasculature as aortic 
vascular SMCs were unaffected by hypoxia. Despite the robustness of my cell 
count data it is still not known if increase in SMC number is due to proliferation. 
Using TUNEL assays it was established that differences in total hypoxic SMC 
counts with and without monocytes were not attributed to increase in 
apoptosis with hypoxic co-culture. However, to confirm differences in total cell 
counts were due to proliferation further work could be done. A traditional assay 
used for determining proliferation is measuring radioisotope labelled 
thymidine incorporation. During cell division labelled thymidine is 
incorporated into replicated DNA allowing the divided cells to be counted on 
scintillation β counters. Having specific normoxic radioisotope work areas and 
only one hypoxic workstation the ability to carry out both hypoxic and 
radioactive work was restricted. Another assay which works on the same 
principle to radio labelled thymidine is 5-bromo-2-deoxyuridine (BrdU) 
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incorporation. Fluorescent antibody labelling of BrdU in permeabilised SMCs 
can then be measured on flow cytometry with propidium iodide staining which 
labels all DNA to calculate proportions of proliferating cells. A further flow 
based assay is CellTrace™ CFSE or carboxyfluorescein diacetate, succinimidyl 
ester. This compound enters cells where, once internalised, is cleaved to give a 
fluorescent product. This fluorescence is then halved when the cell divides 
allowing visualisation of division peaks representing each generation on a flow 
cytometer. Seeing as the increase in SMC number by hypoxia compared to 
normoxia is less than two fold the division index was too low to calculate 
division and thus proliferation by these methods. However, by showing there is 
not an increase in apoptosis in hypoxic co-cultures it is unlikely that increase in 
cell number is not due to SMC proliferation.  
Importantly healthy donor monocytes were able to inhibit hypoxic increase in 
cell number independently to direct cell contact and monocyte hypoxia. 
Suggesting monocytes are constitutively releasing a factor to regulate vascular 
tone. The initiating factor of IPAH development has not been identified but it is 
known that pro-inflammatory cytokines are increased in disease. It would be 
interesting to establish if circulating monocytes have protective role on vascular 
homeostasis which is altered upon disease onset or if the circulating myeloid 
cell baseline phenotypes are different in people predisposed to the disease. Due 
to the small number of monocytes (5,000) used in each co-culture experiment it 
was difficult to recover monocytes to phenotype post co-culture. The cell 
permeable dye alamarBlue® was used to determine relative metabolic activity 
of monocytes post-culture, however, due to this redox indicator being hypoxia 
sensitive it was not a reliable assay. Monocyte survival was explored using 
TUNEL assay on transwell fixed monocytes but again small numbers of 
monocytes used in each experiment meant reliable counts were unable to be 
obtained.  One way to combat this problem would be to upscale the experiment 
using larger wells and transwell inserts which could be an area of future work 
to phenotype monocytes after co-culture.  
Analysis of culture supernatants for proinflammatory cytokines and disease 
linked factors was unable to yield a potential factor which monocyte inhibition 
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of hypoxic SMC proliferation may be attributed to. If monocytes are releasing a 
molecule which is inhibiting hypoxic SMC proliferation then it would be 
expected that supernatants from hypoxic SMC mono- and co-cultures would 
have differential compound content. If time allowed culture supernatants could 
be analysed by mass spectrometry in order to identify differences in hypoxic 
monoculture and hypoxic co-culture supernatants. Having focused on ELISA 
analysis we have not explored the whether non-protein factors may be eliciting 
monocyte inhibition of hypoxic SMC proliferation. By boiling culture 
supernatants it is possible to denature proteins therefore if monocyte inhibition 
of SMC proliferation is still observed it may be attributed to a lipid or another 
non-protein factor. However, cytokine profiles were not initially investigated to 
identify potential target molecules. Profiles were used to phenotype the co-
culture model in order to directly compare to published work in aortic vascular 
SMCs.  
HIV is a retrovirus which infects immune cells leading to acquired 
immunodeficiency syndrome. As therapeutics and prognosis have improved for 
HIV patients, an increase in HIV induced pulmonary hypertension has been 
observed in patients with chronic HIV load. The underlying mechanisms of this 
disease subset are yet to be established however, pathogenesis follows similar 
characteristics to other subsets of PAH (Lederman, 2008). With this in mind 
instead of using the bacterial wall product and TLR4 agonist to maximise 
cytokine responses in monocyte and SMC cultures it may be useful to use a 
TLR3 agonist. Unlike TLR4 which responds to bacterial ligands, TLR3 
recognises double stranded DNA as produced by viruses. Polyinosinic-
polycytidylic acid also known as poly(I:C) is such an agonist. Poly(I:C) is a viral 
mimic of double stranded DNA which activates TLR3 on SMCs. This could be an 
area of future work and would lead to better understanding of the development 
of HIV induced PAH.  
A promising pathway involved in inducing SMC proliferation that can be altered 
by monocytes is the IL- 1 pathway. My data showed exogenous IL- 1ra can 
modulate hypoxic SMC proliferation potentially implicating IL- 1ra as mediating 
monocyte inhibition of SMC proliferation. However, further exploration found 
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IL- 1ra could block DMOG induced SMC proliferation. Having found that 
monocytes were unable to block DMOG induced SMC proliferation and being 
unable to detect any IL- 1ra in monocyte culture supernatants it is unlikely that 
monocyte inhibition of SMC proliferation is due to IL- 1ra. Although monocytes 
were able to inhibit SMC proliferation, the specificity of monocyte inhibition to 
hypoxic induced proliferation was yet to be identified. With this in mind PDGF 
was used to stimulate SMC proliferation. Seeing as monocytes were unable to 
inhibit both growth factor and DMOG induced SMC proliferation it is likely that 
monocyte inhibition of proliferation is specific to hypoxic induced SMC 
proliferation.  
My key finding is that IPAH patient monocytes are unable to inhibit hypoxic 
SMC proliferation suggesting that circulating monocytes have an altered 
phenotype in disease. This is an important finding because it seems to be 
specific for IPAH. Monocytes obtained from patients with PAH associated with 
an immune disorder, systemic sclerosis (SSc), are equally able to inhibit hypoxic 
SMC proliferation as healthy monocytes. It is important to note that all IPAH 
patients were treatment naive but this was not the case for SSc associated PAH 
patients. SSc is a chronic disease and many patients have progressed disease 
before the onset of PAH therefore obtaining a treatment naive cohort is difficult. 
If time allowed I would have liked to obtain more patients and better age and 
sex match the SSc associated PAH patients, IPAH patients and healthy volunteer 
cohorts. To further explore the theory that the circulating monocytes from IPAH 
patients are altered compared to disease and healthy controls, functional 
analysis could be done on the freshly isolated cells. Small yields of monocytes 
obtained after peripheral blood isolation prevented extensive phenotyping to 
be carried out. Despite this both RNA and protein from each patient has been 
stored with analysis postponed until potential targets to investigate are 
identified. One suggestion would be to investigate protein expression of both 
CD14+ and CD16+ markers. It is not known which subset predominates in IPAH 
or if circulating numbers of either subset is altered in disease. Moreover, it 
would be interesting to know if subset numbers are altered between each 
subgroup of PAH.  
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Not only do monocytes display an altered phenotype in IPAH but also IPAH 
SMCs are found to be hyper proliferative compared to their healthy 
counterparts. Patient SMCs showed enhanced proliferation in serum which was 
unaltered in hypoxia or by monocyte co-culture emphasising the importance of 
phenotyping diseased SMCs post-culture. Examination of freshly thawed cells 
showed that IPAH SMCs stained positive for the contractile SMC indication β-
smooth muscle cell actin. Unfortunately post-culture cells were lifted for cell 
counts or lysed therefore preventing identification of SMC phenotype post-
culture. IPAH patient SMC proliferation is likely due to BMPR2 dysregulation 
coupled with increased TGF-β pathway activation as these cells have a mutated 
BMPR2 so the balance between both pathways will be altered. These data 
suggest that both the BMPR2 and TGF-β pathway are important for controlling 
SMC proliferation but that these pathways act independently of hypoxic 
induced SMC proliferation.  Also these pathways are unlikely to be the cause of 
monocyte inhibition of SMC proliferation as monocytes cannot modulate patient 
SMC proliferation. 
HIF dependence of SMC proliferation was investigated using siRNA targeting 
HIF- 1α, HIF- 2α or both together. My data showed that hypoxic SMC 
proliferation was independent of the HIF pathway but I am yet to establish if 
monocyte inhibition of hypoxic SMC proliferation is HIF dependant. Being 
unable to transfect human monocytes themselves this question is more difficult 
to address. One possible solution would be to use an in vivo transgenic murine 
model. With the availability of a myeloid specific HIF knock out mouse it is 
possible to culture pulmonary arterial SMCs in hypoxia and normoxia with and 
without HIF knockout monocytes. However, the difficulty arises with human 
and mouse interactions. It is arguable how biologically relevant mouse 
monocytes are to human SMCs. Ideally mouse pulmonary arterial SMCs could be 
cultured and found to respond to hypoxia as human SMCs. Thus co-cultures of 
both mouse monocytes and SMCs could be phenotyped. Moreover murine 
models of PAH have been difficult to create with mouse vessels being 
particularly resistant to vascular remodelling as characteristic of PAH. 
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Therefore the question of HIF dependence of monocyte inhibition of SMC 
proliferation is still unknown.  
Although it has been much documented that hypoxia induces SMC proliferation 
the mechanism is still unknown. It is known that hypoxia impairs potassium 
channel function. Dysregulation of voltage dependant potassium channels (Kv) 
leads to decreased potassium influx and so release of intracellular calcium ion 
stores. This is perpetuated by chloride ion influx by voltage dependant chloride 
channels (Clv). As seen by growth factor induced SMC proliferation intracellular 
calcium has an important role in controlling SMC proliferation. To reset the 
balance of intracellular calcium, activity of both calcium regulated chloride 
channel (ClCa) and calcium regulated potassium channel (KCa) is needed. These 
channels increase efflux of chloride ions and influx of potassium ions 
respectively. Monocytes may function to regain intracellular balance reducing 
hypoxic SMC proliferation in healthy SMCs but much work is needed to explore 
this option. Patch-clamp techniques could be used to identify membrane 
potentials and channel activity in SMC monocultures and monocyte supernatant 
treated SMC monocultures in both oxygen tensions to identify differences in 
channel functions. 
Interestingly IPAH patients have been found to be deficient in iron with reduced 
serum ferritin. This is also true of other forms of PAH such as associated with 
Chuvash polycythemia and secondary pulmonary hypertension to congenital 
heart disease (Sable, 2012). The importance of iron and hypoxia in pulmonary 
hypertension was emphasised by work from Smith et al who found healthy 
volunteers exposed to 8 hours of isocarpic hypoxia developed increased 
pulmonary arterial pressure. Infusion of 4 g per 70 kg body mass of an iron 
chelator (desferrioxamine mesylate) for 8 hours exacerbated pulmonary 
arterial pressures upon hypoxic exposure. But supplemented iron in the form of 
200 mg iron(III)- hydroxide sucrose significantly reduced pulmonary arterial 
pressures upon hypoxia exposure (Smith, 2008). An essential co-factor for the 
HIF- α regulators prolyl hydroxylases (PHDs) is iron so deficiency may 
constitute increase HIF activity. Although systemic vascular HIF activity has not 
been measured in IPAH patients, an increase in HIF expression both at the 
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mRNA and protein level is seen in IPAH patient diseased vessels. If monocytes 
are releasing iron and iron reduces vascular remodelling thus reduces SMC 
proliferation then this pathway may be responsible for monocyte inhibition of 
SMC proliferation. This theory could be explained by monocyte expression of 
CD163, a haemoglobin scavenger receptor. The CD163 receptor allows 
monocytes to breakdown haemoglobin into heme leading to subsequent 
isolation of iron by heme oxidase (Kong, 2012). Seeing as monocyte isolations 
are not 100 % pure, residual red blood cells may be recycled by monocytes 
allowing release of iron. This theory could be explored by supplementing 
hypoxic SMC culture with exogenous iron in order to establish the effects of iron 
on hypoxic SMC proliferation.  
In conclusion I found that pulmonary arterial SMCs proliferate to hypoxia and 
that this is inhibited by healthy monocyte co-culture in a HIF and contact 
independent manner. Further to this, IPAH patient monocytes and SMCs had an 
altered phenotype compared to healthy controls. Much is unknown with 
regards to the development of IPAH therefore this work is important for 
discovering insights to disease progression. Better understanding of the disease 
could lead to development of better targeted therapeutics in a view to improve 
patient prognosis. 
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7 APPENDICES 
 
7.1 Appendix I 
Cytokine 
Coating 
Ab 
stock 
Coating Ab 
dilution 
Standa
rd 
stock 
Standard 
dilution  
Biotiny
lated 
Ab 
stock 
Biotinylated Ab 
dilution 
Interleukin-
8 
stock 
720 μg 
/ml 
use at 4 μg 
/ml, 55.5 
μl in 10 ml 
stock 
100 ng 
/ml 
use at 2000 
pg/ml, 10 μl in 
500 μl 
stock 
3.6 μg 
/ml 
use at 20 ng /ml, 
55.5 μl in 10 ml 
Interleukin-
6 
stock 
360 μg 
/ml 
use at 2 μg 
/ml, 55.5 
μl in 10 ml 
stock 
120 ng 
/ml 
use at 600 pg 
/ml, 2.5 μl in 
500 μl 
stock 9 
μg /ml 
use at 50 ng /ml, 
55.5 μl in 10 ml 
Interleukin-
1β 
stock 
720 μg 
/ml 
use at 4 μg 
/ml, 55.5 
μl in 10 ml 
stock 
75 ng 
/ml 
use at 250 pg 
/ml, 2 in 20 
dilution then 
17 μl in 500 μl 
stock 
36 μg 
/ml 
use at 200 ng 
/ml, 55.5 μl in 10 
ml 
Interleukin-
10 
stock 
360 μg 
/ml 
use at 2 μg 
/ml, 55.5 
μl in 10 ml 
stock 
95 ng 
/ml 
use at 2000 
pg/ml, 10.5 μl 
in 500 μl 
stock 
27 μg 
/ml 
use at 150 ng 
/ml, 55.5 μl in 10 
ml 
RANTES 
stock 
180 μg 
/ml 
use at 1 μg 
/ml, 55.5 
μl in 10 ml 
stock 
120 ng 
/ml 
use at 1000 pg 
/ml, 4.2 μl in 
500 μl 
stock 
3.6 μg 
/ml 
use at 20 ng /ml, 
55.5 μl in 10 ml 
VEGF 
stock 
180 μg 
/ml 
use at 1 μg 
/ml, 55.5 
μl in 10 ml 
stock 
110 ng 
/ml 
use at 2000 pg 
/ml, 9 μl in 
500 μl 
stock 
18 μg 
/ml 
use at 100 ng 
/ml, 55.5 μl in 10 
ml 
VEGFR1 
stock 
720 μg 
/ml 
use at 4 μg 
/ml, 55.5 
μl in 10 ml 
stock 
440 ng 
/ml 
use at 10,000 
pg /ml, 11.4 μl 
in 500 μl 
stock 
27 μg 
/ml 
use at 150 ng 
/ml, 55.5 μl in 10 
ml 
BMP4 
stock 
360 μg 
/ml 
use at 2 μg 
/ml, 55.5 
μl in 10 ml 
stock 
80 ng 
/ml 
use at 1000 pg 
/ml, 6.25 μl in 
500 μl 
stock 
180 μg 
/ml 
use at 1 μg /ml, 
55.5 μl in 10 ml 
OPG 
stock 
360 μg 
/ml 
use at 2 μg 
/ml, 55.5 
μl in 10 ml 
stock 
105 ng 
/ml 
use at 4000 pg 
/ml, 19 μl in 
500 μl 
stock 
36 μg 
/ml 
use at 200 ng 
/ml, 55.5 μl in 10 
ml 
TGF-β 
stock 
360 μg 
/ml 
use at 2 μg 
/ml, 55.5 
μl in 10 ml 
stock 
220 ng 
/ml 
use at 2000 pg 
/ml, 4.55 μl in 
500 μl 
stock 
54 μg 
/ml 
use at 300 ng 
/ml, 55.5 μl in 10 
ml 
 
 
ELISA antibody concentrations as according to manufacturers’ instructions (R&D 
Systems Inc.). 
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7.2 Appendix II 
 
> 99 % Glycerol (Sigma-Aldrich Ltd) 3 ml 
Deionised water  4800 µl 
1 M Tris-HCl (pH 7.4) (Bio-Rad Laboratories) 100 µl 
100 mM sodium orthovanadate  100 µl 
10 % SDS (Sigma-Aldrich Ltd) 1 ml 
Protease inhibitors in water (Hoffmann-La Roche Ltd) 1 ml 
Total volume  10 ml 
   
 
Recipe for making sodium orthovanadte protein lysis buffer 
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7.3 Appendix III 
 
 
Resolving Gel  
   8 % Gel 1 gel 2 gels 3 gels 4 gels 
Water 8 ml 12 ml 16 ml 20 ml 
40 % Acrylamide (Bio-Rad 
Laboratories Ltd.) 
        
3 ml 4.5 ml 6 ml 7.5 ml 
1.5 M Tris-Hcl pH 8 (Bio-
Rad Laboratories Ltd.) 
        
3.8 ml 5.7 ml 7.6 ml 9.5 ml 
20 % SDS (Sigma-Aldrich 
Ltd.) 
        
7.5 µl 112.5 µl 150 µl 187.5 µl 
20 % APS 150 µl 225 µl 300 µl 375 µl 
TEMED (Bio-Rad 
Laboratories Ltd.) 
        
6 µl 9 µl 12 µl 15 µl 
     Stacking Gel 
   8 % Gel 1 gel 2 gels 3 gels 4 gels 
Water 3 ml 6 ml 9 ml 12 ml 
40 % Acrylamide (Bio-Rad 
Laboratories Ltd.) 
        
620 µl 1240 µl 1860 µl 2480 µl 
0.5 M Tris-Hcl pH 6.8 
(Bio-Rad Laboratories 
Ltd.) 
        
1260 µl 2520 µl 3780 µl 5040 µl 
20 % SDS (Sigma-Aldrich 
Ltd.) 
        
25 µl 50 µl 75 µl 100 µl 
20 % APS 50 µl 100 µl 150 µl 200 µl 
TEMED (Bio-Rad 
Laboratories Ltd.) 
        
5 µl 10 µl 15 µl 20 µl 
      
 
Recipes for making 8 % SDS- PAGE gels  
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7.4 Appendix IV 
 
 
 
10 x Running buffer stocks 
 
Glycine (Fisher 
Scientific) 190 g  
  
Tris Base (Fisher 
Scientific) 30.3 g 
 
  
20 % SDS (Sigma-
Aldrich Ltd.) 50 ml 
 
 
deionised water  to 1 litre  
 
      
Dilute to 1 x solution before use 
 
Recipe for making running buffer for western blots 
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7.5 Appendix V 
 
 
 
10 x Transfer buffer stocks 
Glycine (Fisher Scientific) 14.5 g  
  
Tris Base (Fisher 
Scientific) 29 g 
 
  
20 % SDS (Sigma-Aldrich 
Ltd.) 9.25 ml 
 
 
deionised water  to 400 ml  
 
     immediately before use make 1 x solution 
     
10 x transfer buffer 100 ml  
  
Methanol (VWR 
International Ltd.) 200 ml 
 
 
deionised water  700 ml  
  
 
 
Recipe for making transfer buffer for Western blots 
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7.6 Appendix VI 
 
 
 
Antibody 
   
Dilution 
   
        
HIF-1 α (Novus Biologicals, LLC), NB100-
105, mouse monoclonal 
1 in 500, 8 µl in 4 ml 5 % Marvel in TBS- 
Tween 
        HIF-2 α (Novus Biologicals, LLC), NB100- 
132, mouse monoclonal 
1 in 200, 20 µl in 4 ml 5 % Marvel in TBS- 
Tween 
        Actin (Sigma-Aldrich Ltd.), A2668, rabbit 
polyclonal 
1 in 1000, 4 µl in 4 ml 5 % Marvel in TBS- 
Tween 
 
 
Western blot antibodies and dilutions used  
 
